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Development and Characterization of a Recombinant Vesicular Stomatitis Virus
(rVSV) for the Treatment of Glioblastoma
Abstract
Background: Over the past 30 years, little has changed in the treatment modalities and prognosis of
patients suffering from Glioblastoma multiforme (GBM), the most common and by far the most
devastating adult primary malignant brain tumor. Conventional therapies provide only a marginal increase
in survival of GBM patients, post-diagnosis. Therefore, more novel means of treating GBM are needed to
increase long-term survival and quality of life for those affected. Replication competent oncolytic viruses
(OVs) have recently emerged as a possible option for treatment of high-grade gliomas. Particularly,
recombinant vesicular stomatitis virus (rVSV), an enveloped, negative strand RNA virus, has shown
promising results in preclinical studies. Tumor selectivity of VSV is thought to be associated with tumor
specific defects in the interferon (IFN) pathway. However, largely due to insufficient attention on the role
the immune system plays in efficacy of treatment, potential OVs have been obstructed from moving
through the clinical trial pipeline past Phase I/II studies. rNCP12.1 is a novel recombinant VSV vector
possessing specific mutations in the matrix protein. Thes mutations have been shown to promote viral
attenuation in normal cells while maintaining cytotoxicity in a number of tumor cell lines. We aim to
characterize and further develop this novel agent for the treatment of GBM. Methods: In order to
determine differences between rNCP12.1 and wtVSV and to determine specificity of rNCP12.1 for tumor
over normal cells, cell rounding assays, one-step growth curves, and cytotoxicity assays were performed
in normal glial and tumor glial cell lines. To understand the basis of this selectivity and whether it
correlated with the antiviral responses of IFN, expression levels of IFN and IFN stimulated genes (ISGs)
were quantified, production of active IFN was measured, and the ability of cells to inhibit viral infection in
response to exogenous IFN was determined. In vivo experiments were designed and carried out to test
for oncolytic activity of rNCP12.1 in immunocompetent animal models of intracranial glioma. A single
injection of rNCP12.1 was administered into previously implanted F98-GFP tumors. Tumor load and
parameters of morbidity were assessed at 15 days following tumor implantation and long term at the
time of euthanasia. Viral induced immune responses were assessed by the IFN bioassay and detection of
circulating anti-VSV antibodies were achieved by Western blot analysis and a neutralizing antibody assay.
Experimental methods of virus administration for treatment of glioma were further tested including
multiple injections, injections using different VSV serotypes, continuous infusion of virus using
implantable osmotic pumps, and pre-infected autologous carrier cells. These methods were designed to
enhance anti-tumor effect by managing the negative effects of the tumor microenvironment and of a
functional immune system on viral therapy. Results and Conclusion: rNCP12.1 was shown to be an
attenuated strain of VSV that has clear differences in its growth and induction of the IFN response
pathway in normal cells. It has a preference for growth in tumor cells as determined by viral titers, cell
rounding, and cell viability post infection. This preference varied based on cellular expression of a
particular IFN phenotype. The importance of this molecular versus histological cell profile was evident
even in the performance of rNCP12.1 on human glioma cell lines that differ in their expression of IFN. In
vivo evaluation of rNCP12.1 against a highly IFN resistant rat glioma cell line, F98, demonstrated its ability
to decrease tumor size while eliciting a peripheral response to virus that protects normal tissue but also
shortens its therapeutic window and the ability to sustain reduction of tumor over time. Several
experimental methods in delivery of virus proved to be beneficial, including administering an additional
dose of virus using a different serotype to bypass antiviral neutralizing responses and by shielding virus
from the immune system through the use of tumor carrier cells. As an additional benefit, the latter was
shown to have a unique pattern in eliciting tumor specific antibodies that was different from those
increased by therapy with virus alone. This method also increased recovery of virus from brain tissue even
after 20 days post treatment.

Our data supports the capability of rVSV vectors as treatment for GBM. Specifically rNCP12.1 therapy
increased survival while decreasing tumor load, depending on method of administration. When given
alone, virus is ultimately immunogenic and prompts anti-viral as well as anti-tumor immune responses.
However, when shielded from the immune system, antiviral responses are minimal while anti-tumor
responses are sustained. To this end, therapy cannot be fully addressed without addressing the effects
the immune system has on therapy and on the host. Future studies, should include not only evaluation of
tumor load, morbidity, and side effects of viral therapy but also immune responses especially those that
are likely to enhance therapy past the acute stages of disease.
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ABSTRACT
Background: Over the past 30 years, little has changed in the treatment
modalities and prognosis of patients suffering from Glioblastoma multiforme (GBM), the
most common and by far the most devastating adult primary malignant brain tumor.
Conventional therapies provide only a marginal increase in survival of GBM patients,
post-diagnosis. Therefore, more novel means of treating GBM are needed to increase
long-term survival and quality of life for those affected. Replication competent oncolytic
viruses (OVs) have recently emerged as a possible option for treatment of high-grade
gliomas. Particularly, recombinant vesicular stomatitis virus (rVSV), an enveloped,
negative strand RNA virus, has shown promising results in preclinical studies. Tumor
selectivity of VSV is thought to be associated with tumor specific defects in the
interferon (IFN) pathway. However, largely due to insufficient attention on the role the
immune system plays in efficacy of treatment, potential OVs have been obstructed from
moving through the clinical trial pipeline past Phase I/II studies. rNCP12.1 is a novel
recombinant VSV vector possessing specific mutations in the matrix protein. Thes
mutations have been shown to promote viral attenuation in normal cells while
maintaining cytotoxicity in a number of tumor cell lines. We aim to characterize and
further develop this novel agent for the treatment of GBM.
Methods: In order to determine differences between rNCP12.1 and wtVSV and
to determine specificity of rNCP12.1 for tumor over normal cells, cell rounding assays,
one-step growth curves, and cytotoxicity assays were performed in normal glial and
tumor glial cell lines. To understand the basis of this selectivity and whether it correlated
with the antiviral responses of IFN, expression levels of IFN and IFN stimulated genes
(ISGs) were quantified, production of active IFN was measured, and the ability of cells to
inhibit viral infection in response to exogenous IFN was determined. In vivo experiments
were designed and carried out to test for oncolytic activity of rNCP12.1 in
immunocompetent animal models of intracranial glioma. A single injection of rNCP12.1
was administered into previously implanted F98-GFP tumors. Tumor load and
parameters of morbidity were assessed at 15 days following tumor implantation and long
term at the time of euthanasia. Viral induced immune responses were assessed by the
IFN bioassay and detection of circulating anti-VSV antibodies were achieved by Western
blot analysis and a neutralizing antibody assay. Experimental methods of virus
administration for treatment of glioma were further tested including multiple injections,
injections using different VSV serotypes, continuous infusion of virus using implantable
osmotic pumps, and pre-infected autologous carrier cells. These methods were designed
to enhance anti-tumor effect by managing the negative effects of the tumor
microenvironment and of a functional immune system on viral therapy.
Results and Conclusion: rNCP12.1 was shown to be an attenuated strain of
VSV that has clear differences in its growth and induction of the IFN response pathway
in normal cells. It has a preference for growth in tumor cells as determined by viral titers,
cell rounding, and cell viability post infection. This preference varied based on cellular
expression of a particular IFN phenotype. The importance of this molecular versus
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histological cell profile was evident even in the performance of rNCP12.1 on human
glioma cell lines that differ in their expression of IFN.
In vivo evaluation of rNCP12.1 against a highly IFN resistant rat glioma cell line,
F98, demonstrated its ability to decrease tumor size while eliciting a peripheral response
to virus that protects normal tissue but also shortens its therapeutic window and the
ability to sustain reduction of tumor over time. Several experimental methods in delivery
of virus proved to be beneficial, including administering an additional dose of virus using
a different serotype to bypass antiviral neutralizing responses and by shielding virus from
the immune system through the use of tumor carrier cells. As an additional benefit, the
latter was shown to have a unique pattern in eliciting tumor specific antibodies that was
different from those increased by therapy with virus alone. This method also increased
recovery of virus from brain tissue even after 20 days post treatment.
Our data supports the capability of rVSV vectors as treatment for GBM.
Specifically rNCP12.1 therapy increased survival while decreasing tumor load,
depending on method of administration. When given alone, virus is ultimately
immunogenic and prompts anti-viral as well as anti-tumor immune responses. However,
when shielded from the immune system, anti-viral responses are minimal while antitumor responses are sustained. To this end, therapy cannot be fully addressed without
addressing the effects the immune system has on therapy and on the host. Future studies,
should include not only evaluation of tumor load, morbidity, and side effects of viral
therapy but also immune responses especially those that are likely to enhance therapy
past the acute stages of disease.
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CHAPTER 1.

INTRODUCTION

Glioblastoma Multiforme
Definition and Classification
Gliomas are both benign and malignant neuroepithelial tumors originating from
the supporting glial cells of the central nervous system (CNS) [1]. The accepted standard
for defining tumors of the CNS has been established by The World Health Organization
(WHO) histological grading system, which subdivides tumors based on the glial cell from
which they most likely derive including cells of astrocytic, oligodendroglial, mixed
oligoastrocytic, or ependymal nature. Particularly, astrocytic tumors can be classified
into four distinct histological groups corresponding to their level of malignancy (See
Table 1-1). Grade I tumors such as pilocytic astrocytomas have low proliferative
potential and are the least malignant. Grade II neoplasms are generally of low
proliferative potential yet have a higher capacity to infiltrate surrounding normal tissue.
For this reason, Grade II lesions often recur as high-grade tumors following initial
treatment. Grade III and IV tumors are considered high grade, and, particularly, WHO
grade III tumors are anaplastic lesions that are histologically malignant, displaying
nuclear atypia and high mitotic activity. Lastly, WHO grade IV describes highly
malignant tumors with similar histological features of grade III tumors but with enhanced
proliferation of microvasculature and necrotic centers often surrounded by hypercellular
areas called pseudopalisades which are thought to be cells migrating away from hypoxic
areas of tumor [2]. Included in the Grade IV category are glioblastomas, formerly known
as glioblastoma multiforme or GBM, the most detrimental of high-grade gliomas [3].

Table 1-1.
Histological grading of astrocytic tumors as defined by the World
Health Organization (WHO)
Histological Grade
I
II

III
IV

•
•
•
•
•
•
•
•
•

Tumor (s)
Subependymal Giant Cell Astrocytoma
Pilocytic Astrocytoma
Pilomyxoid Astrocytoma
Diffuse Astrocytoma
Pleomorphic Xanthoastrocytoma
Anaplastic Astrocytoma
Glioblastoma (Glioblastoma Multiforme)
Giant Cell Glioblastoma
Gliosarcoma
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Epidemiology
According to the Central Brain Tumor Registry of the United States (CBTRUS),
there were 311,202 primary brain and CNS tumors diagnosed during 2005-2009; 201,507
of which were malignant. Gliomas comprise 30% of all CNS tumors and 80% of all
malignant tumors. Of gliomas, GBM makes up over 50% and is the second most
commonly diagnosed (16%) primary tumor second only to the nonmalignant meningioma
(35%) (Figure 1-1). Of CNS malignancies, GBM ranks first. Males are typically
affected more than females at a ratio of 1.58, and whites are twice as likely to be
diagnosed with GBM over African Americans. The median age of diagnosis for GBM is
64 with highest rates seen in those over the age of 75 making it a disease of advanced
age. As the most malignant and notorious of brain tumors, mortality is high following
diagnosis. One-year survival is estimated at 35.7% dropping down to 5% at 5 years [4, 5].
Cause(es) of glioma are largely unknown. Because gliomas are a disease seen
more prevalently in industrialized countries, many studies have attempted to find a
relationship between environmental factors such as cell phone usage. Unfortunately,
none have been convincing other than demonstrating an increased risk with past history
of radiotherapy to the head and/or neck. There are known hereditary syndromes
associated with increased risk of glioma, but these are rare. Examples of these include LiFraumeni syndrome, familial adenomatous polyposis syndrome (FAPS), Lynch
syndrome, and Neurofibromatosis (NF) 1, each of which have been associated with single
gene mutations [6].
Diagnosis
Signs and symptoms are important in the diagnosis of CNS tumors. Those that
raise suspicion include constitutional symptoms such as fatigue and headache as well as
dizziness, confusion, memory loss, and behavioral changes. Focal neurological
symptoms may be present and include changes in vision, speech, and motor or sensation,
which vary based on tumor location. Additionally, symptoms indicative of increased
intracranial pressure from mass effect of tumor may be present and include headache
associated with vomiting most noticeable upon awakening. Radiological studies are
extremely important to the diagnosis of GBM and aid in confirming tumor malignancy.
These include computed tomography (CT) or magnetic resonance imaging (MRI), the
latter being the study of choice as it is more sensitive to specific features of malignancy
such as peritumoral edema and areas of abnormal intensity that correspond to foci of
tumor cell infiltration. Often areas of central necrosis are visualized making high grade
tumors a more likely diagnosis than low grade [7].
Standard Treatments for GBM
Regardless of etiology, prognosis for GBM patients is grim with survival ranging
from 3-15 months, depending on available treatment options. Negative prognostic factors
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Figure 1-1. Distribution of primary brain tumors
The distribution of primary brain tumors based on histology are depicted in the pie graph.
The bar graph illustrates distribution of glial specific tumors.
Source: Dolecek T, J. Propp, N. Stroup, and C. Kruchko (2012). CBTRUS Statistical
Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United
States in 2005–2009. Neuro-oncology, 14:1-49 [4].
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include advanced age, infiltrative histological features, poor performance status
(Karnofsky scale), and inability to surgically debulk tumor. For low-grade tumors,
prognosis is best with 5yr survival of Grade I tumors averaging 94% as tumors are
usually cured by surgery alone. On the other hand, surgery is often not feasible for Grade
IV tumors due to infiltration especially into eloquent areas of the brain. Other factors
affecting ability to operate include advanced age and comorbidities. Regardless, the
standard treatment for newly diagnosed GBM includes surgical resection, radiotherapy,
and adjuvant chemotherapy.
Surgical management not only provides tissue for diagnosis as well as relief from
symptoms caused by mass effect, but the extent of resection (EOR) has been shown to
directly influence overall survival. In a retrospective review of GBM patients who
underwent 2 or more craniotomies for tumor resection, outcomes based on gross total
resection (GTR) versus subtotal resection (STR) at time of diagnosis and recurrence were
compared and a significant improvement in survival was associated with debulking of at
least 78% of tumor mass. These numbers improved with increased percentage of
resection [8]. Current studies are focusing on improving both surgical techniques and
imaging strategies in order to enhance this positive effect on survival for patients who
qualify for resection [9]. Even further, the combination of surgery and radiation was
found to increase survival [10]. Conventional radiotherapy regimens consist of 60 Gy of
partial-field external- beam irradiation delivered 5 days per week in fractions of 1.8 to 2.0
Gy [7]. Since the implementation of chemotherapy as part of the standard of care,
survival has increased from 12 to 15 months. Until 2005, there were a number of drugs
evaluated and often experimentally used in the clinical setting as chemotherapy agents for
GBM. These included agents such as procarbazine, a DNA alkylating agent, and the
nitrosourea chemotherapies such as carmustine (BCNU) or lomustine (CCNU). In 2005
following a groundbreaking study by the European Organisation for Research and
Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) on
treatment of newly diagnosed GBM, another chemotherapy agent, Temozolomide (TMZ)
became the agent of choice as this study showed an increase in survival of 3 months
when TMZ was added to radiation versus radiation alone. TMZ is an oral prodrug agent
that is metabolized into its active form, which then methylates DNA at a number of sites
causing DNA damage and subsequent cellular apoptosis. As with many chemotherapies,
GBMs become resistant to TMZ therapy by several mechanisms that involve
dysregulation of DNA repair systems. Unfortunately, the ability to treat with TMZ is
largely limited by its myelosuppressive effects [11].
Despite the most aggressive conventional therapeutic regimen, a majority of
tumors eventually recur within 7 months [7, 12]. These tumors are typically more
aggressive due to newly acquired genetic changes in the tumor cell population promoting
resistance to radio- and chemotherapies [13].
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Molecular Subtypes of Glioblastoma
In accordance with the WHO system, histological characteristics are evaluated to
classify gliomas based on glial origin and malignant potential. This grading system often
falls short in its ability to predict prognosis and response to treatments, as many
histologically similar gliomas respond very different to treatment. This may be due to
technical error as histological grade is dependent upon interpretation by
neuropathologists and borderline histological features often interfere with this
interpretation [1]. On the other hand, underlying genetic profiles of histologically similar
tumors may cause them to behave very differently in response to treatment and therefore
affect long-term survival. The observation that certain Grade IV gliomas have increased
susceptibility to TMZ based on the presence or absence of mutations in a DNA repair
enzyme promoter is an example of this genetic influence. O6-methylguanine-DNA
methyltransferase (MGMT) is a DNA repair enzyme that works by inhibiting cross
linking of dsDNA which prevents the action of alkylating chemotherapeutic agents and is
often responsible for resistance of tumors to these agents. When methylated, the MGMT
promoter is silenced therefore increasing the tumor’s susceptibility to TMZ. Studies have
shown that survival with TMZ therapy is enhanced to 21.7 months versus 12 months in
patients with unmethylated MGMT [7].
It is understood that GBMs are composed of a heterogeneic population of cells,
and therefore several genetic subtypes are currently recognized [13]. Primary GBM
makes up 90% of total GBMs diagnosed and arises de novo without a history of a lower
grade precursor lesion. Primary tumors exhibit a number of frequent genetic alterations
including EGFR amplification, homozygous deletion of the CDKN2A gene coding for
both p16INK4a and/or p14ARF, and chromosome 10 or PTEN mutations. In contrast,
secondary GBMs, comprising only 10% of total GBMs, arise from a lower-grade
precursor lesion and usually carry TP53 and IDH1 mutations in more than two thirds of
cases. Other common genetic alterations of secondary GBMs include allelic losses on
19q and 13q, promoter hypermethylation of the RB1 gene, and overexpression of
PDGFR-A (reviewed in [6]). Taken together, these data clearly indicate that primary and
secondary GBMs represent genetically different diseases yet both share similar
histological feature [14] and while this characterization has not been shown to have an
association with prognosis, it has been exploited in developing more targeted therapies
[13].
This discovery of genetically associated subtypes for GBM has prompted even
more sophisticated analyses that have uncovered more altered genes and pathways likely
contributing to tumor behavior. Of note is The Cancer Genome Atlas (TCGA) Research
Network established in 2006 to generate a comprehensive database of genomic
abnormalities in various cancers. Studies derived from information in this database, have
exposed other associations leading to the proposal of additional genetic classes of GBM.
One particular study revealed four well-defined genetic subtypes of GBM: Proneural,
Neural, Classical, and Mesenchymal. These subtypes are characterized based on the
following genetic profiles: Classical is associated with EGFR overexpression, PTEN loss,
and to a lesser extent chromosome 9p21 deletions targeting p16INK4a and p14ARF;
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Mesenchymal with NF1; Proneural with PDGFRA, IDH-1, and TP53 mutations; Neural
with the presence of neuronal markers such as NEFL, GABRA1, SYT1, and SLC12A5
(Table 1-2). Other defining features of these subtypes include differences in responses to
standard therapies with the greatest response seen in Classical GBM and no benefit seen
with Proneural subtype. On the other hand, the classical subtype is usually associated
with increased age, a known negative prognostic factor while Proneural tumors are
associated with younger age [15].
This and subsequent studies prove that gene expression-based grouping of tumors
can be a more powerful prognostic and predictive factor than histologic grade or age by
revealing unrecognized heterogeneity of histologically similar tumors. Even newer class
subtypes are being uncovered that not only seek to determine differences in expression of
individual gene mutations, but also, groups of genes to identify pathways that may be
dysregulated in a specific tumor type. One such study has shown the enrichment of gene
subsets that merge onto targets such as NFkB1 and EGFR [16-18].
Importance of Chromosome 9 and IFN
One pathway that has been studied for its role in tumorigenesis is the IFN
pathway. In the early 1990s the hunt for tumor suppressor genes increased as many
searched to uncover genes associated with deleted chromosomal material in a number of
tumors. One particular deletion occurred on chromosome 9 and was found to be
associated with multiple primary tumors and cell lines such as malignant human T cell
lines, ALL, and melanoma [19-21]. Early on, the genetic material lost or affected was
thought to be the interferon (IFN) gene cluster as it is located on the commonly deleted
region of the short arm of chromosome 9, 9p21. One of the first studies looking at the
relationship between cancer and chromosome 9 deletions included a study by Collins et
al 1991 that revealed deletions of 9p were found most likely in high grade tumors and
further mapping revealed the locus to involve IFN/ [22]. This was confirmed by
subsequent studies that showed a prevalence of IFN gene deletions and/or sequence
rearrangements in human glioma cell lines and high-grade primary and recurrent tumors
[23, 24].
Others proposed that the IFN gene clusters may be affected due to their proximity
to another gene whose function could be important in tumorigenesis. After the discovery
of p16/ink4a an inhibitor of pRb phosphorylation through negative regulation of cyclin
D/cdk4 [25] and its location on chromosome 9 [26] the focus shifted from IFN to
p16/ink4a as a culprit of malignancy in a number of GBM tumors [27-30]. In fact, more
recent studies based on TCGA database confirm that the classical subtype of GBM which
harbors mostly EGFR mutations also expresses deletions of 9p21 targeting p16/INK4a
and p14ARF [15]. These two mutations occur simultaneously in 94% of GBMs tested.
Despite p16’s correlation with chromosome 9 deletions, we still know that IFN is
affected and that defects in the IFN pathway provide a survival advantage over normal
cells. Many therapies have been developed exploiting either the growth inhibitory
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Table 1-2.
Chromosomal aberrations significantly associated with molecular
subtypes of glioblastoma multiforme
Chromosomal
Aberration*
7p11.2 
7q21.2 
7q31.2 
7q34 
7p11.2 
4q12 
17q11.2 W
10q23 W
9p21.3 W
13q14 W
9p21.3 

Gene
Affected
EGFR
CDK6
MET
EGFR
PDGFRA
NF1
PTEN
CDKN2A/
CDKN2B
RB1
CDKN2A/
CDKN2B

Classical

GBM Subtype
Mesenchymal Neural§



Proneural



















*= Low level amplification; = High level amplification; W = Hemizygous deletion;
= Homozygous deletion
§
Neural subtype is significantly associated with presence of neuronal markers, not
specific chromosomal aberrations.
Source: Verhaak, R, K. Hoadley, E. Purdom, V. Wang (2010). Integrated genomic
analysis identifies clinically relevant subtypes of glioblastoma characterized by
abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17: 98-110 [15].
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actions of IFN on tumor cells or the inability of tumor cells to produce protective IFN
responses. Heymann et al demonstrated a correlation between changes in genetic
material and IFN bioactivity in malignant T cell lines showing that several cell lines with
normal dosage of IFN genes had deficiencies in producing IFN or in IFN sensitivity [20].
Experimental Therapies for GBM
Though cure is the ultimate goal, with a median survival of only 12-15 months
post-diagnosis, therapies for GBM that are able to prolong progression free survival
(PFS) with a high quality of life are warranted. There are a number of studies occurring
at various stages of the drug approval process that are aimed at doing just this (Figure
1-2). These not only involve experimental therapies that exploit newly defined genetic
characteristics of GBM, but they also involve the search for more efficient methods of
administering existing chemotherapeutic agents. Because GBM is a “local” disease in
that there have been very few confirmed instances of extra-axial metastases, possibly due
to short survival times post-diagnosis, improved methods of local administration are
being developed [31-33]. Gliadel, a carmustine (BCNU)-containing implantable
degradable polymer wafer, is FDA approved as an adjuvant treatment with surgery and
radiation of newly diagnosed GBM as well as an adjuvant to surgery in patients with
recurrent disease. Its safety was proven in phase I trials and, later, phase III trials
demonstrated an increase in survival by 8 weeks versus placebo wafers. Advantages of
the system include the ability to bypass administering toxic levels of drug needed to cross
the blood brain barrier when carmustine is given systemically therefore preventing side
effects such as myelosupression. On the other hand, wafers have been associated with
increased intracranial pressure caused by malignant edema, seizures, and post
implantation infections [34]. Another example of a local delivery system for GBM
includes Convection-Enhanced [intratumoral] Delivery (CED). This system involves
stereotactically implanted catheters that deliver therapy by high flow infusion over a
specified period of time. Advantages of this system are its ability to pump drug
uniformly through the extracellular matrix over large areas of brain. Catheters can be
placed either within tumors or in the tumor bed after surgical resection. Unfortunately,
CED has been limited to small supratentorial tumors away from the sagittal sinus located
in the midline [35]. Also, in theory, drug distribution should be uniform however
distribution has often been found to be variable and unpredictable with CED delivery
[36]. Nevertheless, a number of chemotherapy agents as well as targeted drugs such as
cytotoxins have been tested using this mode of delivery [37].
Though chemotherapy is an accepted part of the therapeutic regimen for GBM,
the agents are broadly acting and function by damaging DNA in both tumor and normal
cells. On the other hand, targeted therapies work by selectively killing tumor cells
according to differences in expression of genetic pathways and markers. For example, we
know that EGFR overexpression is found in ~50% of GBMs and the receptors are
constitutively active in ½ of these. This path has been shown to be the major genetic
aberration in the classical genetic subtype of GBM and is the major genetic feature of
primary GBM tumors. Therapies that target EGFR have been studied in several Phase
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Figure 1-2. Description of the multi-phase drug approval process
Source: Food and Drug Administration
(http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm)
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I/II trials and include the tyrosine kinase inhibitor, gefitinib, as monotherapy and as
combination with other chemotherapeutic agents [38-40]. These drugs are considered
antitumor therapies as they specifically inhibit the growth of tumor cells through
inhibiting their mitogen-signaling cascade. Unfortunately, results of clinical trials to date
have not shown an increase in PFS or overall survival (OS) in patients treated with EGFR
inhibitors for glioma but they have shown promising results for non-small cell lung
cancer (NSCLC) in Phase III trials and these inhibitors are currently being marketed as
first line of therapy in patients with specific EGFR activating mutations [41, 42]. There
are a number of ways in which this pathway can become overactive in cancer other than
at the receptor binding step therefore, other inhibitors directed against more downstream
signaling factors such as PI3k/akt/mTOR have been developed and are subjects of current
clinical trials including combination therapy with direct inhibitors of EGFR [43, 44].
Immunotherapy, another novel therapeutic strategy for treating GBM, functions
by using the body’s immune cells and signals such as cytokines as cancer fighting agents.
There are two types of immunotherapy, passive immunotherapy and active
immunotherapy. Passive immunotherapy is the application of immunological agents
such as antibodies or cytokines that act against tumor cells without directly activating the
immune system. For instance monoclonal antibodies (mAb) directed against TAAs can
be used as immunotherapy and one such agent has been FDA approved for the treatment
of glioblastoma. Bevacizumab is a human mAb directed against the VEGF ligand, a
major player in the dysregulation of angiogenesis of glioblastomas. This antibody
sequesters VEGF and prevents binding to its receptor on the endothelium. Another
example of passive immunity is the adoptive transfer of immune cells such as
lymphocyte activated killer (LAK) cells or cytotoxic T lymphocytes (CTLs) that are
activated, ex vivo, and then reintroduced to the patient either systemically,
intratumorally, or into the tumor bed after surgical resection. As is the case of LAKs,
these cells undergo cytokine-dependent activation, which is usually non-specific since
cells are never exposed directly to tumor-associated antigens (TAAs). Alternatively,
cells can be activated by exposure to TAAs as occurs with adoptive immunity involving
CTLs which are then re-administered to the patient causing direct cytotoxicity upon
contact with tumor (reviewed in [45]).
Alternatively, active immunotherapy works by stimulating the immune system
against tumor by injecting sources of TAAs such as short peptides, tumor lysates, or
whole tumor cells, or by injecting immune cells such as dendritic cells (DCs) that have
been coupled to and/or activated by TAAs. In a phase I study, DCs pulsed or co-cultured
with autologous tumor lysate were used as an adjuvant vaccine therapy in patients with
newly diagnosed and recurrent glioblastoma after surgery and radiation but during TMZ
treatment. Results showed that median overall survival of vaccinated patients was 31.4
months from time of diagnosis and three year survival rate, 47% compared to the US
average of 14 months and 7.8%, respectively. These results were even more pronounced
in patients with tumors of the mesenchymal subtype, a group of tumors shown to be less
responsive to conventional therapies [46]. An ongoing randomized, multicenter phase III
to be completed in June of 2013 will determine whether this immunotherapy (DCVaxBrain) is effective for newly diagnosed glioblastoma [47].
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Viruses have also been utilized as targeted therapies for GBM. They can work by
introducing genes specifically in tumor cells usually by non-replicating viral vectors;
however, more recent studies have used replicating viruses as vehicles to augment gene
therapy. In non-replicating vectors, genes that are crucial to viral replication are
substituted by a therapeutic gene of interest [48]. Whether by replicating or nonreplicating vectors, possible genes that can be incorporated into the viral genome include
suicide genes, immunomodulators, or tumor suppressors.
A suicide gene is one that codes for an enzyme necessary in the metabolism of a
non-toxic pro-drug to its active, cytotoxic form [49]. One of the most studied examples
is the combination of the Herpes Simplex Virus (HSV) enzyme thymidine kinase (TK)
and the pro-drug form of nucleoside analog antiviral agents such as ganciclovir (GCV) or
valaciclovir (VCV). These pro-drugs are phosphorylated by TK to their toxic form
allowing them to target and kill actively proliferating cells. An example of this
therapeutic regimen includes the conditionally replicative adenovirus AdV-TK with the
antiviral VCV currently undergoing phase II trials in combination with radiation for the
treatment of resectable glioblastoma [47, 48]. Another example of a suicide gene/prodrug combination includes the delivery of a yeast enzyme cytosine deaminase (CD) by
viral vector. This enzyme converts 5-fluorocytosine (5-FC) pro-drug into its active
metabolite, 5-fluorouracil (5-FU) [49]. A therapy using this suicide gene/prodrug
combination is currently being studied in Phase I/II trials for recurrent glioblastoma using
the Toca 511 retroviral replicating vector (RVV) expressing CD [48, 50].
Delivery of immune stimulatory genes has proven to be of importance
considering the notion that the CNS is immune “privileged”. This privilege is based on
the absence of lymph vessels and nodes within the CNS, few antigen presenting cells and
circulating T lymphocytes, as well as presence of the blood brain barrier (BBB), the
gatekeeper of all that moves into and out of the CNS. Specialized immune cells however
do exist within the CNS and include microglia that when active, serve as the brain’s
major APC [45, 51]. Other antigen presenting cells such as dendritic cells are found
hovering around areas associated with breaches in the BBB as in the sub-ventricular zone
(SVZ) until they are activated. Naïve T cells are not found in the CNS [52-54] but are
able to enter when activated peripherally. In GBM patients, the immune system is often
suppressed not only because of therapeutic corticosteroids that aid in minimizing the risk
of mass-effect caused by malignancy-associated edema but also because of higher levels
of immune suppressive cells such as regulatory T cells (T-regs), known to be involved in
self tolerance, and higher levels of immunosuppressive cytokines such as prostaglandin
E2 (PGE-2), TGF- , and IL-10 (reviewed in [55]) [56]. An example of a novel therapy
that promotes anti-tumor responses includes the viral vector, M032, an HSV construct
carrying the IL-12 gene. This cytokine has been shown to trigger T-helper 1 (Th1)
responses that aid in the recruitment of antitumor immune cells such as CTLs and NKs
[57, 58]. Results in preclinical studies demonstrated inhibition of human xenograft brain
tumors and treated animals experience prolonged survival, even when virus was
administered in the hemisphere opposite the implanted tumor. Memory of antitumor
immunity was confirmed by the inability of re-challenge with tumor cells to establish
tumors [58]. A phase I trial is currently underway for the treatment of patients with
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recurrent GBM [59]. Lastly, tumor suppressors, genes that are often muted in tumor cells
on the road to becoming malignant, can be delivered by viral vectors. For instance, the
tumor suppressor p53 is found to be down-regulated in over half of secondary GBMs
[60]. This has been shown to have a negative effect on susceptibility to radiation in these
tumors. Ad-p53 vector is a replication-defective adenovirus vector with a deleted E1
replication gene that is substituted by the p53 tumor suppressor gene. This vector was
shown to increase radiosensitivity of GBM cells in vitro [61]. In a dose-escalation,
multicenter Phase I trial of intratumorally injected Ad-p53, functional p53 protein was
found to be expressed in tumor tissue however transduction of tumor cells was limited,
reaching only to within 5mm of the injection site. This revealed an obstacle encountered
by many of the non-replicating vectors, the issue of widespread distribution [62].
The push for more effective agents with a capacity to propagate through
surrounding tissue turned the attention toward replication competent viruses, many of
which have a natural affinity for replication in tumor cells. As I will discuss, these tumor
selective viruses are broken down into two major categories, those that are naturally
occurring and those that have been genetically engineered to grow preferentially in tumor
cells [63].
Oncolytic Viruses as Novel Treatments for Cancer
Definition and Classification
Oncolytic viruses (OVs) are viruses that selectively replicate in and kill tumor
cells. As a result of this selectivity, normal cells are typically unharmed as infection to
these cells should be minimal. This selectivity is based on various characteristics of both
tumor and virus. Viruses, either by genetically engineered alterations or by natural
ability, are able to exploit cellular defects that promote tumorigenesis in cancer cells.
While these defects offer growth enhancing and survival advantages, they, inadvertently,
weaken defense mechanisms permitting the replication and take over of viruses [64]. As
the virus hijacks the cell’s transcriptional and translational machinery, tumor cells are left
unable to maintain its own growth and eventually die by either apopotosis or tissue
necrosis [65-68].
History
The idea that viruses could be used as therapy for cancer was observed and
documented at the turn of the 20th century when a number of patients were found to have
spontaneously regressing tumors after experiencing acute viral infections [69]. The most
encountered cancer displaying this phenomenon were those of blood lineage however
cases of regression were observed in solid tumors such as cervical carcinoma as well
[69]. Possibly the first recorded account of a case involving viral-induced tumor
regression was discussed during an oral presentation by Dr. George Dock, a Hematology
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professor from the University of Michigan who described a patient with acute leukemia
that was discovered to have experienced a complete, though temporary, remission after a
flu-like illness [70, 71]. Another popular case came from observations made by Dr. de
Pace who presented at the International Cancer Congress in Paris in 1910 his findings
involving a patient with cervical carcinoma who received an attenuated rabies vaccine
after a dog bite and subsequently experienced regression of her tumor [63, 72]. Building
on these observations, a research duo at Sloan-Kettering in New York showed the
potential of oncolytic viruses in vivo first with animal models then in human patients
with the first clinical trial using Egypt 101, a virus thought to be West Nile virus isolated
from sera of infected patients. The trial included patients with cancers ranging from
melanoma to pancreatic adenocarcinoma and results showed that of 34 patients, 4
displayed tumor regression and 27 demonstrated systemic infection, 14 of which viral
replication was observed in biopsied tumor samples [73]. Keeping with the momentum
of these findings, another trial several years later involved 30 patients with epidermoid
cervical carcinomas who received an intratumoral injection of another potential OV,
adenovirus (known at that time as adenoidal-pharyngeal-conjunctival virus, APC).
Results were surprising as 65% of treated tumors had areas of necrosis, with tumor
shedding so extensive that some patients experienced severe hemorrhage (reviewed in
[69]) [74]. Unfortunately, these results were short lived and over half of those treated
died from cancer within a few months of treatment [75, 76].
Other studies were carried out using viruses such as mumps virus (1974) and
hepatitis virus (1949) [77, 78]. Unfortunately, many of these studies brought negative
attention to the field as safety concerns became paramount. Several viruses used, like
hepatitis B virus and West Nile virus, are extremely virulent in humans in their nonattenuated forms. The means by which these viruses were obtained would have been
considered unethical under our current standards. Often, samples for therapy were
derived from infectious body fluids or tissues from patients with active viral infections
(reviewed in [69]). As a result, not only was there a need for more defined standards for
these trials but there was also a need for viral agents that were less toxic in humans. The
1990s brought with it a new age of discovery in molecular techniques such as
recombinant DNA technology while interest in more novel cancer therapies in the
research community grew. A renewed focus developed in the field of oncolytic virology
leading to the use of engineered viral vectors for treatment of cancer. Replicationdefective viruses, including engineered adenovirus and retrovirus vectors, were
evaluated. Unfortunately, these agents carried with them a number of problems including
inadequate delivery and distribution within the tumor mass, and consequently, a lack of
long-term efficacy. A push for effective agents with less toxic profiles has led to studies
using more attenuated forms of replication competent viruses, such as Herpes Simplex
Virus (HSV), Conditionally Replicating Adenoviruses (CRAds), and paramyxoviruses
like Newcastle Disease virus and measles viruses (reviewed in [69]) [70].

13

Examples and Mechanisms of Action
Advantages of OV therapy include the ability to genetically modify or create
“designer viruses” that have enhanced specificity for binding to and replicating in tumor
cells. A unique property of replicating viruses is their individual growth kinetics. Their
ability to replicate and produce viral progeny without re-administering additional virus is
a kinetic advantage not possessed by conventional chemotherapy or by non-replicating
viral vectors [70].
There are a number of viruses that have been and are currently being tested in
both preclinical and clinical studies ranging from DNA to RNA viruses, animal to human
viruses, and naturally occurring to genetically engineered viruses. Each have there own
advantages and disadvantages. For instance, though sequelae of infection by human
viruses such as HSV are well-recognized, the effects on therapy due to pre-existing
immunity can potentially diminish efficacy of treatment. On the other hand, many
animal viruses have come to the forefront as potential therapies and while it is less likely
that humans have come into contact with these viruses, the concern, though unlikely, of
species adaptation causing pandemics as has been seen with swine influenza remains a
consideration [79]. Concerning glioma, viruses from all categories are currently being
considered as potential therapies. As can be expected, the viruses with a longer history of
use in cancer therapy such as HSV and AdV are further along in the clinical trial pipeline
than others, however viruses such as VSV are beginning to emerge as plausible
contenders. A search on clinicaltrials.gov in January 2013 revealed at least 10 ongoing or
completed phase I and II clinical trials of oncolytic virotherapy for GBM using a number
of viruses from HSV to retrovirus (Table 1-3).
Adenovirus
Adenovirus (AdV) is a non-enveloped linear dsDNA virus belonging to the
Mastadenovirus genus of the family, Adenoviridae. AdV is commonly encountered in
the human population especially in children under four years of age, and usually causes
self-limited infections involving the upper respiratory tract, conjunctiva, and, less often,
the gastrointestinal tract [80]. There are over 50 serotypes of AdV with serotype 5 being
the most used as viral based therapies for cancer [81]. AdV is one of the more studied
and understood oncolytic viruses and its ease of recovery and ability to alter virally coded
proteins for tumor targeting serve as advantages of their therapeutic use [82, 83]. CRAds
are engineered adenoviruses that harbor partial or complete deletion of viral genes
unessential for replication in tumor cells.
Onyx-15 is the first adenoviral vector in clinical trials for the treatment of glioma
[84]. This vector lacks E1B-55kD gene, a gene thought initially to function by degrading
cellular p53 therefore making its replication specific for transformed cells that lack p53
activity [85]. However subsequent studies demonstrated that the most likely explanation
for its oncolytic mechanism involves inhibition of intracellular RNA transport [86, 87]. A
number of clinical trials for glioma have been carried out with AdVs. Phase I studies
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Table 1-3.

Current oncolytic viral therapies in clinical trials for the treatment of GBM
Oncolytic
Mechanism:
Viral Factor/
Host Target
E1A deletion/
pRB dysregulation
Fiber knobRGD
motif/ CAR
under-expression

Clinical
Trials.gov
IDa

Delivery
Methodb

Phase TrialStatus

Outcomesc

References

NCT01582516

CED

Phase Irecruiting

Safety of
intervention in
recurrent GBM;
PFS, OS at 6
months

[88-90]

Family:
Adenoviridae
Structure: Nonenveloped
linear dsDNA

E1B-55kDa
deletion/ p53 dysregulation and/or
RNA transport

N/A

i.t.

Phase Icomplete

Intervention
safe at MTD;
Mild antitumor
effect;
4.9 mo median
survival

[84-87, 91]

Family:
Herpesviridae
Structure:
Enveloped
linear dsDNA

Deletion in
ICP34.5 gene/
eIF2a regulated
protein synthesis

N/A

i.c. postresection

Phase Icomplete
Phase IIrecruiting

Phase I:
Intervention
safe at MTD;
3 patients with
PFS of 3 years;
recovered virus
from tumor
Phase II:
Efficacy in adult
with recurrent
GBM

[92-95]

Virus
(Vector)

Characteristics

Adenovirus
(Δ24-RGD)

Family:
Adenoviridae
Structure: Nonenveloped
linear dsDNA

Adenovirus
(Onyx-015)

Herpes
simplex
virus
(HSV1716)
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Table 1-3.
Virus
(Vector)

Continued
Characteristics

Herpes
simplex
virus
(G207)

Family:
Herpesviridae
Structure:
enveloped
linear dsDNA

Parvovirus
(ParvOryx
or H-1PV)


Family:
Parvoviridae
Structure: nonenveloped,
ssDNA


Oncolytic
Clinical
Mechanism:
Trials.gov
Viral Factor/
IDa
Host Target
ICP34.5 deletion/
NCT00028158
eIF2 regulated
NCTprotein synthesis;
00157703
UL39 replaced
(with
with lacZ reporter/
radiation)
decreased neurotoxicity and
increased
sensitivity to
antivirals

Naturally
occurring/ IFN
defects

Delivery
Methodb

Phase TrialStatus

Outcomesc

References

i.t and i.c
postresection

Phase I/IIcomplete

Phase I:
Intervention
was safe at
MTD; modest
increase in OS,
PFS; virus
recovered from
tumor
Phase I/II:
Safety and
effectiveness of
intervention
with radiation

[96-101]

Phase I/IIarecruiting

Safety and
efficacy of
intervention in
progressive
primary or
recurrent GBM;
PFS, OS, and
viral replication
in tumor

[102-107]

NCTi.t + i.c. post01301430
resection
versus i.v +
i.c. postresection
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Table 1-3.
Virus
(Vector)
Newcastle
disease virus
(NDV-HUJ)

Reovirus
(Reolysin)

Continued
Oncolytic
Mechanism:
Viral Factor/
Host Target
Family:
Naturally
Paramyxooccurring/
viridae
IFN defects;
Structure:
PKR and
Enveloped
MxA
negative ssRNA deficiency

Clinical
Trials.gov
IDa

Delivery
Methodb

NCT01174537

i.v.

Family:
Reoviridae
Structure:
Non-enveloped
segmented
dsRNA


NCT00528684

i.t.

Characteristics

Naturally
occurring/
overactive
Ras pathway
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Phase TrialStatus

Outcomesc

Phase I/II- Not Phase I:
yet recruiting Intervention
was safe at
MTD in
recurrent
GBM; 1
permanent
regression
and 2 long
term
survivors
Phase II: PFS
in GBM
Phase I/IIcomplete

Phase I:
Intervention
was safe at
MTD in
refractory
GBM; 1 long
term survivor
at 6 years
Phase II:
results
pending

References

[108-111]

[112-117]

Table 1-3.
Virus
(Vector)
Measles virus
(MV-CEA)

Poliovirus
(PVSRIPO)

Continued
Outcomesc

Oncolytic
Mechanism:
Viral Factor/
Host Target
Family:
H protein of
Paramyxovaccine strain/
viridae
CD46 overStructure:
expression
Enveloped
P and V
negative ssRNA proteins/
Defective IFN
pathway

Clinical
Trials.gov
IDa

Delivery
Methodb

Phase TrialStatus

NCT00390299

i.c postresection only
versus i.t + i.c
post-resection

Phase I/IIcomplete

Safety, PFS,
and antiviral
responses in
recurrent
glioma

[118-123]

Family:
Picornaviridae
Structure: Nonenveloped
positive ssRNA


NCT01491893

CED

Phase Irecruiting

Safety at
MTD in
recurrent
GBM; PFS
and OS

[124-131]

Characteristics

Polio IRES
rhinovirus
IRES/
decreased
neuro-toxicity
Necl-5
(CD155) overexpression
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Table 1-3.
Virus
(Vector)
Retrovirus
(TOCA 511)

Continued
Characteristics

Family:
Retroviridae
Structure:
enveloped
ssRNA

Oncolytic
Mechanism:
Viral Factor/
Host Target
Naturally
occurring/
antiviral
defects
Cytosine
deaminase
insertion
(5FC 5FU)

Clinical
Trials.gov
IDa

Delivery
Methodb

Phase TrialStatus

Outcomesc

References

NCT01156584
NCT01470794

i.t. versus i.c.
post-resection

Phase Irecruiting

Safety at
MTD and
efficacy in
recurrent
GBM; PFS at
6 months

[132-136] [50,
137]

a

Keyword search on clinicaltrials.gov included glioma, glioblastoma, brain cancer, virus, oncolytic virus
CED, convection enhanced delivery; i.t, intratumoral; i.v, intravenous; i.c, intracranial
c
PFS, progression free survival; OS, overall survival; MTD, maximum tolerated dose
b
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with Onyx-15 as adjuvant treatment for recurrent glioblastoma reported the virus to be
well tolerated and safe at the maximum dose, however very little antitumor effect was
observed with a median survival time of 4.9 months similar to the median survival of
untreated patients (reviewed in [138] and [65]) [91]. There have been no additional
clinical trials scheduled using Onyx-015 for GBM. However a modified version of the
Onyx-015, H101, has completed Phase III trials and was approved in 2005 as an adjuvant
therapy for the treatment of head and neck cancers in China. H101, therefore, is the first
oncolytic virus to be marketed for clinical use worldwide [139].
24-RGD is another CRAd being studied as a potential therapy for GBM. It is a
genetically engineered vector that harbors a partial deletion of 24 base pairs in its E1A
gene. This deletion decreases its ability to bind to pRb so replication is permitted in cells
with pRb defects. Coxsackie adenovirus receptor (CAR), is a well known cellular
receptor of many AdV serotypes and its expression has been found to be very low on
tumor cells including glioma [140-142]. In order to bypass the need to interact with
CAR, an alternative binding strategy used by a number of adenoviruses was inserted into
the 24-RGD. The addition of the Arg-Gly-Asp (RGD) motif, known to interact with
cellular v integrins, into the adenovirus fiber knob allowed this CrAd to maintain
tropism in glioma cells in a CAR-independent fashion [88, 143]. In vivo testing of
human glioma xenografts treated with 24-RGD showed complete tumor regression in 9
of 10 treated mice and increased survival in all treated mice. These results were even
more pronounced when viral treatment was preceded by tumor irradiation [89]. A phase
I trial studying 24-RGD in patients with recurrent glioma using convection enhanced
delivery is ongoing [90].
Herpes simplex virus
HSV is an enveloped, linear dsDNA virus of the family, Herpesviridae. Primary
infection with HSV ranges from asymptomatic to gingivostomatitis. It is known that
HSV possesses a neurotropic phenotype, therefore, after initial infection, virus migrates
through nerve endings to cranial ganglia where it remains latent. Recurrent infections
can manifest in a number of ways from perioral “fever” blisters, conjunctivitis, and Bell’s
palsy, to more serious infections such as encephalitis. HSV prevalence is high, with
~90% of the population demonstrating seroconversion [144].
There are several advantages to using HSV as an oncolytic therapy. It has been
shown that HSV genes associated with neurovirulence are different from those having
oncolytic properties which provides a means of genetic manipulation to create more
oncolytic but less neurotropic viral vectors. In addition, because of its sensitivity to antiviral drugs such as VCV and GCV, a naturally built-in safety mechanism can be used as
precaution for uncontrolled HSV infection. Several disadvantages of HSV oncolysis
include low production of viral progeny per cell as well as the high prevalence of
previous infection in the adult population (reviewed in [83]).
The first example of an HSV oncolytic virus is HSV1716. It is a null mutant of
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the gene coding for 34.5 (ICP34.5), a virulence factor whose absence results in selective
replication in dividing cells [92]. During viral infection, products of gene replication are
sensed by double-stranded RNA- dependent protein kinase R (PKR) that, in turn,
phosphorylates eIF2 into its active form, serving as an off switch of cellular protein
synthesis. ICP34.5 deactivates eIF2 by encouraging its dephosphorylation therefore
allowing protein synthesis to continue. Without ICP34.5, normal cells can stop protein
synthesis in the presence of viral infection. Cells harboring defects in PKR or PKR
related signals, such as the case with ras deregulated tumor cells, have unopposed protein
synthesis in the presence of virus, allowing tumor selective replication [93, 145]. Several
clinical trials have been carried out using HSV1716 including those looking at safety of
intratumoral (i.t.) injection pre-resection and intracranial injection post resection. All
trials demonstrated safety at the maximum dose without signs of neurotoxicity, a major
concern with HSV related therapies. Additionally, three patients experienced over 3
years PFS and biological endpoints confirmed replication in tumor samples post-injection
[94]. Phase II studies are currently being prepared in Europe using HSV1716 (Seprehvir)
however no results have been reported to date [95].
Another HSV-based OV currently being evaluated in clinical trials is G207. This
virus harbors two separate genetic alterations, one being a deletion in the ICP34.5 coding
gene, RL1. The other alteration includes the silencing of the UL39 gene by insertion of
LacZ. UL39 is a gene that encodes a subunit of the viral ribonucleotide reductase (ICP6).
Inactivation of this gene not only increases HSV susceptibility to antivirals such as GCV
and VCV but also dampens its neurotropic phenotype, resulting in a virus unable to cause
encephalitis. Alterations in this gene, therefore, improve the safety profile of G207 over
wildtype [96-98]. Previous phase I trials tested G207 by administering therapy in 2
stages, 13% of dose was given by stereotactic injection and the remainder several days
later at time of resection. Results confirmed G207 to be safe with no signs of
neurotoxicity at maximum dose. Median time to progression was 3 months, with median
overall survival of 23 months post-diagnosis, approximately 7 months after viral
inoculation. One patient experienced more than 5 years PFS, and this patient was found
to have the highest viral load present in tumor samples collected at resection [99, 100,
146]. Another Phase I trial was completed to determine synergistic effects of
intratumoral G207 with either focal radiation or gamma knife surgery. No results have
been published to date [101].
Parvovirus
Another DNA virus, newer in the clinical trial network for GBM, is parvovirus
(Parvo), a small non-enveloped single-stranded DNA rodent virus surrounded by an
icosahedral capsid. It is a member of the Parvoviridae family and represents a group of
autologous parvoviruses that are able to replicate in and lyse tumor cells by several
mechanisms. First, they are able to replicate more efficiently in transformed cells as
these cells, with their high proliferative rate, provide active factors important in DNA
synthesis and transcriptional machinery. These factors are crucial in the processing of
Parvo replicative forms (RF), which are dsDNA formed during self primed DNA
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synthesis and contain both parental and newly synthesized DNA strands [102, 147].
Parvo is also able to inhibit IFN responses of transformed cells even after exposure to
IFN inducers such as polyI:C by preventing the activation of specific pattern recognition
receptors [103]. Advantages of oncolytic parvo include its nonpathogenic phenotype in
humans, usually only causing asymptomatic infection, unlike its relative, parvovirus B19.
It has been shown to elicit viral replication in brain tumors following systemic
administration, and replication is restricted to proliferating tissues. On the other hand,
difficulty of producing large quantities of parvovirus by co-transfection in helper-free
virus-producing cells along with its immaturity in clinical trials threaten to limit its
oncolytic potential (reviewed in [148]).
The most studied parvovirus for treatment of glioma includes the naturally
occurring virus, H-1PV (ParvOryx). Preclinical studies have demonstrated its ability to
infect glioma cells with strong cytotoxic effects [105, 149]. In vivo experiments using a
rat glioma model, following either a single i.t. injection or multiple i.v. injections of
ParvOryx, results showed tumor regression, a significant increase in survival, and
evidence of viral presence in brain tumors confirming its ability to cross the BBB after
systemic administration [106]. An ongoing Phase I/II trial of ParvOryx in patients with
progressive primary or recurrent tumors is coming to a close and has been focused on
determining safety and MTD in groups receiving either an initial i.t. or i.v. injection both
followed by injection to post-resection tumor bed. These results will be the first of any
trial evaluating a parvovirus in patients with recurrent GBM [107].
Newcastle disease virus
In addition to DNA viruses, there are a number of RNA viruses that are being
considered as treatment for GBM and are currently in varying stages of clinical trials.
These include both naturally occurring and genetically engineered RNA viruses.
Newcastle Disease virus (NDV) is an avian paramyxovirus of the order,
Mononegavirales, therefore it characteristically contains a negative-sense ssRNA genome
which codes for pleiomorphic viral particles. Though NDV is primarily a disease-causing
agent of fowl, it has a broad host range and has been shown to infect cells of other
species including murine and human cells [150]. Two naturally occurring, nonengineered strains of NDV have been studied in Phase I clinical trials for glioma, NDVHUJ which is non-pathogenic in avian hosts (lentogenic), and the moderately pathogenic
(mesogenic) MTH68/H strain. Their mechanism of oncolysis has been attributed to the
ability to exploit interferon defects in tumor cells (reviewed in [63]). Several studies have
been geared toward improving their oncolytic activity through genetic manipulation of
NDVs anti-IFN genes allowing for robust IFN production in normal cells leaving IFN
defective tumor cells vulnerable to viral infection [108].
Advantages of NDV oncolytic therapy include its safety profile when given
intravenously. Because its natural host is avian, there is no pre-established immunity to
virus in humans. NDV is a naturally occurring oncolytic virus and produces large
numbers of progeny per infected cell. Disadvantages to therapy include the risk of species
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adaptation and its high mutation rate, a characteristic of all RNA viruses [83]. Phase I
trials have been completed using the NDV-HUJ strain in patients with recurrent GBM.
NDV-HUJ is a gradient purified virus derived from an attenuated vaccine strain [109].
Patients received daily i.v. injections, 5 days/week until one year of tumor progression
was observed. Results showed virus to be well-tolerated with no signs of toxicity other
than transient fever associated with infection. One patient displayed complete but not
permanent regression while this patient and 2 others experienced long term survival,
living approximately 15 months with recurrent disease after viral treatment [109, 138]. A
phase II trial of NDV-HUJ in recurrent glioma is ongoing and has extended the use of
oncolytic treatment to sarcoma and neuroblastoma patients as well [111].
Reovirus
Reovirus is a non-enveloped virus with a segmented, dsRNA genome. It is of the
family, Reoviridae, along with its relative, rotavirus, an important enteric virus causing
substantial disease of the gastrointestinal tract in humans. Reovirus, on the other hand,
causes milder GI symptoms, which usually resolve without intervention [151]. It is a
naturally occurring oncolytic virus whose oncolytic activity stems from its ability to
exploit cells with overactive ras or ras- signaling [112, 113]. In many cancer cells,
upregulation of ras confers a resistance to cell death; however, this results in inhibition of
active PKR, responsible for cellular protein shut off during viral infection [64, 112].
Advantages of reoviral therapy include its safe profile when administered in the brain
[114], its naturally occurring anti tumor activity through cell specific mutations to ras
signaling, its high progeny: cell ratio, and the fact that all genes in the viral genome have
known functions. Disadvantages to therapy include pre-immunity in the human
population and its high rate of mutation during replication cycles (reviewed in [83])
[115]).
In preclinical studies, reovirus was found to inhibit growth of ipsilateral tumors in
immunocompetent glioma rat models despite the presence of pre-existing immunity.
Virus safety was also confirmed in non-human primates by the lack of significant toxicity
following intracranial inoculation [114]. Reolysin, the non-attenuated Type 3 Dearing
strain of reovirus, has been tested as an adjuvant therapy in phase I trials at doses ranging
from 107-1010 in patients with refractory GBM. Results showed treatment to be well
tolerated and safe at the maximum dose delivered. Median survival was 21 weeks with
one patient still living at six years post treatment according to latest updates [116, 138].
Phase II of this series has been completed using the highest dose reached from phase I
however no results have been published to date [117].
Measles virus
Measles virus (MV) is an enveloped, negative strand RNA virus belonging to the
Morbillivirus genus of the family, Paramyxoviridae. It is known to be a highly infectious
human pathogen transmitted by respiratory droplets from infected individuals. Flu-like
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symptoms usually occur within 10 days and progress to the characteristic maculopapular
rash. Small white lesions called Koplik’s spots can often be seen on the buccal mucosa
before the development of rash [152]. With the advent of vaccination programs for
prevention of the spread of measles, endemic transmission has been eradicated from the
Americas since 2002 though outbreaks continue to occur worldwide [153, 154].
The replication cycle of measles involves binding of viral haemagglutinin (H)
protein to a predominantly B and T lymphocyte receptor, SLAM (signaling lymphocyticactivation molecule) [118]. Attenuated forms of MV such as that derived from the
Edmonston B vaccine, predominantly bind to CD46, a complement-regulatory protein
[119] important in the protection of cells against complement-mediated lysis. Cells
independent of SLAM and CD46 signaling, specifically those of epithelial origin, have
been shown to use Nectin4 for receptor activity during MV infection [155, 156]. As
such, both CD46 and Nectin4 are often overexpressed in tumors, with CD46 shown to be
overexpressed in glioma [157-161]. By targeting tumor specific overexpression of MV
specific receptors, measles virus can be considered a naturally occurring oncolytic virus.
MV-CEA is an example of an attenuated strain, which has been genetically engineered to
express human carcinoembryonic antigen (CEA). CEA is a tumor marker highly
expressed in cancers ranging from colorectal to pancreatic carcinomas, however CEA
overexpression has not been observed in gliomas. For this reason, its presence in sera of
patients infected with the MV-CEA construct serves as a monitor of viral gene expression
[120]. Advantages of measles therapy include its wide host range and ability of
attenuated virus to selectively replicate in tumor cells based on naturally acquired
mutations in the viral attachment protein [115]. Attenuated strains are considered to have
preferred safety profiles based on the extensive history of their use in vaccination
programs that have improved morbidity and mortality worldwide [83]. On the other
hand, despite altered attachment proteins, virus may still be able to bind to CD46 and
SLAM on normal cells. This serves as a disadvantage in using measles virus as a cancer
therapy since SLAM signaling during measles infection has been shown to facilitate
transient immunosuppression [162]. In addition, much of the population has been
vaccinated against the virus therefore strong immune responses directed against the H
protein may be experienced [152]. Lastly, as with replication of most RNA viruses,
measles has a high mutation rate due to the error-prone RNA-dependent RNA
polymerase that could potentially alter selectivity during treatment.
In vitro experiments with MV-CEA have demonstrated strong antitumor effects
against glioma cells, which have translated into antitumor activity in subcutaneous and
orthotopic U87 glioma animal models. Further in vivo studies of MV-CEA in an
orthotopic glioma model in macaque monkeys found the vector to be safe, causing no
neurotoxicity when given intracranially [122]. An ongoing phase I trial is evaluating
safety and MTD of MV-CEA following i.t. injection versus i.t. injection administered
post-resection in patients with recurrent glioblastoma. There have been no reported
preliminary results however the study will tentatively be completed by June 2013 [123].
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Poliovirus
Another RNA virus being considered as therapy for GBM is poliovirus, a
pathogen notorious for causing disease worldwide before the launch of a global initiative
in the 1980’s resulted in its eradication from the Americas in 2002 [163]. Poliovirus
(polio) is a non-enveloped +ssRNA enterovirus belonging to the family, Picornaviridae
[164]. Polio is transmitted by fecal-oral route and usually causes asymptomatic infection
in the majority of cases. In instances when virus is not cleared, polio can spread through
the blood to other sites including the CNS. Because polio is naturally neurovirulent,
destruction of motor neurons can cause poliomyelitis manifesting as flaccid paralysis that
may lead to death if control of respiratory function is affected [124]. As an RNA virus,
the replication cycle occurs exclusively in the cytoplasm of host cells. Polio genome
characteristically includes an important segment of RNA known as the internal ribosome
entry site (IRES) from where one open reading frame initiates coding of a large precursor
polypeptide that is further cleaved into the virus’s eleven proteins [115, 164].
There are several important components to polio’s oncolytic activity, the first
involving its cellular binding receptor, CD155 (or Necl-5) [124]. Necl-5 has been shown
to be over-expressed in a number of tumor cells including cancers of glial, breast, and
hepatocellular origin [125, 165]. The other component of polio’s oncolytic activity
involves the manner in which the virus is able to recruit host cell machinery for its
benefit. Polio uses a 5’cap independent protein translation mechanism so during its
replication cycle, the virus must seize host cell machinery in order to form new viral
progeny. This is done through the actions of 2A protease (2Apro), which is able to
cleave the scaffold (eIF4G) connecting eukaryotic mRNA 5’cap to ribosomes. These
cleaved scaffold fragments are then free to aid in linking the polio IRES to cellular
ribosomes for its own translational benefit. This takeover subsequently leads to
inhibition of translational dependent antiviral responses and rapid cytopathic effects can
be detected as soon as 2-3 hours post-infection [126].
Many cancers with their increased need for protein synthesis in order to maintain
their uninhibited growth have been shown to have cap-independent translation
mechanisms [166]. Along with this independence, some tumor cells appear to have less
control over recruitment of ribosomes to viral RNA as a number of cellular proteins
involved in seizing viral genomes are mislocated to the nucleus and not in the cytoplasm
where viral replication actually occurs [167]. In addition, several studies have shown that
inhibitors of many deregulated mitogen pathways in cancers such as EGFR, which are
known to be interconnected with eIF4G, decrease poliovirus translation and cytotoxicity
in GBM cells [168]. This serves as another example of how deregulation of pathways
during tumorigenesis affects susceptibility to viral infection.
The construct used in preclinical and clinical studies is the PVSRIPO. In order to
minimize neurovirulence in normal CNS, the poliovirus IRES is exchanged for the IRES
present in human rhinovirus type 2 (HRV2), a known pathogen of the human respiratory
tract. The resulting construct is a polio/rhinovirus chimera known as RIPO. PVSRIPO
was derived from using an attenuated Serotype 1 Sabin vaccine poliovirus instead of
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wildtype virus [128, 169]. Advantages to poliovirus cancer therapy include its ability to
be easily engineered especially in manipulating genes known to contribute to
neurovirulence. The neuro-attenuated construct, PVSRIPO, quickly kills cells with
accelerated growth rates such as transformed cells [129]. Disadvantages include the
extensive patient population that have already been immunized against polio however
preclinical studies have revealed that oncolysis is not decreased by pre-existing immunity
in animal models [124, 130]. Also, its error-prone RNA-dependent RNA polymerase has
been shown to cause revertants implicated in poliomyelitis following vaccination. By
using the PVSRIPO construct with replacement of polio IRES, the known target for
mutation in revertants, the chances of this occurring is unlikely [170]. A phase I trial is
currently evaluating the use of PVSRIPO administered by CED in patients with recurrent
glioma. Outcomes to be determined include safety, maximum tolerated dose,
progression-free survival and overall survival [131].
Retrovirus
The last virus being considered in clinical trials for the treatment of GBM are
retroviruses, which are enveloped ssRNA virus of the family Retroviridae. This family
of viruses has until recently been a less popular alternative for replicating viral therapy
against brain tumors as it defies several important characteristics of other OVs. First, an
important feature of retroviruses, particularly replicating retroviral vectors (RVVs) is
their unique replication cycle. In order for replication of the RNA genome to occur, the
retrovirus carries with it a reverse transcriptase that synthesizes a DNA replication
intermediate from its RNA genome. The intermediate is integrated into the host cell
genome for subsequent transcription and translation using the host cell machinery. A
property of oncolytic viruses, as the name implies, is their ability to lyse tumor cells.
RVVs however are non-lytic, a direct result of their need to integrate into the host
genome (reviewed in [83]). Integration is also known to be an important feature of
retroviral-induced tumorigenesis.
Approximately 11% of human cancers are caused by viral infections.
Malignancies, such as lymphoma and sarcoma, have been associated specifically with
retroviral infection [171]. Insertional mutagenesis has also proven to be an issue in
previous gene therapy trials using replication defective retroviral vectors. For instance,
clinical trials for several X-linked immune diseases such as Severe Combined
Immunodeficiency (SCID) and Wiskott-Aldrich Syndrome (WAS) resulted in
development of acute T lymphoblastic leukemia (T-ALL) after DNA intermediates
integrated into the host genome in close proximity to proto-oncogenes [132, 172-174].
Therefore, the use of these viruses to treat cancer may appear to be more of a risk than a
benefit.
As we know, however, there are a number of advantages to retroviral therapy.
First, RVV constructs, particularly those being considered for treatment of glioma, have
two mechanisms of targeting tumor cells; they are selective for dividing cells as they do
not contain nuclear localization signals necessary for active nuclear uptake in quiescent
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cells [133, 175] and they selectively replicate in cells harboring defects in their antiviral
responses. RVVs are less immunogenic in the CNS where virus-infected cells have been
shown to escape antiviral responses [176]. As a consequence of integration into the host
genome, RVVs maintain a persistent infection in tumor cells, which act as a storage for
virus that can be called upon to replicate at later times [83, 134, 175].
The most studied retrovirus for treatment of cancer is the simple
gammaretrovirus, amphotropic murine leukemia virus (A-MLV). Derived from this
prototypical retrovirus is the construct Toca511, which has been genetically engineered to
express the yeast enzyme, cytosine deaminase (CD) that converts the anticancer pro-drug
5-fluorocytosine (5-FC) to its active form, 5-fluorouracil (5-FU). Toca511 is the most
used construct in preclinical and clinical trials for GBM and is a great example of an OV
that functions by a suicide gene/pro-drug combination [56, 135]. Preclinical studies
using an orthotopic mouse GBM xenograft model demonstrated survival of 90% of
treated mice at ~100 days post-infection versus 40 days in controls [133]. In two
different syngeneic immunocompetent mouse GBM models (CT26 in BALB/c mice and
Tu-2449 in B6C3F1 mice), survival was significantly increased in BALB/c mice from
30.5 days in controls to >90 days and from 33 days to > 180 days in B6C3F1 mice.
Subsequent rounds of 5-FC pro-drug prolonged survival even without having to
administer more retrovirus proving its stability after incorporation into the host genome.
Even before the last cycle of pro-drug, tumors shrank until they were no longer detected
microscopically [134]. Until recently, only one phase trial has been performed using a
retrovirus for treatment of GBM. This phase III trial, unfortunately, was unsuccessful
most likely due to the use of a replication defective construct [136]. There are two
ongoing phase I trials evaluating replication competent Toca 511 for the treatment of
recurrent high-grade glioma using either intratumoral injection followed by
administration of 5-FC [50] or post-resection injection followed by 5-FC [137]. The
study is planned to complete in December of 2013.
Future of Oncolytic Therapy: Challenges to Overcome
As more oncolytic viruses are considered for use in cancer therapy, several
important challenges in achieving optimal efficacy will need to be addressed as they have
proven to be a barrier in moving therapies through the clinical trial pipeline (Figure 1-3).
The first challenge is that of finding the most effective delivery of treatment in order to
maintain tumor cytotoxicity. This challenge is not necessarily unique to OV therapy, as a
number of problems exist with the administration of chemotherapeutic agents, which
have led to more experimental methods for administering treatment such as CED or
polymer wafers. One method of delivery for OV therapy includes single or multiple
intratumoral injections. Tissue analysis following injection often shows very little spread
of virus within the tumor mass with most virus concentrated near the injection site [177].
Aside from high interstitial pressure exerted by tumor mass [178], the unique tumor
microenvironment often plays a significant role in impeding the spread of virus. This
microenvironment is composed not only of surrounding tumor, normal brain, and
patrolling inflammatory cells but also players in promoting angiogenesis, growth factors,
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Figure 1-3. Challenges of oncolytic viral therapy
Oncolytic viruses encounter a number of obstacles in achieving therapeutic efficacy.
These include uptake and ultimately clearance by immune mediated cells in the systemic
circulation as well as neutralization by viral specific antibodies. The tumor
microenvironment can also serve as a hindrance to viral oncolysis. For instance,
increased pressure secondary to tumor mass and associated inflammation impede the
intratumoral infusion of virus. Elements of the extracellular matrix such as collagen may
also prevent migration by sequestering virus before it reaches tumor.
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and components of the extracellular matrix (ECM). Collagen, a major component of the
ECM, forms protein networks that act as physical barriers to viral penetration often
sequestering virions before they can reach less superficial tumor cells. Several OVs have
been developed that express genes specific for combating this barrier such as a
replication restricted adenovirus expressing collagen cleaving proteins, matrix
metalloproteinases (MMPs) [179]. Co-treatment of OV with collagenase has been shown
to be effective as well [180].
Just as intravenous administration of chemotherapies result in suboptimal delivery
due to the blood brain barrier along with drug metabolism and clearance (reviewed in
[181]), OV therapy can be hindered also by the same factors (reviewed in [182, 183]).
Intravenous administration exposes virus to circulating cells and factors of systemic host
immunity that further inhibit therapy. Though an extremely convenient method as it does
not require an invasive procedure for administration, i.v. delivery often causes premature
neutralization of virus even before virus is able to reach its target [184, 185]. These
antiviral responses are also associated with morbidity in patients as seen by fever, altered
mental status, and other signs and symptoms encountered in a number of OV trials [65,
184, 185]. Exposure to the immune system is one of the most vexing challenges faced by
viral therapy as it can be both a benefit and impairment to treatment. Unfortunately,
preclinical studies have not always been designed in a way to completely understand the
involvement of the immune system in OV therapy. Many preclinical studies have
utilized immunocompromised animal models to show proof of principle of viral therapy
in human-derived tumors [86, 186]. As we have seen, though antitumor effect is
significant in these models, this often does not translate into tumor shrinkage in human
trials. Though the immune system can be suppressed in glioma patients, immunity still
has an effect on therapeutic efficacy of virus when given intratumorally and systemically.
In a preclinical study using an immunocompetent animal model of metastatic lung cancer
to evaluate vesicular stomatitis virus (VSV) as cancer therapy, neutralization of i.v.
administered virus by circulating antibodies was shown to eliminate delivery of
unshielded “naked” virions to tumors [65, 187]. Several studies have tested a number of
methods for circumventing the immune system. One method uses a “cloaking device”
which coats virus with chemical conjugates preventing binding of complement and/or
uptake by immune cells [188]. Temporarily ablating the immune system is another
option and several studies have looked at simultaneous administration of
immunosuppressing agents. Cyclophosphamide (CPA) is a multifunctional nitrogen
mustard alkylating agent used as an anticancer drug and in the prevention of graft versus
host disease. Its immunosuppressive activity has been shown to be caused by the ability
to deplete proliferating lymphocytes [189-192]. Rapamycin is another
immunosuppressant that works by inhibiting mTORC1, a pro-tumor signaling pathway
found to stimulate innate immune responses through type I IFN. It has been shown in a
number of preclinical trials to increase viral replication and positive outcomes when
given in combination with OV therapies such as VSV, myxoma virus (Myxv), and
vaccinia virus (JX-594) [177, 193, 194].
An even more novel approach involves shielding virus from the immune system
through the use of cellular vehicles. Many different cell types have been used as cell
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carriers and include T lymphocytes, mesenchymal progenitor cells, and neural stem cells
all showing an affinity for growth within tumor or for the tumor microenvironment.
These cells are usually infected, ex vivo, and readministered systemically for viral
transport. Upon infection, viruses can be transported by adhering to the surface of carrier
cells, as has been shown with retroviral vectors. Adherence to the surface, however,
eliminates the ability of the cell carrier to amplify viral dose through active viral
replication [195]. Virus can also be transported to sites of tumor by using cells
permissive to viral replication. This allows the cell to serve as a viral factory increasing
the amount of virus while en route [187, 196-199]. Autologous tumor cells are currently
being evaluated for their use as viral carriers. Host derived tumor cells, the actual targets
of OVs, instinctively home to sites of pre-existing cancer. They are highly permissive to
viral replication and are able to increase original dose of virus by the time they reach the
tumor site (Figure 1-4). In a syngeneic model of lung cancer in immunocompetent
animals, i.v. administration of 106 tumor cells infected with VSV at a multiplicity of
infection (MOI) of 10 were able to amplify viral dose by a 105 at 24 hours post infection
versus 102.5 with naked virions [187]. Though this method has sparked some controversy
based on existing safety standards and the possibility of seeding tumor in other locations,
preclinical results have been promising and in comparison to naked viral therapy in the
face of pre-existing immunity, virus-carrying cells were shown to substantially improve
survival in animals with established lung tumors, with majority of animals surviving
>100 days post-treatment [65, 187].
Another method for increasing tumor cytotoxicity includes increasing immune
responses that are directed against tumor antigens. Gliomas are known to be
immunogenic as they possess a number of tumor-associated antigens (TAAs) that can
elicit immune responses triggering the influx of various immune cells within and
surrounding tumors. Just as we have seen with viruses, tumors often develop ways to
evade immune surveillance and responses either by secreting immunosuppressive
molecules that dampen immunity (i.e. TGF which has been found to upregulate
regulatory T cells) [200-202], by shielding TAAs from patrolling immunity, or by the
dysfunction in mechanisms involved in immunological activation [203].
Oncolytic viruses can ignite otherwise weak antitumor immune responses. A
phase I trial of the HSV construct, G207, for recurrent GBM demonstrated the ability of
this OV to increase glioma-infiltrating immunocytes (GIIs) in treated patients [99, 138].
Viruses can also be used to modify tumor cells making them more detectable to the
immune system. By using autologous tumor cells as vehicles, the same method that
provides an advantage of shielding virus from adaptive immune responses, virallymodified tumor or viral oncolysate have been shown to also induce an immune response
against unmodified tumor cells from which they are derived. Several tumor models have
tested this feature using a variety of viruses ranging from influenza, vaccinia, and NDV
[204] for treatment of a number of cancers such as melanoma and glioma. A phase II
study initiated in 1975 using NDV oncolysate as a post-surgery adjuvant vaccine in
patients with AJCC stage III melanoma has shown a >55% survival rate at 15 years from
vaccine administration. By analyzing the immune repertoire of surviving patients, an
increased CD8+ T cell subset representing terminally differentiated effector cells based
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Figure 1-4. Carrier cell strategy
Outlined procedure involved in isolating autologous tumor cells from primary tumor
mass and using cells as infected vehicles for the delivery of oncolytic viruses
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on their heightened ability to produce TNF- and IFN- were associated with antitumor
effect and survival [205]. A more recent Phase I study in 2004 tested the use of irradiated
autologous tumor cells as carriers for recombinant Newcastle disease virus (rNDV) as
treatment for GBM. Results showed OS of 100 weeks versus 49 weeks in controls with
39% two year survival versus 11% in untreated. Increased immune activity directed
against tumor was observed in vaccinated patients by an increase in CD8+ tumor
infiltrating lymphocytes (TIL) and memory T cell reactivity (demonstrated by IFN-
ELISPOT assay) [206]. As demonstrated, these key inflammatory responses are crucial
to long-term survival and anti-tumor activity even after virus has been cleared [45]. More
studies will be needed to further evaluate this method of delivery however preliminary
results are promising.
Vesicular Stomatitis Virus
Characterization
In addition to the previously mentioned viruses that have been or are currently
being evaluated in clinical trials for GBM, there are a number of up and coming viral
agents that have shown promise in preclinical animal studies as well as in clinical trials
for a number of other cancers. One such agent is vesicular stomatitis virus (VSV). VSV
belongs to the order, Mononegavirales, an order of characteristically enveloped viruses
possessing non-segmented negative sense, single stranded RNA (NNS RNA) genomes.
Included in this order are the families Paramyxoviridae, Bornaviridae, Filoviridae, and
Rhabdoviridae (Figure 1-5).
A number of important human pathogens belong to these families and include
respiratory syncytial virus (RSV) of the Paramyxoviridae family, Ebolavirus of the
Filoviridae family, and Borna disease virus of the Bornaviridae family [207, 208]. VSV
is a member of the Rhabdoviridae family, the simplest of Mononegavirales viruses.
Much of what is known about replication and transcription of these viruses has been
determined through studies of Rhabdoviruses particularly, VSV. The two major genera
of rhabdoviruses known to infect mammals are vesiculovirus, of which VSV is the
prototype, and lyssavirus, of which rabies virus (RABV) serves as the prototype [207].
Lyssavirus genus is made up of not only RABV but also rabies like viruses which are all
zoonotic pathogens causing usually fatal encephalitis in animals [209]. Though RABV
and VSV share very similar structural and genetic makeup as members of the same viral
family, disease sequelae from their respective natural infections are very different, with
RABV causing a slow and almost uniformly fatal and destructive disease and VSV
causing an acute and generally mild disease with rare neurological symptoms [210].
Rhabdoviruses infect a wide range of hosts from vertebrates and invertebrates to
plants. Aside from a few species including rabies that primarily infect vertebrates, most
other rhabdoviruses, including VSV, are considered arboviruses, requiring transmission
via arthropod hosts such as blackflies, sandflies, and mosquitoes. There are several VSV
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Figure 1-5. Select representatives of the order, Mononegavirales
Source: Ictvonline.org- International Committee on Taxonomy for Viruses
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serotypes found worldwide; however, two distinct serotypes are predominantly found
within the Americas, which include New Jersey (VSV-NJ) and Indiana (VSV-IND). The
most prevalent serotype is VSV-NJ, accounting for ~80% of natural infections [211,
212]. These serotypes share approximately 50% amino acid sequence homology and
infection of one serotype does not confer protection against future infection of the other
[207, 213].
Disease Manifestations and Modes of Transmission
Vesicular stomatitis (VS) is the disease caused by VSV infection and presents as
an acute, nonfatal, but debilitating disease in cattle, swine, and horses. Signs of infection
in animals include formation of fluid-filled vesicular lesions of the mouth, tongue,
hooves, and teats [214], which often coalesce and rupture leaving areas of painful
ulcerations that may cause infected animals to refuse food and water. Eventually,
animals experience severe weight loss with lowered milk production and productivity
[215]. Manifestations of VS are often confused with foot and mouth disease, another
infection of livestock caused by the picornavirus, foot and mouth virus. This disease is
known to be more debilitating therefore establishing the correct diagnosis is paramount as
it can have unfavorable agricultural and economical consequences if spread of infection
is not controlled. Geographically, VS is more prevalent in areas surrounding the borders
of Central and South America with outbreaks occurring seasonally, during warmer
temperatures [212]. In the United States, outbreaks typically occur every 10 years
however, within the last decade, they have been more consistent with bursts of infection
observed almost annually since 2005 [216].
As noted, VSV is an arbovirus, therefore, natural infection of vertebrate hosts
follows the bite of an infected insect. Additional modes of transmission may occur and
include aerosolization or contact with skin lesions of the infected. Experimental
inoculation of livestock can cause clinically relevant disease that is dose dependent and
varies based on route of administration. Viremia in experimentally inoculated livestock
is rare but possible [217]. On the other hand, experimental inoculation of mice results in
viremia and often death due to encephalitis depending on age of animal (adult versus
nestling) and route of administration [212, 218-220].
VSV is not considered a major human pathogen, unlike its close relative, rabv, or
other vesiculoviruses found worldwide such as Chandipura virus and Isfahan virus [221,
222]. Resulting from its broad tropism, the virus can infect humans, however, infection
is usually asymptomatic or may manifest as mild flu-like symptoms. Seroconversion is
rarely detected in the general population and those with positive serology usually have
either a history of exposure to infected cattle or have handled virus in a lab setting [207].
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VSV Structure
Due to its simplicity, VSV has been the most extensively studied virus in its order
and these studies have provided much of what is presently known about the life cycle of
Mononegavirales as a whole. Other attributes of VSV that deem it the prototype of
Rhabdoviruses aside from its simple genome include its broad cell tropism and high
yields in cell culture [207]. The VSV genome consists of 11.2 kilobases (kb), which
serially transcribes 5 monocistronic mRNAs used to translate the 5 major viral proteins:
the nucleoprotein (N), the phosphoprotein (P), the matrix protein (M), the glycoprotein
(G), and the large RNA polymerase (L) (Figure 1-6).
As most Rhabdoviruses, excluding some bacillus shaped plant Rhabdoviruses,
mature VSV virions have a characteristic bullet shape measuring 180nm x 75 nm. These
virions acquire an envelope composed of the host cell membrane from which they bud.
Embedded in and protruding from the envelope are G proteins arranged in trimeric
spikes. Surrounded by the envelope is a core ribonucleoprotein (RNP) composed of the
NNS RNA genome encapsidated by N proteins keeping the genome compact hence
resistant to cellular RNase. Molecules of viral M protein are attached to the inside leaflet
of the viral envelope between the membrane and the nucleocapsid core keeping the RNP
in a rigid helical formation [207]. The RNA-dependent RNA polymerase (RdRp) is a
complex formed by the P and L proteins (L-P3 complex) during transcription and L, N,
and P (L-N-P complex) proteins during replication. The active RdRp is also responsible
for additional processing of transcripts which include the addition and methylation of a
5-cap and addition of a 3-poly(A) tail (reviewed in [207, 223].
VSV Replication Cycle
As with most RNA viruses, the replication cycle of VSV occurs exclusively in the
cytoplasm. Each VSV structural protein plays an important role in these events
beginning with adsorption of virus at the cell membrane, followed by entry and
uncoating, transcription, replication, assembly, and finally culminating with budding of
infectious particles from the host cell.
Specifically, binding of virions to the host cell surface occurs between viral
glycoprotein and a universally expressed host cell receptor [207]. Phosphatidylserine
(PS) was previously considered as the possible cellular receptor, however newer data
challenge this proposal with one study suggesting the role of the endoplasmic reticulum
chaperone protein gp96 as a facilitator of viral attachment with host cells [224-227].
Following adsorption, virus is endocytosed through a clathrin-dependent receptormediated pathway. As virus is exposed to decreasing pH during endocytosis, G protein
undergoes a conformational change resulting in fusion of the viral envelope and
endosomal membranes. As virus traffics through endosomal compartments, M releases
its rigid hold on the RNP while remaining bound to the endosomal membrane allowing
the RNP core to then be released into the cytoplasm [228]. This uncoating step leaves the
RNP available for transcription by the pre-packaged RdRp in order for synthesis of new
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Figure 1-6. Vesicular stomatitis virus
Schematic of the characteristic bullet-shaped vesicular stomatitis virion, depicting the
layout of the 11.2 kilobase negative single stranded RNA viral genome from 3’ to 5’.
N, nucleocapsid; P, phosphoprotein; M, matrix; G, glycoprotein; L, large RNA
polymerase

36

viral proteins needed for subsequent rounds of transcription and ultimately replication.
Directionality of transcription of the negative sense RNA genome by the active
polymerase occurs uninterrupted from 3’ to 5’ in the specific order of 3’(l)-N-P-M-G-L(t)5’ with the first event being synthesis of the 47 nucleotide RNA leader sequence, l,
located in the 3’ untranslated region (UTR)of the genome. This sequence is responsible
for encouraging transcription of viral genes. The last event involves transcription of the
trailer sequence, t, located in the 5’ UTR. As mentioned, each mRNA contains a 5’ cap
and terminate with a poly(A) tail. Transcriptional attenuation occurs with an
approximately 20% to 30% decrease of transcript synthesis at each contiguous gene
junction. This results in a gradient of mRNA from the more abundant 3’ located N
transcript to the least abundant 5’ located L transcript (reviewed in [207].
In addition to its role in transcription, RdRp is responsible for making new
genome that can be used for amplifying transcription and for packaging into new virions.
Therefore, a transitional product involving a positive-sense, antigenome replication
intermediate (RI) is made by the RdRp for this purpose. Once message is made and
newly synthesized N and P accumulate, then genome replication can occur [207]. Next
assembly of new virions ensues as newly synthesized genomes are encapsidated and then
condensed into a skeleton form. The recent 3D constructed image by cryo-electron
microscopy of the VSV virion has revealed that assembly is initiated at the tip of the
bullet shaped virion with M serving as a facilitator through its multiple interactions with
neighboring M proteins, overlying plasma membrane, and the underlying RNP [229].
The ultimate step in the life cycle is budding of newly made, mature virions preferentially
from the basolateral surface of infected epithelial cells [230, 231]. These areas have been
found to harbor G protein containing lipid domains [232] along with higher
concentrations of membrane bound M protein [233] and cellular budding machinery
[231, 234]. As these new virions are released from the cell, they attain a new envelope
derived from the host cell membrane [207].
The Multifunctional Matrix Protein
In order to promote quick and efficient replication, a number of viruses encode for
proteins that have multiple functions in the viral life cycle [46, 235, 236]. One such
example for VSV is the matrix protein (Figure 1-7). M is comprised of only 229 amino
acids making it the smallest of virally encoded proteins weighing in at 26kDa. Though it
is the smallest, it is also the most abundant protein in the VS virion and participates in
many aspects of the viral life cycle from assembly to budding [207]. In addition to the
full-length matrix protein, M1, VSV expresses two additional shorter matrix polypeptides
known as M2 and M3 (Figure 1-7C) [237]. These shorter proteins are synthesized from
the same open reading frame, but from downstream AUG codons therefore exhibiting Nterminal truncations compared to full length M1. M2 starts with methionine at position
33 and M3 at Methionine 51. These proteins are incorporated into virions at very low
levels and, as will be discussed, have been found to play a role in the virus’s
characteristic cytopathic effects during infection [237].
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Figure 1-7. The matrix (M) protein
(A) Reconstruction of cryo-EM images illustrating the four interactions of the N-terminus
of matrix with adjacent matrix proteins and with adjacent nucleocapsid proteins. (B)
Crystal structure of the thermolysin cleaved globular core of the matrix protein revealing
3 alpha helices surrounded by 7 beta sheets. (C) Schematic of the full-length matrix
protein depicting important functional domains including the amino acid start sites for
matrix variants, M2 and M3. (A) reprinted with permission from Peng G, J. Tsao, S.
Schein, T. Green, M. Luo, and Z. Hong Zhou (2010.) CryoEM model of the bulletshaped vesicular stomatitis virus. Science 327 (5966): 689-93 [229] and (B) Gaudier, M.,
Y. Gaudin, and M. Knossow (2002). Crystal structure of vesicular stomatitis virus matrix
protein. Embo J 21:2886-92 [238]. Cryo-EM, Cryo-electron microscopy; AA, amino
acid; NCT, nucleocytoplasmic transport
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Matrix Structure
The crystal structure of the M protein was solved in 2002 by Gaudier et al and
was shown to be similar in structure to proteins of other NNS RNA viruses important in
budding and viral assembly [238-241] (Figure 1-7B). In order to achieve crystallization,
matrix was treated with thermolysin, cleaving the protein at the N terminus and at the
hydrophobic loop known to be involved in M polymerization. Resultant thermolysin
cleaved M monomers (Mth) corresponded to amino acids 48-121 and 122-229 and these
two fragments were held together by a hydrophobic, globular core [238]. A number of
domains have been found to be responsible for the multi-functionality of matrix and a
more recent 3D structure created from cryo-electron microscopic studies has shed more
light on the topography of these domains and how they interact with other proteins in the
virion. It was shown that the N and M layers in the virion are both made up of a separate
single helix and the N terminus of M (M-hub) has 4 contact points, important in
maintaining the virion’s rigid bullet structure (Figure 1-7A). Contact point 1 joins Mhub to an N in the upper helical turn, while M-hub contact-point 2 connects M-hub to an
N subunit in the lower helical turn, confirming previous data that the N-terminus (AA421) of M is important in binding to the RNP core [242]. Contact-point 3 binds laterally to
the C-terminus of M (MCTD) of the trailing M subunit in the same helical turn while
contact-point 4 binds to MCTD of the M in an upper helical turn [229]. This further
validates what is known about the protease sensitive loop of matrix[243, 244].
The functional domains of matrix have been shown to be genetically separable
from each other with domains involved in assembly and budding being different from
those involved in CPE [242, 245] (Figure 1-7C). In addition, these functions are carried
out in very different parts of the infected cell reflected by the approximately 10% of
matrix associated with the inner leaflet of the plasma membrane, where assembly and
budding is known to occur, with the remaining matrix located either in the cytoplasm or,
to a lesser degree, in the host cell nucleus. With so many roles being carried out in
different cellular compartments by one agent, it is not surprising that separate matrix
populations created by genetic truncations could provide the virus with several options
for carrying out its functions simultaneously.
Assembly and Budding
During VSV assembly, as the RNP begins to form a helical structure, M subunits
attach to the outer surface of the nucleocapsid and rigidify the forming RNP skeleton
starting from the tip to the trunk or base of the forming bullet shaped structure. The
exposed surface of M not bound by neighboring M or the RNP creates an area for binding
G trimers associated with the soon to be acquired envelope membrane [229]. The
importance of M to assembly has been demonstrated by deletion or mutation of M
especially seen with temperature-sensitive mutants of VSV that produce very low levels
of spherical or pleomorphic-shaped particles at non-permissive temperatures.
Complementation of these mutant viruses with wildtype matrix restores the classical
bullet shape of the virions [246].
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The multiple interactions of M with other VSV structural proteins also help
promote viral budding from infected host cells [229, 231]. Significance of M in budding
was demonstrated in studies showing the transient expression of M alone causes
evagination of host cell membrane and ultimately release of membrane-enclosed vesicles
[247]. Point mutations in the proline rich motif, 24PPxY27, located in the N terminus of
M (late-budding or L-domain) greatly diminishes vesicular budding and the infection
with viruses possessing mutations in the L domain show a decrease in budding by 70% of
wildtype infection. This motif has been shown to facilitate budding through interactions
with host cell E3 ubiquitin ligase, Nedd4, via its WW-domains [241, 248].
Cytopathic Effects
In addition to its role in assembly and budding, M is responsible for the
phenotypic cytopathic effects (CPE) observed during VSV infection. CPE manifests as
cell rounding, activation of apoptosis, and inhibition of host gene expression. In baby
hamster kidney cells (BHK), a major cell model used in studies of VSV, CPE can be
observed as early as 1 to 2 hours post-infection at high multiplicities of infection (MOIs)
or 4-5 hours post-infection at lower MOIs [241]. M’s importance in CPE stemmed from
a number of studies including those using temperature sensitive mutant viruses. For
instance, tsO82, a mutant found to have a mutation in matrix, was non-cytopathic in
chick embryo fibroblasts [249] and this defect correlated with an inability to shutoff host
gene expression [245]. The fact that expression of M alone, in the absence of other viral
proteins, is able to elicit cell rounding and apoptosis emphasizes its role in CPE [242,
250-254].
Cell rounding and apoptosis
Cell rounding and induction of apoptosis are well-known characteristics of VSV
infection. This change in cell morphology is an effect of cytoskeletal dysfunction
specifically due to matrix interaction with tubulin as co-immunoprecipitation revealed
interaction between the acidic C-terminus of tubulin and the basic N-terminus of M
[251]. More recent studies, however, revealed that matrix may not associate with actin or
tubulin for at least 1 hour post-infection [228]; however, interaction between M and
dynamin [255] through a domain located in the N-terminus of matrix may indirectly
affect actin components of the cytoskeletal network [256]. In support of M’s role in cell
rounding, a temperature sensitive mutant, tsG33, known to harbor mutations in the matrix
protein, was shown to be deficient in cell rounding in BHK-21 cells at non-permissive
temperatures. In this same study, M was able to cause cell rounding in the absence of
other viral proteins and blocking M activity by microinjection of complimentary
antisense oligonucleotides inhibited cell rounding [250].
Induction of apoptosis is also a feature of VSV-induced CPE. Apoptosis was first
verified by the presence of DNA laddering and nuclear fragmentation that occurred
simultaneously with, but was not dependent on, viral replication [257, 258]. The
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expression of M, alone, is able to elicit apoptosis and is evident by activation of caspase3 in HeLa and BHK cells [259]. M’s ability to activate apoptosis leads to cell rounding
and in cells where M-induced apoptotic pathways are blocked, cell rounding is also
inhibited [252].
Inhibition of host gene expression
Another feature of viral-induced CPE includes the inhibition of host gene
expression or host cell shutoff. There are several stages of gene expression that can be
inhibited and these not only include transcription and translation of the host genome but
also transport of message from the nucleus into the cytoplasm as well (e.g.
nucleocytoplasmic transport or NCT) (Figure 1-8). As previously mentioned, leader
RNA (l), located in the 3’ untranslated region plays a significant role in encouraging viral
transcription [207]. Along with this role, l has been shown to be involved in inhibition of
host cell gene expression as it migrates to the nucleus early in infection and inhibits
initiation of RNA polymerase II and III dependent transcription [260-262]. However, l is
not sufficient to shutoff host gene expression on its own and another viral protein was
identified as playing a major role in this process. That protein was found to be M [263,
264]. Not only is matrix implicated as the viral protein involved in host shutoff, Lyles et
al showed that its ability to do this leads to induction of apoptosis and cell rounding [253,
254].
Inhibition of transcription and translation
Evidence of M’s role in host shutoff include its ability to localize to the nucleus of
infected cells [265] along with studies showing the temperature sensitive matrix mutant,
tsO82, expresses defects in host shutoff during infection [245]. Expression of M, alone,
inhibits not only host directed transcription but also its own transcription when expressed
from plasmids transcribed by host RNA polymerase II, a property not possessed by other
viral proteins [242, 254]. This inhibition was shown to be independent of promoter type
(hIFN cellular promoter versus SV40 viral promoter) [266]. Activity of RNA
polyermase (RNAP) I, II, and III are effected with RNAP II being the most sensitive to
viral inhibition [267, 268] due to inactivation of transcription factor, TFIID [269, 270].
VSV host shutoff also involves inhibition during translation through alterations of
eIF4F initiation complex [271, 272]. Inhibition at this level favors mRNAs already
existing in host cells prior to infection while new mRNAs or mRNAs present after
infection are not inhibited. This along with the fact that VSV inhibits host transcription
helps promote translation of viral mRNA as increases in viral translation occurs
simultaneously with decreases in host mRNA translation [273].

41

Figure 1-8. Multiple steps in the inhibition of host gene expression by VSV matrix
protein
There are multiple steps in the process of host gene expression that may be targeted by
VSV in order to promote the viral life cycle. (A) Inhibition of transcription particularly
of genes transcribed by host RNA polymerase II (B) inhibition of NCT by binding at the
nuclear pore complex and (C) inhibition of translation caused by viral induced alterations
of the eIF4F.
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Inhibition of nucleocytoplasmic transport (NCT)
Lastly, inhibition of NCT is a major feature of VSV-induced CPE specifically in
inhibition of host gene expression. Inhibiting movement of mRNA into the cytoplasm
would theoretically prevent expression by decreasing the availability of mRNA to the
translation apparatus. As stated, there is a population of matrix found in the nucleus
unlike other viral proteins [265] and movement of M into the nucleus is supported by the
presence of nuclear localization signals (NLS) [274]. NCT inhibition occurs when matrix
is bound to the nuclear envelope and this activity is reversed in the presence of a mAb
directed against M (M) [275]. At the nuclear envelope, M specifically binds to the
nuclear pore complex (NPC) where it alters NCT activity mediated by the nucleoporin,
Nup98, and shuttling mRNA export factor, Rae1. Mutant viruses unable to bind at the
NPC are able to migrate to the nucleus but are defective in inhibition of transcription
andNCT seen by an increase in the amount of nuclear mRNA [276-278].
More recent studies question the actual role of Matrix and Nup98/Rae1
interactions in host cell shutoff during VSV infection. Rae1 knockout cells were shown
to have no effect on the accumulation of nuclear mRNA after wildtype infection however
there was a decrease in the inhibition of host transcription. In addition, without Rae1, M
is unable to bind to Nup98 although M is able to bind Rae1 in the absence of Nup98.
These data implicate the importance of Rae1 as a bridge for interaction between matrix
and other host factors such as Nup98 and that these connections are important in CPE
observed during VSV infection. This also suggests a more vital role for these complexes
in the inhibition of transcription [279].
Matrix domains important for CPE
In addition to the aforementioned domains important to viral assembly and
budding, genetically separable domains have also been identified as being important in
viral induced CPE [242, 252]. These domains are summarized in Table 1-4. PSAP
domain located between amino acids 37-40 (37PSAP40) at the N-terminus of matrix was
initially studied for its possible role in viral budding mechanisms. It was believed to act
as an L domain considering this motif is highly conserved in other vesiculoviruses [222,
280] and has been proven to function as an L domain in a number of other viruses
including hepatitis E virus and Ebola virus [281, 282]. In addition, another highly
conserved region in the matrix protein much like PSAP, the 24PPxY27 motif, has been
confirmed as an L-domain whose function is vital to VSV budding [241]. Studies
eventually showed that this is not the case and that mutations in 37PSAP40 alone have no
effect on budding; however, in combination with PY mutations, 37PSAP40 may help
rescue the defective budding phenotype of PY mutants [283, 284]. Recent studies have
implicated PSAP as being more vital to viral CPE especially as it relates to cell rounding,
caspase activation, and ultimately, viral yield. Substitution of 4 alanines for PSAP
(PS>A4) resulted in a highly attenuated virus in vitro and in an in vivo mouse model. On
the other hand, PS>A4 resulted in the opposite phenotype in arthropod cell lines, with
enhanced CPE seen by increased cell rounding, detachment, and activation of caspase 3
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Table 1-4.

Functional domains of VSV matrix protein

Role of Matrix

Specific Motif

References

Dynamin Binding

Amino Acid
Domain Location
1-10

NS

[255]

RNP association

1-24

NS

[229]

24-27

PPPY

[229, 231, 241, 246248]

37-40

PSAP

[282, 283]

33-67

NS

[285]

a. 33-51
b. 37-40

a. NS
b. PSAP

Budding
1. Binds to WW
motifs on cellular
proteins (Nedd4)
2. Binds tSG101
Mitochondrial
targeting
CPE
1. Cell rounding
and apoptosis
2. Inhibition of host
gene expression

a. [237, 242, 252,
259, 265]
b. [284, 286, 287]

51-59

NS

[245, 275, 277-279,
288]

Assembly

123-125

LXD

[231, 238, 243, 244]

Self association

120-129

PAVLA

[229, 238, 243, 244]

Note: NS, not specified
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[286, 287].
Another domain important to viral CPE was addressed in the previously
mentioned studies using temperature sensitive mutant, tsO82 [249]. This mutant
expresses a mutation in matrix in which a methionine at position 51 is replaced with an
arginine (M51R). This substitution renders it defective in host gene expression
inhibition, and through complementation with assembly mutants, a genetic distinction
between these functional domains was further confirmed [245]. Studies using M51R
expressing plasmids have shown that while wildtype matrix co-localizes with
components of the nuclear pore complex at the nuclear rim, M51R mutants do not
suggesting NPC-matrix interactions are determined by this domain and are important for
the inhibition of host gene expression [277, 288]. In addition, another genetically
modified matrix mutant, M(D), which possesses alanine substitutions at positions 52-54
show that these mutations do not inhibit the ability of matrix to migrate into the nucleus,
however by their inability to interact with the NPC, inhibitory activity on gene expression
is diminished [275].
Jayakar and Whitt eventually demonstrated a major influence of M51 mutations
in the expression of the matrix protein. Mutations introducing an alanine at this position
in combination with the same mutation at position 33 (M33, 51A) prevented the synthesis
of the shorter matrix protein products, M3 and M2, respectively, and resulted in synthesis
of only the full-length matrix protein, M1. These proteins were shown to be important in
eliciting viral induced CPE and virions that do not express these proteins have a delay in
cell rounding that can be recovered by co-expression of M2 and M3. Surprisingly in
these mutants, virus yield is not affected and inhibition of host gene expression
determined by protein visualization of [35S] Met labeled infected cell extracts showed no
significant differences from wild-type infection [237].
In all, viruses harboring mutations corresponding to position 51 are attenuated
likely due to their inability to inhibit the expression of specific genes important in
antiviral responses such as Type I interferons (IFN/) [266, 289-291]. It is the M51
mutation specifically that has been the main focus of studies geared toward developing
VSV as an oncolytic virus. Furthermore, this mutation is thought to be responsible for
the virus’s preferential replication in tumor cells lacking a functional IFN response
pathway [292-294].
VSV as an Oncolytic Agent
Proposed Mechanism of Oncolysis
As described, the matrix protein’s role in VSV cytopathic effects are illustrated
through its ability to prevent the expression of host genes, including those crucial to
regulating viral infection. Previous studies have not only demonstrated inhibition of IFN
expression by wildtype matrix, but also that viruses expressing a host shutoff defective
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matrix protein are actually inducers of IFN [292]. Many tumors harbor defects in the
interferon pathway giving them a survival advantage over normal cells while leaving
them susceptible to infection by numerous viruses including VSV. To this end, it should
be expected that VSV would have a growth advantage in transformed cells based on their
inability to fight off infection. This expectation has been proven true in a number of
tumor cells from different origins including prostate, breast, and colon. Furthermore,
pretreating cells with IFN is able to protect normal cells from infection while tumor cells,
with very little ability to respond to IFN, remain sensitive to viral infection [291].
By using matrix mutant, with the inability to shut off host gene and protein
expression, the oncolytic potential of VSV vectors is improved. These mutants create a
similar environment much like the one observed with IFN pretreatment. During
infection, accumulating IFN forms a “cytokine cloud” around surrounding cells that
stimulates downstream signals protecting IFN responsive cells from further infection
while the IFN-resistant tumor cells are left vulnerable (Figure 1-9) (reviewed in [289]).
IFN Pathway
In understanding the mechanism of VSV oncolysis, it is important to have a
general understanding of normal antiviral responses. Innate immune responses are
crucial in the survival of cells against VSV infection as the virus is extremely sensitive to
the antiviral actions of the IFN pathway. In animals with defective innate responses, such
as IFN receptor (IFNAR)- deficient mice, VSV rapidly replicates to high levels before the
adaptive immune response can neutralize virus [295]. Interferons (IFNs) are specific to
vertebrates [296] and virtually all nucleated cells maintain the capacity to produce and
respond to IFN [297].
There are two main families of IFN, designated type I (/) and type II (). The
26 genes coding for Type I IFNs are found on human chromosome 9 and include 13
IFN genes, 11 of which are functional, a single IFN, and 11 IFN pseudogenes
(reviewed in [297]). More recently added type I IFNs include IFN ,  , ,  , and (reviewed in [298]). Type I IFNs have multiple antiviral effects including the ability to
activate immune effector cells such as natural killer (NK) cells, macrophages and
dendritic cells (DCs) [296, 299]. Though IFNs are considered major players in innate
immunity, their ability to influence DC maturation indicates a role in bridging the innate
and adaptive immune systems. IFNs also have antitumor effects, demonstrated by their
connection to the tumor suppressor, p53 pathway, which is dysregulated in cancers of all
types [300]. The IFN-I receptor, IFNAR, is found in the plasma membrane and is
composed of two major subunits, IFNAR1 and IFNAR2. Separately, each subunit serves
as a docking site for intracellular signaling molecules. Once bound to IFN, these subunits
become a heterodimer triggering an elaborate downstream antiviral signaling cascade that
will be discussed in more detail (Figure 1-9B). All Type I IFNs bind to this receptor,
however, depending on the bound IFN, distinct downstream signaling can be observed
[301].
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Figure 1-9. VSV and the IFN pathway
(A) PRRs such as RIG-I and TLRs recognize pathogens, setting off an alarm in the form
of a downstream signaling cascade that leads to the translocation of IRF3/7 and NFB to
the nucleus where they initiate the expression of IFN-I genes. (B) IFN protein is
translated and secreted by cells into the extracellular environment where it binds to its
receptor. IFN works in an autocrine and paracrine fashion to increase the translocation of
Stat 1 and 2 to the nucleus where they upregulate a host of IFN stimulated genes (ISGs).
(C) During wtVSV infection, the matrix protein is able to block multiple stages of host
gene expression including genes involved in creating antiviral responses. This enables
viral replication and subsequent infection of surrounding cells. (D) During infection with
VSV matrix mutants, M is unable to block host gene expression, therefore, allowing IFN
gene expression to continue. Tumor cells, with defects in host gene expression are
unable to create an IFN induced antiviral state, which allows uncontrolled spread of
virus. (E) Cells having an intact IFN response, are able to amplify IFN signal by
downstream ISGs, protecting other IFN responsive cells from viral infection at multiple
stages of the viral life cycle.
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Pattern Recognition Receptors (PRRs)
There are multiple ways in which viruses elicit downstream IFN expression.
Initial responses involve recognition of pathogen associated molecular patterns (PAMPS)
by pattern recognition receptors (PRRs) located in various compartments of the host cell.
Membrane associated PRRs include Toll-like receptors (TLRs) while cytosolic PRRs
include retinoic acid–inducible gene (RIG)-I-like receptors (RLRs), and the nucleotidebinding domain, leucine-rich repeat–containing (NBD-LRR) proteins (NLRs) (reviewed
in [302]). Several PRRs are activated in response to VSV infection. These include
TLR3, TLR7, and RIG-I (Figure 1-9A).
Upon binding of dsRNA replication intermediates, the endosome bound TLR-3
recruits adaptor molecule TIR-domain containing adaptor inducing IFN- (TRIF). TRIF
activates downstream signals by two different cascades. The first works through
phosphorylation of interferon regulatory factor 3 (IRF-3) and IFN regulatory factor 7
(IRF7), which promotes formation of an IRF3/7 heterodimer that migrates to the nucleus
where it is able to bind to IRF-binding elements in the IFN-/ promoter. In the second
cascade, TRIF activates Inhibitor of kappa B kinase (IKK) complex, which leads to the
dissociation of NF-B from its inhibitor allowing its nuclear translocation, where it binds
to and increases expression of IFN-I genes. Both, IRF3/7 and NF-B are required for the
robust transcriptional activation of type I IFN during viral infection (reviewed in [302]).
However, it has been shown in the case of VSV, that cells with silenced TLR3 still resist
infection proving that there must be other vital pathways involved in anti-VSV responses
[303]. For instance, TLR-7 is another endosome associated PRR found mostly in
dendritic cells, especially plasmacytoid DCs (pDCs). TLR-7 predominantly binds
ssRNA, which sparks recruitment of the adaptor protein myeloid differentiation factor 88
(MyD88). MyD88 activates IRF-7 downstream, which, again, forms a heterodimer with
IRF3, promoting IFN expression in the nucleus. In comparison to TLR3, TLR7 is
extremely important in antiviral signaling of VSV infection. Bone marrow cells derived
from both MyD88 and TLR7 deficient mice expressed diminished levels of IFN in
response to VSV infection. This decrease in antiviral response was also observed in vivo
as well [304].
Cytoplasmic PRRs have particular importance in eliciting IFN related antiviral
responses as well. These receptors, known as RLRs, work through NF-B and IRF-3 to
promote robust IFN-I responses. Retinoic acid-inducible gene-I (RIG-I) and melanoma
differentiation-associated gene-5 (Mda-5) are two recognized RLRs important in RNA
virus signaling however RIG-I is more important to VSV infection. RIG-I (also known
as Ddx-58) recognizes 5’-triphosphates on viral RNAs, such as those encoded by
negative- stranded viruses [305]. After detection, RIG-I activates the mitochondriabound interferon beta promoter stimulator-1 (IPS-1), which phosphorylates kinases,
TANK-binding kinase 1 (TBK1) and IKKi that then activate IRF-3 and NF-B,
respectively (reviewed in [302]). The importance of RIG-I in host responses against
VSV has been shown through experiments in which RIG-I knockout MEFs were unable
to upregulate IFN- activity causing 101.5 higher viral titers than in normal cells [306].
Alternatively, overexpression of RIG-1 inhibits replication of VSV in L929 cells by
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decreasing titers 102-3 versus control cells [303].
Interferon Stimulated Genes (ISGs)
Following the initial induction of IFN-I genes, newly synthesized IFN act through
paracrine and autocrine signaling to augment antiviral responses in a positive feedback
loop (reviewed in [303]). Upon binding to its receptor, IFN ignites a phosphorylation
cascade that results in activation of tyrosine kinases, Tyk2 and Janus kinase 1 (JAK1),
both bound to the intracellular portions of IFNAR. Signal transducers and activators of
transcription, known as STAT 1 and STAT2, are subsequently phosphorylated which
promotes formation of a STAT1/2 heterodimer. The heterodimer is transported to the
nucleus where it binds to IRF9, forming the IFN-stimulated gene factor 3 (ISGF3)
complex that binds to the IFN-stimulated response element (ISRE) in the promoter of a
multitude of interferon stimulated genes (ISGs) [296]. ISGs are the major operatives of
the IFN pathway and over 300 ISGs are known to exist though most of their functions are
not yet understood [307, 308]. Several have well-known IFN-mediated antiviral
activities. These include the 2’, 5’-oligoadenylate synthetase (OAS)/RNaseL pathway.
OAS is triggered by dsRNA to activate RNase L, which degrades both host and viral
RNA. Another well-known ISG is the dsRNA-activated protein kinase (PKR), which
responds to dsRNA by phosphorylating translation initiator factor eIF-2 promoting
cessation of protein synthesis. Lastly, the Myxovirus resistance (Mx) proteins, which
will be discussed in more detail, are GTPases that prevent virus infection mostly at the
transcriptional level (reviewed in [307]). Though important, OAS, PKR, and Mx are not
the only ISGs involved in protection of cells against VSV. Following IFN-I
pretreatment, triple (OAS, PKR, Mx) knockout MEFs still mounted an antiviral response
against VSV infection [309] confirming that other ISG effectors are obviously playing
some role in anti-VSV responses and may include broadly acting effectors such as IRF1or more specific effectors such as guanylate binding proteins (GBPs).
Interferon regulatory factor 1
Interferon regulatory factors (IRFs) are a family of transcription factors made up
of nine members in humans and mice [310]. The first of these identified was IRF-1,
initially shown to activate IFN-I in the absence of viral infection. Though IFN-inducible,
IRF-1 is constitutively active in a number of cells with levels dependent upon the cell
cycle, which are increased during cell cycle arrest [311]. Serving as a transcription factor
is IRF-1’s main mechanism of action and inactivating the ability to bind to DNA
eliminates its activity [312]. IRF-1 protein is mainly located in the nucleus where it is
known to not only increase expression of IFN but other ISGs as well including OAS,
PKR, and GBP. It specifically recognizes a sequence in the promoter region very similar
to that recognized by the ISG3 complex therefore, it is thought that these two activators
of IFN also activate a similar subset of ISGs [310]. Because IRF-1 is itself induced by
viral infection, de novo synthesis of IRF-1 is believed to be important in eliciting IFN
responses [313]. Though IFN-I can cause upregulation of IRF-1, its strongest inducer is
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IFN- therefore a number of additional stimulated genes involved in other pathways
including apoptosis and anti-proliferation is also activated by IRF-1 [310].
Aside from its role in antiviral responses, other roles of IRF-1 include antitumor
activity [314] and modulation of the immune system, including adaptive responses
involving sculpting the antigen specificity of CD8+ T cells [315]. Studies involving IRF1 knockout MEFs demonstrated IFN-I continued to be upregulated following infection
with Newcastle disease virus though upregulation with polyI:C was impaired (reviewed
in [310]).
Myxovirus resistance protein
Myxovirus resistance (Mx) proteins are members of the dynamin-like GTPase
family of interferon stimulated genes [316]. There are two Mx proteins encoded by two
separate genes in humans while there are 3 separate Mx genes in rats. Human MxA is a
cytoplasmic protein active against a number of RNA viruses including VSV. Cells that
constitutively express MxA experience a decrease in viral transcription by 50 fold [317].
Alternatively, MxB has not been shown to have any antiviral activity [316]. In rat, Mx1
is found in the nucleus where it inhibits nuclear replicating viruses such as influenza,
while the cytoplasmic Mx2 is more effective against viruses that replicate in the cytosol
such as VSV. Mx3, like human MxB, has no known antiviral activity [318]. Mx protein
activity is thought to attributed to the ability to sense nucleocapsid like structures and
prevent them from participating in replication in the nucleus, in the case of Mx1, or in the
cytoplasm, in the case of Mx2 [318].
Guanylate binding protein
Guanylate binding proteins or GBPs are highly conserved proteins belong to the
dynamin-like family of GTPases, like Mx proteins. There are seven members of the
human GBP family [319] and 11 known murine GBPs [320]. GBPs are cytoplasmic
proteins. Specifically, mGBP-2 has been shown to localize to intracellular vesicle-like
structures although the importance of this localization on function has not yet been
described [321]. GBP promoters contain several ISRE’s that are regulated by other ISGs
such as IRF1 [322]. GBPs demonstrate antiviral activity, though weak in comparison to
the antiviral responses of Mx proteins [322]. Particularly, HeLa cells stably transfected
with hGBP-1 exhibited resistance to VSV-induced CPE, making less virus than control
cells. Cells with silenced expression of hGBP1 that were treated with IFN produced the
same amount of virus as cells with normal hGBP1 levels however these same cells
pretreated with IFN- had increased viral replication and less antiviral responses than
parent cells. This demonstrates that though GBP is responsive to IFN-I, upregulation is
more important in IFN-II signaling [323].
Outside of its role in antiviral responses, GBPs are implicated in having an
antitumor effect. Adding to the above results, the overexpression of mGBP2 enhances
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proliferation in NIH3T3 cells similar to the effects of IFN- while the opposite holds true
for hGBP1 and IFN- in HeLa cells which have anti-proliferative effects in this cell line
[324]. Further, hGBP1 and hGBP2 were recently shown to be upregulated in EGFR
activated cells, causing a downstream induction of matrix metalloproteinase-1 (MMP-1)
driving invasion of GBM cells making it a novel target in treatments of GBM [325].
Phospholipid scramblase 1
Phospholipid scramblase 1 (Plscr1) is another ISG that has been identified as a
possible IFN-induced antiviral component in VSV infection [326]. Plscr1 is a calcium
binding protein whose location is dependent on its state of palmitoylation. It can either
be found in the nucleus bound to DNA or in lipid-raft-associated plasma membrane,
promoting calcium induced bidirectional movement of phospholipids [327]. The N
terminal cytoplasmic domain is proline-rich and likely serves as a binding motif for other
proteins containing SH3 and WW domains [328]. Based on location, plscr1 antiviral
activity is believed to involve inhibition of viral adsorption and enhancement of IFN
signaling at the plasma membrane. Cells with decreased Plscr1 activity are insensitive to
the antiviral effects of IFNs and are more sensitive to VSV infection, confirmed by
elevated viral titers relative to wildtype cells. Plscr1 is known to upregulate the
expression of a number of other ISGs including GBPs, OAS, RNase L, and PKR [329].
Defective IFN Responses
There are a number of ways that tumor cells can bypass the anti-proliferative
effects of IFN. These include acquired defects in the ability to make IFN (i.e.
chromosomal aberrations) and to respond to IFN (i.e. alterations in signaling cascade).
As has been described, many tumors have deletions in chromosome 9 in the location of
the IFN-I gene cluster. Chromosome 9 aberrations are commonly encountered in GBM,
and allow cells to escape growth arrest and induction of apoptosis [330]. The variable
nature of IFN resistance was acknowledged in a comparison between two GBM cell
lines, one known to have homozygous deletions in chromosome 9 and another without
chromosomal defects [23]. Both were equally resistant to the IFN-induced apoptosis.
This raises the importance of non-chromosome 9 abnormalities that may lead to IFN
resistance including dysregulation of IFN regulatory factors and other interferon
inducible genes [331]. In an evaluation of STAT1 expression in GBM tumors, it was
shown that tumors expressing STAT more likely expressed an inactive form located in
the cytoplasm versus the active, nuclear form [332]. Other IFN pathway constituents that
have been implicated in tumorigenesis include IKK complex, important in activation of
NF-kB and the interferon regulatory factor, IRF1 [333, 334]. On a more global scale,
downstream IFN effects on p53 signaling have been implicated in disruption of antiviral
responses in tumor cells. IFN can activate expression of p53 through an ISRE found in
its promoter and as we know, p53 is a regulator of cell cycle and one of the most
common targets of mutation in cancer [300].
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Other Viral Antagonists of the IFN Pathway
Tumor selective targeting of the IFN pathway is not unique to VSV. In addition
to blocking host gene expression, other viral mechanisms used to escape immune
responses include sequestering IFN or IFN related responders and by cleaving or even
degrading antiviral products of the IFN pathway. There are over 170 virus-encoded IFNantagonists known in 93 different viruses, some highly conserved among various RNA
families (reviewed in [335]). An example is the conserved V proteins of the
Paramyxoviridae family in the order Mononegavirales. Particularly, V proteins prevent
dimerization of the cytosolic PRR, MDA-5, and also target STAT for proteasomal
degradation [336, 337]. The highly conserved Z proteins of New World Arenaviruses
antagonize antiviral responses by binding to and inhibiting RIG-I activity [338].
Comparable to VSV matrix, the non-structural NS1 proteins of influenza virus are
multifunctional proteins with multiple mechanisms for antagonizing the IFN pathway.
Just as matrix, NS1 can inhibit host gene expression by blocking RNA export. NS1 can
also bind to dsRNA which prevents activation of the OAS/RNase L pathway and inhibits
transcription of antiviral genes by preventing dsRNA-dependent transcription factors
from being activated [339]. Coronaviruses use its non-structural protein, Nsp1, to
degrade cellular mRNA, a nonspecific mechanism for blocking antiviral gene expression
[340]. Specifically, SARS coronavirus utilizes the accessory protein, ORF6 to inhibit
transport of STAT1 to the nucleus by blocking nuclear transport protein, preventing the
feedback loop vital for augmenting IFN responses [341]. Lastly, rabies virus, another
member of the Rhabdoviridae family, is also able to inhibit antiviral responses during
infection. Unlike VSV, however, rabies uses its phosphoprotein (P) to prevent
phosphorylation of the regulatory factor IRF-3 as well as inhibit STAT1 signaling.
Rabies takes a targeted multistep approach to antagonizing IFN whereas VSV inhibition
is more global [342].
Advantages of VSV Oncolytic Therapy
As with most OVs, there are both advantages and disadvantages of using VSV as
an oncolytic vector. The first advantage is that VSV is a naturally tumor selective virus,
having a replication advantage in tumor cells that harbor defects in the IFN pathway
[294]. Even more, VSV can be easily manipulated using reverse genetic techniques to
enhance tumor selectivity as demonstrated by the genetically engineered matrix mutants.
Virions can also be engineered to express foreign genes, accommodating up to 4.5kb of
foreign RNA without significantly altering replication and viral gene expression [207]. A
more recent study reported the insertion of the hepatitis C NS protein measuring
approximately 5.9kb without affecting replication [343]. Other examples include VSV
vectors expressing immune enhancing molecules such as IFN or tumor associated
antigens that boost antitumor immunity [344, 345]. For instance, a therapeutic regimen
using a VSV vector expressing the surrogate tumor antigen, ovalbumin, utilized a
virolytic and immunotherapeutic approach for the treatment of ova expressing B16
melanomas in a mouse model. Results showed enhancement of immune activation
against ova by increasing tumor antigen specific CD8+ T cells, which aided in
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enhancement of viral oncolysis as well [346].
The fact that VSV is not considered a human pathogen is also a benefit of VSV
oncolytic therapy. Seroconversion is rarely seen in the human population so the risk of
pre-immunity is extremely low [207]. Even in cases of pre-immunity, as has been
observed in cattle after natural VSV infection, immunity is not durable and animals may
be re-infected with the same VSV strain in subsequent years despite high serum
neutralizing antibody titers [213]. Whereas DNA and lentiviral vectors run the risk of
insertional mutagenesis due to integration into the host genome, the use of RNA viruses
such as VSV makes insertional mutagenesis highly unlikely. Lastly, the quick replication
cycle makes it easier to produce large amounts of virus and its broad host range facilitates
its therapeutic use in a multitude of tumors [291]. Viral yields in baby hamster kidney
cells (BHK-21) are about 100,000 particles per cell, of which about 10% can be
infectious [207]. Other cell types that have been tested include kidney, brain, and heart
with titers equaling 107, 106, and 105 respectively [346].
Disadvantages of VSV Oncolytic Therapy
On the other hand, there exists a number of disadvantages to VSV oncolytic
therapy. First, as with other RNA viruses, VSV has a high rate of mutation, with RdRp
errors occurring every 1:10,000 nucleotides or approximately 1 mutation/virion [347].
As a result, the risk of reversion to wildtype will continue to be a factor as VSV moves
from bench to bedside. Previous studies using one of the more popular VSV mutants,
M51, has shown that the possibility of reversion, though present is extremely rare in this
case. It is proposed that when using this particular IFN inducing vector, the likelihood of
a wildtype revertant rising to dominance would be virtually impossible [289].
VSV along with several other viruses such as rabies, HSV, and measles, are
known to be neurotoxic [348-350]. Evidence for VSV neurotoxicity stemmed from
studies in which mice were experimentally challenged with virus given either intranasally
or intracranially. Understanding the neurotoxic phenotype of VSV is important
specifically in developing VSV as an oncolytic treatment for brain tumors as protection
of normal cells is crucial [219, 351].
One study initially aimed at determining ways of lessening neurotoxicity resulted
in uncovering what can be considered a disadvantage, though a necessary one, of VSV
therapy, the adaptive immune response. As discussed, with natural infection, preimmunity does not protect animals, long term, against subsequent infection with the same
serotype [213]. However, studies using experimentally infected animals revealed that
long lasting immunity is attainable following i.v. challenge with either wtVSV or
attenuated viruses (VSV-M51-CT9, VSV-CT1; CT mutants are defined as having
truncated cytoplasmic domains of the VSV glycoprotein) [220]. These differences may
be attributed to variations in routes of administration and species of infected animals,
however adaptive immunity still serves as a hurdle to efficient delivery of viral therapy,
therefore, understanding the natural progression of adaptive immunity is important.
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The timeline leading to the activation of adaptive immune responses has been
determined using a mouse model. Within one week of infection, neutralizing
immunoglobulin M (IgM) antibody appears first followed by appearance of neutralizing
IgG antibodies (nAb). Strong adaptive responses including antibody and cytotoxic Tlymphocytes are directed against N and G proteins [352] however, nAbs are specifically
directed towards the G protein. Further, passive immunity with G antibodies, but not
antigen specific T cells, protect against systemic infection (reviewed in [207]). The
importance of adaptive immune effectors was revealed in studies using immunodeficient
animals. B-cell-deficient mice are highly sensitive to VSV and usually succumb to
infection within 9 days. On the other hand, T cells contribute to long-term survival as Tcell-deficient mice succumb to neurotoxicity closer to 30 days post- infection [352]. In
creating a safe and effective VSV therapy that can be moved from preclinical to clinical
studies for the treatment of GBM, a balance must be met between lessening neurotoxic
effects of viral infection and achieving optimal delivery with long lasting therapeutic
effects.
Examples of VSV-Derived OVs in Preclinical and Clinical Trials
Several VSV-derived OVs have been well characterized with studies confirming
increased safety and efficacy over wildtype virus [289] (reviewed in [68]) (Table 1-5).
Vectors of interest possess mutations ranging from the phosphoprotein (VSV-rp30a)
[353], glycoprotein (VSVG) [354], and matrix protein (M51) (reviewed in [355]). I
will discuss several mutants that have been more heavily studied in preclinical and more
recently, in clinical trials, though not for GBM.
AV1 and AV2
AV1 (attenuated virus 1) and AV2 (attenuated virus 2) are interferon-inducing
VSV mutants originally identified by their small plaque size in non-IFN defective cells
and large plaques in IFN defective cells [356]. These constructs are based on mutations
found in two temperature sensitive mutants, T1026R and TP3, respectively [357]. AV1
contains the classical M51R matrix mutation where AV2 contains two additional
mutations V221F and S226R. Just as previous studies have shown that, M51R mutants
are defective specifically in their ability to inhibit NCT of IFN message, AV viral
mutants were also found to have the same phenotype, with IFN- mRNA found in both
the nuclear and cytoplasmic pool of mRNAs in culture media from AV-infected cells
[289]. A panel of tumor cells ranging from breast cancer to colon cancer were tested and
found to be highly susceptible to infection with these attenuated viruses. To specifically
test attenuation in animals, AV’s were compared to wildtype virus in an
immunocompromised PKR-/- mouse model. AV’s were tolerated up to a 107 pfu (plaque
forming units) dose while only 10 pfu of wildtype caused death in these animals. Several
other studies have been carried out in tumor bearing animals, specifically using the single
matrix mutation found in AV1. In animals harboring lung tumors, systemic and
intranasal administration of AVs resulted in an increase in survival relative to UV-
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Table 1-5.

VSV-derived oncolytic viruses for the treatment of GBM

VSV Vector

Oncolytic
Mechanism

Defects in IFN
pathway
AV2
Defects in IFN
pathway
VSV-M51 (AV3) Defects in IFN
pathway
VSV-rp30a
Selective adaptation
in glioma cells

Viral Protein/
Mutation(s)

References

AV1

Matrix/ M51R

[289, 356-359]
[289, 356, 357]

VSV-IFN

Matrix/ M51R,
V221F, S226R
Matrix/ M51
deletion
Phosphoprotein/
not reported
Large
polymerase/
not reported
Insertion of IFN

Defects in IFN
pathway
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[187, 193, 285, 289]
[353, 355, 360]

[344, 361-363]

inactivated virus. Tumor load was also reduced as tumors treated with UV-inactivated
virus reached a volume of 750mm3 by 10 days post-implantation whereas AV treated
tumors never surpassed approximately 200mm3 throughout the study [289]. Another
study demonstrated the variability in response of tumors of the same type to VSV
oncolysis in vivo. Animals harboring subcutaneous prostate tumors were either treated
intra-tumorally or systemically with wt-VSV or M51 mutant. In one prostate tumor
(LNCaP), both viruses caused tumor reduction however in the other prostate tumor (PC3), cells remained resistant and grew at the same rate as untreated tumors [358]. Lastly,
an evaluation of M51R mutant treatment against human gliomas was carried out in a
xenograft mouse model of subcutaneously implanted U87 tumors. This study revealed
that M51R mutant completely eliminated tumors within 21 days post-infection without
viral induced morbidity whereas untreated animals reached euthanasia criteria as a result
of tumor load by 1 week [359]. To date, no clinical studies have been carried out for
either of these attenuated viruses.
VSV-M51
VSV-M51, also known as AV3 when expressing a fluorescent reporter gene,
contains a single amino acid deletion in matrix at position 51. Initial in vitro studies
tested the susceptibility of primary gliomas and glioma cell lines to infection, which were
all found to be highly susceptible to oncolysis by the mutant vector [289]. In safety and
efficacy studies using xenograft models of U87 and U118 human malignant glioma in
nude mice, intratumorally and intravenously administered virus markedly reduced tumors
compared to UV inactivated treated animals. Intravenous administration of VSVM51
was found to significantly prolong survival in mice with unilateral U87 tumors (median
survival of 113 versus 46 days) and bilateral U87 tumors (73 versus 46 days). No
toxicity was observed in this study. Therefore, VSVM51given systemically was able to
migrate to intracranial tumor and decrease tumor load while prolonging survival in this
model [285].
A subsequent study using the GFP expressing VSVM51 construct, AV3, in an
immunocompetent model of lung cancer sought to determine if the adaptive immune
responses which have been shown to attenuate VSV oncolysis could be circumvented by
using cell carriers, a novel mode of systemic administration. AV3 infected cells were able
to shield viral antigen during transport to tumor site where they then released virus,
infecting malignant cells and not surrounding normal tissue. Repeat administration of
infected cells improved therapeutic efficacy when compared to naked virion injection
with durable viral replication observed up to 6 days post-treatment. Two cell carriers,
tumor derived cells and leukemic cells, were tested for their ability to migrate to tumor
following i.v. administration. Tumor carriers were found to localize in the lungs whereas
leukemic carriers migrated to the lungs and throughout the body [187].
Whereas most studies are based on the premise that VSV selectively targets
tumors due to IFN defects, not all tumors fall into this category, as was described with
VSV-resistant prostate tumors. There are also groups of malignant gliomas that have
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been found to have active IFN pathways resulting in less responsiveness to VSV therapy.
Some of these tumors harbor defects in mTORC1 pathway, a pathway that signals IFN
activation [364, 365]. A recent study tested the use mTORC1 inhibitor, rapamycin, as an
adjuvant to VSVM51 in vitro and in an immunocompetent intracranial rat glioma model
to determine enhancement of antitumor effect. By reducing IFN activity, combination
therapy significantly increased survival while specifically targeting and reducing
intracranial tumors [193]. As with the other AV constructs, there are no ongoing or
previous clinical trials for VSVM51.
VSV-rp30a
Unlike most VSV therapies, VSV-rp30a is a naturally occurring mutant derived
through repetitive passage in glioma cells whose evolutionary pressure led to tumor
specific mutations that enhance viral fitness in glioma cells [353]. Its increased fitness is
attributed to two confirmed mutations, one in the P protein and the other in the L protein
of VSV [355] however the exact mutational changes in these proteins have not been
revealed. In vitro studies comparing the wildtype virus to the glioma-adapted VSV-rp30a
demonstrated a replication advantage of both viruses in human glioblastoma cell lines
over non tumor cells marked by increased cell rounding and decreased cell viability. As
expected, VSV-rp30a displayed increased growth ability in tumor cells relative to
wildtype at earlier time points. Following IFN- or polyI:C pre-treatment, some
protection was observed at early time points in glioma cells with complete protection in
normal cells. These results corresponded to MxA expression levels following either viral
infection or pre-treatments, with a boost in MxA observed in all normal cell types and
varying levels in glioma cells ranging from little to no expression. This suggests the
variable nature of IFN defects in GBM cells which may explain differences in
susceptibility to viral oncolysis in different tumors [353].
In an immunodeficient, xenograft mouse model of human intracranial and
metastatic glioma, VSV-rp30a was shown to not only target intracranial tumors but also
migrated to sites of extra-cranial tumors as well. Though longer time points were not
included in this study in order to determine differences in survival and tumor load
reduction, it was shown that virus effectively replicated in transplanted tumors at up to 72
hours post-infection and that several glioma tumors possessing different genetic
aberrations in the p53 pathway were equally susceptible [63, 360]. As of yet, no clinical
trials are planned for VSV-rp30a.
VSV-IFN
 (mIFN, mouse IFN; rIFN, rat IFN; hIFN, human IFN)
Since the IFN pathway is the most accepted proposed mechanism for selective
replication of VSV in tumor cells leading to oncolysis, a VSV construct expressing IFN
(VSV- IFN) was developed. It was originally tested for treatment of hepatocellular
carcinoma (HCC) but has since been evaluated as treatment for multiple myeloma (MM).
In vitro, VSV-hIFN has been shown to have a non-lytic phenotype in normal human
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cells while remaining oncolytic in malignant cells [344]. To verify safety in animals,
intravenous and intranasal VSV- mIFN was administered in immunocompetent mice
and was shown to be significantly attenuated compared to wild-type VSV [344], however
subsequent studies demonstrated neurotoxicity when given intravenously causing fatal
encephalitis in inoculated animals [361]. Additional studies have evaluated VSVIFN for treatment of HCC and MM. To first determine safety and MTD,
immunocompetent Sprague Dawley rats and rhesus macaques were administered
intrahepatic VSV- hIFN with no adverse events appreciated. However, in an orthotopic
syngeneic model of HCC in Buffalo rat, intratumoral administration caused neurotoxicity
with VSV- hIFN construct that lessened by using species-specific rVSV-rIFN. No
results of tumor load reduction were determined in this study [361]. In studying VSVhIFN as a treatment for multiple myeloma, significantly prolonged survival and antitumor activity was demonstrated in an immunocompetent mouse model of subcutaneous
and disseminated myeloma. Species-dependent responses were also observed in this
study, as mIFN construct prolonged time to progression in the mouse model over the
use VSV-hIFN [362]. A phase I trial at Mayo clinic testing VSV- hIFN for treatment
of adult primary HCC or recurrent primary liver cancer is in progress and planned to be
complete by June 2013 [363].
As with OVs derived from different viruses, there can be differences in the
oncolytic profile of alternate constructs derived from the same virus. Each may possess
their own advantages and disadvantages, therefore, an understanding of underlying tumor
biology of the cancer type being treated is important. Van den Pol and associates
compared several VSV constructs in their potential as a treatment for GBM. Of those
tested, VSV-M51, VSV- CT9-M51 (CT9- truncation of G protein cytoplasmic tail),
VSV-p1-GFP (insertion of GFP at the 3’ end of the genome), and VSV-p1-RFP (insertion
of red fluorescent protein (RFP) at the 3’ end of the genome) were safest and most
effective at destroying malignant glioma while other constructs including VSV-G and
VSV-rp30a were least effective [355]. These may prove to be the best vectors to
consider for phase trials in the treatment of GBM as newer more tumor selective
constructs become available.
rNCP12.1
rNCP12.1 (recombinant Non-CytoPathic isolate 12.1) is a novel attenuated
replication competent VSV vector developed by Whitt and associates due to its noncytopathic effects in a number of cell lines [237]. It was originally isolated after
establishment of a persistent infection in BHK-21 cells with another M mutant, M33,
51A. As discussed, due to the mutations at positions 33 and 51 in the matrix protein, this
mutant is unable to express the truncated matrix products, M2 and M3. In effect, M33,
51A mutant is defective in cell rounding especially in BHK-21 cells while maintaining
wildtype cytotoxicity in several other cell types, particularly HeLa and 293 cells. No
defects in host cell shutoff were appreciated for this mutant [237]. Because M33, 51A
causes only ~40-50% of cells to round following infection [237], cells that remained flat
were further cultured to maintain a persistent infection as confirmed by viral expression
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of an inserted green fluorescent protein and from viral titers. Resultant virus from this
persistent infection was found to have two mutations in the matrix protein in addition to
M33,51A. These additional mutations are located in the C-terminus of matrix and
correspond to T133A and S226G. The matrix of the original non-cytopathic variant,
NCP12, was subcloned into a wt background and this recombinant vector was designated
rNCP12.1 [237].
Whereas M33, 51A causes approximately half of BHK21 cells to round following
infection, rNCP12.1 cell rounding is negligible in BHKs. However, in other transformed
cell types such as HeLa and HEK293 cells, cell rounding is present but variable [366]
(Figure 1-10). Therefore it was implied that the cell rounding phenotype of rNCP12.1 is
cell type specific and may depend on the presence of some host factor. Further
characterization revealed that, like M33, 51A, host cell shutoff was similar to wtVSV at
8hpi. However, unlike wtVSV, viral gene expression was decreased especially for M and
G proteins, which could be due to an overall increase in antiviral host response [366]. In
keeping with other studies that support the genetic separation of domains involved in
budding and assembly from those involved in CPE [242] rNCP12.1 budding, though
slightly decreased from wtVSV, maintained efficiency. Viral yields were approximately
10 fold less than wt at 18 hours post infection (hpi). Of the four mutations in the matrix
of rNCP12.1, position M51 is the most important in its overall phenotype. M33A and
T133A alone displayed CPE similar to wt whereas S226G expressed intermediate cell
rounding but yielded virus similar to wt levels. M51A alone made 10 fold less virus than
wt. More than likely, the overall phenotype of NCP12.1 is due to an additive effect of the
combination of these mutations (Table 1-6).
This phenotype has been exploited in our lab in several ways. First, because of its
decreased cytotoxicity in normal cells coupled with its near normal assembly and
budding function, rNCP12.1 was used to recover a recombinant VSV vector lacking the
M gene (M-PLF). Until this time, recovery of VSV vectors lacking M were impossible
due to the inhibition of gene expression caused by expression of wt M needed for
complementation [366]. In addition, its use has been important in developing an
oncolytic virus for the treatment of glioblastoma. To this end, preliminary results have
been promising and will be described in further detail in this dissertation.
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Figure 1-10. Cell rounding phenotype of rNCP12 in different cell types
rNCP12 is the parent virus of rNCP12.1. Phase contrast micrographs, taken at 10X
magnification, show differences of cell rounding by NCP12 and wtVSV infection in (A,
B) BHK cells, (C, D) HeLa cells, and (E, F) HEK 293 cells at 24hpi.
Reprinted with permission: H.R. Jayakar, VSV M protein domains involved in assembly
and cytopathogenesis, 2001 [366].
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Table 1-6.
Virus

Characterization of individual mutations in matrix mutants
Mutation

Virus Yielda

Host Shut Offc

Wild-type

None

+++

Cell
Roundingb
+++

M33A

M33A

+++

+++

ND

M51A

M51A

+

+

ND

M33,51A

M33A
M51A

+++

+

+++

T133A

T133A

+++

++++

ND

S225G

S225G

+++

++

ND

rNCP12.1

M33A
M51A
T133A
S225G

+

-

+

a

+++

+++ indicates wildtype levels of virus titers (~5x108-1x109), and + indicates atleast 10
fold reduction in yield
b
+++ indicates >90% of cell rounding in BHK21 cells by 24hpi, and + indicates <50%
rounded cells; - indicates no cell rounding
c
+++ indicates >50% host cell shutoff by 8hpi; + indicates <50% host cell shutoff
ND, not done
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CHAPTER 2.

MATERIALS AND METHODS
Cells and Viruses

All cells were maintained as a monolayer culture at 37ºC, 6% CO2. All medium
was supplemented with 100U/mL of penicillin and streptomycin (Table 2-1). The rat
F98 and C6 glioma and human U87 glioma cell lines were previously transduced with the
pFB retrovirus (pFB-GFP) (Stratagene, La Jolla, CA) expressing GFP to allow
visualization of tumor load in brain sections. Cells stably transduced with GFP were
sorted using flow cytometry to generate a cell population homogeneously expressing high
levels of GFP.
All recombinant VSV constructs were made in the Lab of Michael A. Whitt, PhD
and contained genes of the Indiana serotype with the exception of the glycoprotein of the
New Jersey serotype (GNJ) for rNCP12.1NJ-GFP (Table 2-2).
Cell-Rounding Assay
Rat glioma (C6, F98), human glioma (U87, A172, and T98G), and PRAs were
plated in 35-mm-diameter dishes and infected with rNCP12.1-GFP (NCP12.1-dsRed in
U87, C6, F98) at an MOI of 10 (rat glioma) and MOI of 1 (human glioma) for one hour
at 31oC. Inoculum was removed, and the cells were washed once with serum-free
medium and then incubated at 37°C for varying times. At 24hpi, medium was removed,
and cells were washed twice with phosphate- buffered saline (PBS) and fixed with 3%
paraformaldehyde at room temperature for 20 min, followed by two washes with PBS
containing 20 mM glycine. Cells were observed by bright field and fluorescence
microscopy (Zeiss, Axiovision) to determine presence of viral and tumor cell fluorescent
markers.
Growth Kinetics
Rat glioma cells and PRAs were seeded into 96 well plates for 24 hours then
mock infected by incubation in serum free media or infected with either wt-VSV or
rNCP12.1-GFP for one hour at 31oC at an MOI of 10. Inoculum was removed and cells
were washed with serum free (SF) DMEM three times. Fresh D10 was added to all cell
lines and incubated further at 37oC. At various time points (T=6, 12, 24, 8, 72hpi; 1wpi)
supernatant was removed and infectious virus was determined using a plaque assay on
BHK cells.
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Table 2-1.

Cells

Cell Type
BHK21 cells
Mouse Embryonic
Fibroblasts (MEF)
L929 mouse fibroblasts
Rat Fibroblasts (FR)
Primary Rat Astrocytes
(PRAs)
F98 (GFP)c Rat Glioma
C6 (GFP) Rat Glioma
U87 (GFP) human glioma

T98G human glioma

A172 human glioma

Obtained from
Lab of Dr. Michael Whitt
ATCC (Manassas, VA)

Culture Medium
DMEMa + 5% FBS (D5)
DMEM + 10% FBS (D10)

Courtesy of Dr. Lawrence
Pfeffer (Pathology,
UTHSC)
ATCC (Manassas, VA)
Special Protocolb

DMEM + 10% FBS

ATCC (Manassas, VA)
ATCC (Manassas, VA)
Courtesy of the Lab of
Neurosurgery (Christopher
Duntsch, MD, PhD;
UTHSC)
Courtesy of the Lab of
Neurosurgery (Christopher
Duntsch, MD, PhD;
UTHSC)
Courtesy of the Lab of
Neurosurgery (Christopher
Duntsch, MD, PhD;
UTHSC)

a

DMEM + 10% FBS (E10)
DMEM + 10% FBS
DMEM + 10% FBS
DMEM + 10% FBS
EMEMd + 10% FBS

EMEM + 10% FBS

EMEM + 10% FBS

Dulbecco’s Minimum Essential Medium supplemented with 5% Fetal Bovine Serum
Primary rat astrocyte cultures were obtained by dissecting and removing striata from
E17 rat embryos. Cells were dissociated, plated, and allowed to grow to confluency for
approximately 10 days.
c
Cells were purchased and later transduced to express GFP. Protocol described
separately
d
Eagle’s Minimum Essential medium
b
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Table 2-2.

Virus constructs

Virus
wtVSV-GFP

Serotype (Strain)
Indiana (N, P, M, G
genes- San Juan; L geneMudd Summers)

Constructed by
Michael A. Whitt, PhD

rNCP12.1I-GFP

Indiana (N, P, M, G
genes- San Juan; L geneMudd Summers)

Himangi Jayakar, PhD

rNCP12.1NJ-GFP

New Jersey (N, P, M, G
genes- San Juan; L geneMudd Summers, G geneOgden)

Himangi Jayakar, PhD

rNCP12.1I-dsRed

Indiana (N, P, M, G
genes- San Juan; L geneMudd Summers)

Himangi Jayakar, PhD
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Cytotoxicity Assay
Rat glioma cells and PRAs were seeded into 96 well plates then mock infected
with serum free media or infected with either wt-VSV or rNCP12.1 at an MOI of 10 at
31oC for 1 hour. Inoculum was removed and replaced with D10 and cells were incubated
at 37oC. At various times post infection (T=6, 12, 24, 8, 72hpi; 1wpi), supernatants were
harvested and used to determine growth kinetics as described. Cell viability at the same
time points was determined using the CellTiter 96Aqueous One Solution Cell
Proliferation Assay (Promega) according to the manufacturer’s protocol.
IFN Protection Assay
Rat glioma cells and PRAs were plated in 96 well plates and 24 well plates
respectively. Cells were counted after plating using a hemocytometer to confirm a
normalized cell count. Culture media was removed from cells and rat IFN (rIFN;
provided by Dr. Lawrence Pfeffer, Department of Pathology, UTHSC) was added starting
with 1000U (high dose experiment) and 100U (low dose experiment) of IFN at 2 fold
serial dilutions. Cells were incubated overnight at 37oC. At 24 hours post-treatment, IFN
was removed and cells were infected with wtVSV at an MOI of 3 for 1-2 hours at 31oC.
Inoculum was then removed, fresh D5 was added, and cells were incubated at 37oC
overnight. At 24hpi, D5 was removed and cells were washed three times for 5 minutes
each with 1XPBS. Cells were then fixed with 3% paraformaldehyde for 20 minutes then
treated with 1% TritonX-100 at room temperature for 5 minutes to permeabilize the cell
membrane. The cells were stained with an -VSV N specific monoclonal antibody
(10G4) conjugated to Rhodamine. Cell rounding and presence of virus was determined
by fluorescence microscopy (Zeiss, AxioVision). Protection was defined as the amount
(U) of IFN at which less than 50% cells were infected.
pI:C Induction of IFN
Cells were plated in 60mm plates and cultured until 70% confluent. Cells were
treated for 4 hours with 25, 50, or 100g pI:C in SF-DMEM or transfected with 0.1, 1, or
10g pI:C in a ratio of 1:1 with Lipofectamine 2000. pI:C treatment mixture was
removed, D10 was added, and cells were incubated at 37oC. Supernatants were collected
at 24 hours post-treatment and IFN activity was determined using the IFN bioassay
described. Cell lysates were harvested and stored at -20oC or used directly for qRT-PCR
studies. In a subsequent time course experiment, cells plated in 60mm plates were treated
with 10g of transfected pI:C only, and supernatants were collected at t=2.5, 4, 6, 12, 18,
24 hours post-transfection. Supernatants were used to determine presence of active IFN
using the IFN bioassay and remaining cells were lysed with 1 ml Trizol reagent
(Invitrogen), harvested, and stored at -20oC or used directly in qRT-PCR studies.
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IFN Bioassay
Supernatants from immune-stimulated cells (pI:C pretreatment or viral infection)
were collected at various time points following treatment and applied at 2 fold serial
dilutions on L929 mouse fibroblasts pre-plated in 96 well plates to reach 70% confluency
at the time of the experiment. After a 24 hour incubation, the supernatant was removed
and L929 cells were infected with wtVSV at an MOI of 0.5 for 1 hr at 31oC. Inoculum
was removed, fresh media was added, and cells were incubated at 37oC. Rat IFN
(rIFN) was used as the standard for scoring of the IFN bioassay. Units for rIFN were
determined with respect to the international reference standard for mouse interferon
alpha/beta, mouse IFN-/ (NIH) and stored in aliquots having a known titer of
106U/mL. At 36-48hpi, media was removed and the assay was scored as determined by
the dilution factor at which 50% inhibition of CPE was observed [367]. This dilution was
then compared to the known concentration at which the standard inhibited 50% CPE.
Based on the data in Table 2-3, the highest dilution at which rIFN standard inhibited CPE
is 1.5625U/125L=0.0125U/L=12.5U/mL. From this information, we can determine
the original amount of IFN in each sample prior to dilution (Example: CPE in sample #5
started at 25U/125L therefore titer of the original sample would be 200U/mL. Sample 2
showed no CPE therefore an additional study evaluating higher dilutions would be
necessary. Sample #4 showed no protection, therefore IFN titer of this sample is
undetectable).
Viral Infection for IFN Bioassay and ISG qRT-PCR
Cells were plated in 60mm plates and grown to 80% confluency. Cells were then
mock-infected (SF media) or infected with either wt-VSV or rNCP12.1 at an MOI of 10,
for 1 hour at 31oC. Inoculum was removed and cells were washed twice with SFDMEM, then incubated overnight at 37oC in 2mL of D-10. At time points, T=6, 12, 18,
and 24hpi supernatants were harvested and centrifuged to remove cellular debris.
Remaining cells were lysed in 1 ml Trizol reagent (Invitrogen), harvested, and stored at 20oC or used directly in qRT-PCR studies. In order to be used for IFN bioassays, virus
was separated from supernatant of infected cells using Millipore Amicon Ultra-4
centrifugal filters with Ultracel membrane of 100,000 NMWL cutoff. Samples were
centrifuged twice at 5000rpm for 10 minutes at 4oC, using a new filter for the second spin
cycle. Standardization of this IFN bioassay using virus-containing samples will be
explained in Appendix B. A small aliquot of ultra-filtered supernatant was used to
ensure all virus was removed using a standard plaque assay on BHK21 cells.
qPCR to Determine Expression of IFN
1
Semi-quantitative RTPCR was carried out to detect expression of IFN1 in virally
treated FR and C6 rat glioma cells at 6 and 12hpi. Infected cells were lysed in 1mL
Trizol and total RNA was extracted. A One step RT-PCR (Qiagen) was carried out
according to manufacturer protocol using IFN1 specific primers (Table 2-4). DNA
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Table 2-3.

Sample
IFN std
SF only
Sample 1
Sample 2
Sample 4
Sample 5
Sample 6

Scoring for IFN bioassay
Initial Concentration (U/125
 L) Final Concentration (U/mL)
100

800
+
+
-

50

400
+
+
-/+

25

200
+
+
-/+
+

12.5

100
+
+
+
+

70

6.25

50
+
-/+
+
+
+

3.125
 1.5625

25
12.5
-/+
+
+
+
+
+
+
+
+
+
+

0.78125

6.25
+
+
+
+
+
+

Table 2-4.

qRT-PCR UPL primers for interferon stimulated genes

Gene

Left Primer

Right Primer

ggtggaccctccacattg
IFN1
(interferon beta 1
fibroblast)
IFN4
(interferon
alpha 4)

tagtcgatggagagggcagt

cagcagctcagtgacctcaa

Mx1 (myxovirus/ ccagcacctgaatgcctac
influenza virus
resistance 1)

UPL
Probe #
18

taggggaggttcttgcattc

62

tggagtactggatgatcagagg

94

GBP1
(guanylate
binding
protein 1)

cagaaaaggaaaaggagattgaag ttctgtgtttcctccaacagc

66

Plscr1
(phospholipid
scramblase 1)

tcagattctggttcatcagcag

cgtatcttccaccgcaaagt

113

RIG-I
(Ddx58, DEAD
box polypeptide
58)

gaagattctggaccccacct

tgaatgcactgcacctcatc

73

IRF1
(interferon
regulatory
factor 1)

aagggaagttacctgaggacatc

gctgaagtctccatagacagtagagag

92

Cyclophilin B

acgtggttttcggcaaagt

cttggtgttctccaccttcc

97

71

fragments were separated by 2% agarose gel and visualized under UV light following
treatment with ethidium bromide.
Quantitative RT-PCR (qRT-PCR) to Determine Expression of IFN
 1 and ISGs
After Trizol extraction of total RNA, RNA concentration in each sample was
determined by spectrophotometer at A260. One microgram of RNA per reaction, along
with M-MLV reverse transcriptase (Invitrogen) and random hexamers were used to
synthesize cDNA. Next, quantitative PCR was performed on the LightCycler 480
(Molecular Resource Center, UTHSC) using Universal Primary Library (UPL) protocol
for rat gene expression (Roche) (Table 2-4). Universal probes are specific for the
detection of the rat transcriptome and are labeled with fluorescein at the 5’ end and a dark
quencher dye at the 3’end that allow detection by standard SYBR Green I filters. The
LightCycler 480 Taqman90 protocol was used which is pre-programmed to perform the
following cycles: activation of DNA Polymerase for 5 minutes at 95 oC; amplification of
cDNA for 40 cycles which includes 10 seconds at 95oC denature, 20 seconds at 60oC
annealing, and 10 seconds at 72oC extension; cool down for 30 seconds at 40oC.
Western Blot Detection of Neutralizing Antibodies
To detect the presence of -VSV antibodies in the sera of treated animals, blood
was collected at the time of sacrifice by transcardiac method (described below). The
cellular components were separated from blood by centrifugation and serum only was
stored at -20oC until used. 104 pfu rNCP12.1 were prepared for electrophoresis in
reducing sample buffer LSB +BME. Proteins were separated using 9% acrylamide 10%
SDS gel electrophoresis then transferred to polyvinylidene fluoride (PVDF) microporous
membrane. Membranes were blocked using 5% Non-fat dry milk/TTBS for two hours
and viral proteins probed with rat sera from treated or control animals diluted to 1:100 or
with positive control, R6-F, at 1:5000 (R6-F is a rabbit polyclonal antibody directed
against detergent treated wtVSV). Blots were incubated for two hours at room
temperature or overnight at 4oC followed by treatment with goat -rat secondary
antibody conjugated to Horse Radish Peroxidase (HRP) (Jackson ImmunoResearch
Laboratories) at a dilution of 1:5000 for two hours at room temperature. Signal was
visualized using chemiluminescence (SuperSignal West Dura, Pierce) followed by
exposure to and development of X-ray film.
Neutralizing Antibody Assay
In 96 well plate, BHKs were plated and cultured overnight in D5. Serum samples
were treated at 56oC for 35 minutes in order to neutralize any residual virus. 200 pfu of
wtVSV were added to two fold serial dilutions (1:2 to 1:1000) of test sera. Negative
control included FBS only and positive control included TN-1, a polyclonal antibody
developed in rabbit against i.v. injection of UV-inactivated intact wtVSV. Serum or
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TN-1 plus virus was incubated at 37oC for 35-45 minutes then added to cells overnight at
37oC. Neutralizing antibody titer was determined by the inverse of the dilution required
for 50% inhibition of infection at 24 hours post-treatment (e.g. 1:1000 dilution
corresponds with a neutralizing titer of 1000).
Animal Studies
Tumor Implantation
All animal experiments were conducted under the guidelines of the UTHSC
IACUC (Institutional Animal Care and Use Committee). Both Wistar and Fischer 344
rats were obtained from Charles River. To establish intracranial gliomas, six week old
250-300 gram male adult rats were anesthetized by administration of ketamine/xylazine
i.p. at a dosage of 87mg/13 kg body weight (0.1mL/100g body weight). Animal was
placed in a stereotaxic frame and skin was prepped using iodine. By sterile technique, a
1.0 cm incision was made in the midline of the skull along the sagittal suture starting just
behind the plane connecting the eyes. The cranium was exposed and a Burr hole 3.0mm
lateral to the bregma on the right of the bregmatic suture was created without
compromising the dura. 1 x 105 rat glioma cells (C6-GFP; F98-GFP) were injected
intracranially using a 25L Hamilton Syringe. Injections were given slowly over 30
seconds at a depth of 3mm below the dura. Following administration of cells, the needle
was left in place for approximately 2 minutes then retracted slowly over 30 seconds.
Following implantation, the Burr hole was sealed with bone wax and the skin incision
was sutured using 4.0 monofilament. Throughout the procedure, animals were kept on a
warming blanket in order to maintain body temperature. Post-op, animals were treated
with oxygen to aid in recovery from anesthesia.
Measures of Morbidity
Morbidity was determined based on weight trends and the rat coma scale (RCS)
(Table 2-5). The RCS was developed by Christopher Duntsch, MD, PhD (UTHSC
Department of Neurosurgery) as an adaptation of the human Glasgow coma scale (GCS),
a widely used assessment tool for neurological function especially following traumatic
brain injury. Components of the RCS involve level of consciousness, motor function,
and spontaneous eye movement. Additional manifestations of distress are not accounted
for in the RCS therefore we created a supplemental assessment to help determine the
need for euthanasia which include rat-specific signs and symptoms such as chattering and
lack of grooming (Table 2-6). Certain signs are more severe in nature and would call for
euthanasia when they are present as animals are less likely to recover from these.
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Table 2-5.

Rat coma scale

Neurological
Response
Level of
Consciousness
(LOC)

Score*
4
Moves
spontaneously
without
stimulation

3
2
Moves
Moves with
spontaneously
pain stimulus
when picked up
for 3 seconds
by tail and put
back down

1
Does not
move with
pain stimulus

Motor

N/A

No motor
deficits

Paresis (hemi/
quadri/
forelimb/
hindlimb
involvement)

Plegia (hemi/
quadri/
forelimb/
hindlimb
involvement)

Eyes

Opens
spontaneously

Opens with
stimulation

Open to pain
stimulus

Does not open

*Highest total score, 11 (4+3+4); Lowest total score, 3 (1+1+1)
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Table 2-6.

Additional signs of distress

Sign
Sneezing/ coughing
Bowel changes (usually
diarrhea)
Porphyrin stain around
eyes
Ruffled hair
Huddles in corner
Hunched
Chattering/ vocalizing
Urine stained coat
Late seizure activity
Increased work of
breathing

Severity
Low
Low

Predicted Outcome
Usually recover

Low
Medium
Medium
Medium
Medium
High
High
High
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Monitor weight and RCS
every day versus every 3
days
Pending death

Cerebrospinal Fluid (CSF) Collection
The procedure for CSF collection was adapted from the protocol described in
Sharma et al, 2010 [368] and performed as a terminal procedure. Immediately following
induction of deep anesthesia, animal was placed in position on the CSF collection
apparatus provided by the UTHSC Department of Comparative Medicine, Laboratory
Animal Care Unit, in order to maintain proper head positioning and easier identification
of access to the cisterna magna, located between the occipital protuberance and the
posterior tubercle of the atlas. Once secured, hair covering the occipital region was
shaved. A winged 25 gauge x 3/4 inch needle (BD Vacutainer Safe Lok) with infusion
tubing was connected to a 1cc syringe. The needle was slowly inserted into the site of the
cisterna magna directly below the occipital protuberance at an angle as close to parallel as
possible to the position of the spine. Once dura mater was penetrated as detected by a
subtle decrease in resistance, gentle negative pressure was applied by slow suction using
the 1cc syringe. Approximately 50 -70^L of CSF can be obtained by this method.
Transcardiac Blood Collection
Collection of blood by transcardiac method was performed as a terminal
procedure following induction of deep anesthesia. A 1-2cm incision was made on the
skin of the abdomen and widened with scissors to make a skin flap for access to the intraabdominal cavity. After entering the abdomen, the xiphoid process was elevated and the
diaphragm was appreciated. The diaphragm was pierced with the scissors and the
incision was widened in order to enter the thoracic cavity inferiorly. Once inside the
thoracic cavity, the left ventricle of the heart was identified and 0.2 cc heparin was
injected to prevent coagulation during blood collection. After ~30-60 seconds, a 27
gauge x ½ needle attached to a 3cc syringe was inserted into the left ventricle and blood
was collected and stored immediately on dry ice to be used for subsequent studies.
Preparation of Concentrated Virus for Intracranial Injections
Forty 150mm plates of BHKs were grown to 80-90% confluency. Cells were
infected at an MOI of 3 in 10mL of SF-DME (no penicillin or streptomycin, -P/S) for 1
hour at 31oC. After one hour, 10mL additional SF-DME -P/S was added to cells and
cells were incubated at 37oC overnight. Supernatants from infected cells were harvested
and cellular debris was removed by centrifugation (2550rpm for 10 minutes at 4oC using
JS 4.2 rotor). A small aliquot of supernatant was collected and stored at -20oC for later
titering. Next supernatant was passed over a 20% sucrose cushion (TN pH 7.2) and virus
was pelleted at 28,000 rpm for 60 minutes at 4oC. Viral pellet was resuspended in 100L
sterile TN pH 7.2 + 10% sucrose. A small aliquot of pelleted virus was tittered using a
standard plaque assay on BHKs and viral yield was compared to titers of pre-pellet
aliquot to determine efficiency of recovery.
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rNCP12.1 Single Injection
Three to five days post-tumor implantation, rats were divided randomly into
groups and viral injection was administered using the same injection procedure as
performed for tumor implantation. Through the pre-existing Burr hole, a single dose of
rNCP12.1-GFP at either 105, 106, 107, or 108 pfu/ 25L Tris-Saline + 10% sucrose (TN10) buffer was administered by Hamilton syringe. Vehicle only (TN-10) was given to
control animals. Animals were monitored daily for changes in weight and for signs of
illness or treatment-related neurological deficits. On day 15 post-tumor implantation,
animals were sacrificed and the brains were harvested for further tissue processing. A
second group of treated and control animals were followed until RCS score, weights,
and/or other clinical signs called for euthanasia.
Alzet Pump
On day five post- tumor implantation, ALZET pumps were prepared and filled
with viral agent or viral vehicle in a sterile field according to manufacturer’s instructions.
Pumps were placed in 0.9% sterile saline and incubated for 4-6 hours at 37oC as priming
for the delivery of agent at the time of implantation. Animals were anesthetized and
placed onto the stereotaxic frame. The previous incision site created during tumor
implantation was opened and slightly widened to allow enough space for the pump
implant. Injection of rNCP12.1-GFP was administered as described. Following
injection, pre-filled ALZET pumps were implanted taking care to not damage the catheter
and needle. The needle was inserted directly into the pre-made Burr hole. Once in place,
the overlying skin was sutured with the pump in order to secure it into place. The
incision site was again sutured with 4.0 monofilament. Animals were followed until RCS
score, weights, and/or other clinical signs called for euthanasia.
Serotype Switch
On day 5, post-tumor implantation, rats were divided randomly into groups and
viral injection was administered as described. A single dose of rNCP12.1-GFP, Indiana
serotype was administered at a dose of 109 pfu/ 10L TN buffer by Hamilton syringe.
Control animals received TN buffer vehicle only. On day 10, post-tumor implantation, a
second dose of 109 pfu/ 10L rNCP12.1-GFP was administered. Half of treated animals
received Indiana serotype as the second injection and the other half received New Jersey
serotype. On day15 post-tumor implantation, animals were sacrificed and the brains were
harvested for further tissue processing. A second group of treated and control animals
were followed until RCS score, weights, and/or other clinical signs called for euthanasia.
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Test for Tumorigenicity of Pre-Infected Tumor Cells
Three 10cm dishes of F98-GFP cells were plated and grown overnight. Cells
were infected at an MOI of 0.1 or 10 with rNCP12.1-GFP for one hour at 31oC. Cells
were washed three times with SF-DME, trypsinized, centrifuged and resuspended in 5mL
of PBS. Uninfected cells were also trypsinized, centrifuged and resuspended in 5mL of
PBS. Cells were counted and aliquots of infected (MOI of 0.1 and 10) to uninfected cells
at a ratio of 1:10 or 1:1 were made based on cell counts using a hemocytometer. A total
of 100,000 cells/10l were prepared and implanted by the standard protocol.
Pre-Infected Tumor Cell Carriers in Tumor Bearing Rats
F98-GFP glioma cells were plated in 10cm dishes and grown overnight. Cells
were infected at MOI of 3 for one hour at 31oC. Cells were washed three times with SFDME, trypsinized, centrifuged, and resuspended in 5mL PBS. Cells were diluted to 1000
cells/ 10L and implanted per usual protocol.
Recovery of Virus from PC-Treated Animals
Sera, CSF, and non-fixed brain tissue from several animals was harvested. A
0.5cm area starting at the needle track continuing rostrally was excised from brain tissue
and placed in 2mL PBS in a 15mL conical centrifuge tube. Tissue was homogenized for
2-3 minutes and cellular debris was removed by centrifugation. One hundred microliters
of each sample was added to cultured BHK cells for 1 hour at 31oC. Samples were
removed, warm agar containing D5 was applied, and cells were incubated at 37oC. At
24-36 hpi, agar was removed and cells were fixed and stained to detect VSV
nucleocapsid using an VSV-N mAb (10G4) conjugated to Rhodamine. Fluorescence
images were captured and processed using Zeiss Axiovision.
3

Tissue Processing
Brains were harvested at the time of sacrifice following vascular perfusion and
fixation. For all experiments, perfusion included a vascular flush of 200mL 0.9% NaCl
followed by fixation with 200mL 4% paraformaldehyde. For brain tissue harvested from
animals treated with rNCP12.1-GFP pre-infected tumor cells, only a vascular flush of
400mL 0.9% saline was done without fixative as tissue was needed for qRT-PCR
analysis. Following fixation, brains were soaked in 4% paraformaldehyde (except for
brain tissue harvested for qRT-PCR) for 24 hours and then 20% sucrose for 2 days.
Cryosectioning of brain tissue was done starting at the site of injection (needle track) in
10 m thick sections for samples used for Hematoxylin (Gill’s) and Eosin Y (Fisher
Scientific, Suwanee, GA) (H&E) staining and at 14m thick sections for
immunohistochemistry (IHC). The site of sectioning at and adjacent to the needle track
was chosen as we assume this is the most likely site for tumor implantation although
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variations do occur. For IHC staining of tissue, sections were treated with 2% NFDM
(nonfat dry milk) in 0.2M PBS/0.3% triton X-100 to block nonspecific staining. Tissue
was washed three times for 15 minutes each in PBS at room temperature. The primary
antibodies, rabbit -GFAP at 1:80 and mouse-VSV N protein (10G4) at 1:3, were used
to probe for the astrocytic marker, GFAP, and VSV Nucleocapsid (N) protein,
respectively. Signal was amplified using the secondary antibodies, goat-rabbit
conjugated to Cy5 (blue) and goat -mouse conjugated to Cy3 (red) (Jackson
ImmunoResearch Laboratories) both at a concentration of 1:100 for 1-2 hours at room
temperature. All antibodies were diluted in 0.1% Triton-X /PBS containing the serum of
the species from which antibody was derived. Lastly, slides were washed and
coverslipped. Fluorescent markers were visualized using laser scanning confocal
microscopy (Zeiss LSM 510 AIM version 3.2 software). Slices were captured at
magnifications of 0.4X, 10X, 20X, and 40X.
Tumor Measurement
Tumor surface area was determined based on images collected from fluorescence
microscopy (Leica). Using NIH Image J software, an outline of GFP- expressing tumors
was traced and surface area was determined using a pre-set calibrated scale in millimeters
(Set Scale command). For rNCP12.1 pre-infected tumor cell experiment only,
ImageScope (Aperio ePathology Solutions) software was used to measure and calculate
tumor load.
Statistical Analysis
All data were analyzed using Prism Graphpad 6.0 software and expressed as mean ±
standard deviation. A One-Way ANOVA with multiple comparisons to an untreated
control group was done for experiments having 3 or more groups while a two tailed t-test
was used for comparison of the means for experiments having no more than two groups.
For the evaluation of rNCP12.1-GFP pre-infected cells, multiple t-tests were done
comparing treated versus untreated groups at each time point. The Kaplan-Meier
analysis of survival for animal experiments was done using a log-rank (Mantel-Cox) test.
P values of <0.05 were considered to be statistically significant.
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CHAPTER 3.

RESULTS

In Vitro Characterization of rNCP12.1
rNCP12.1 Retains Its Non-Cytopathic Phenotype in Normal Brain Cells While
Remaining Cytopathic in Most Tumor Cell Lines
As discussed, rNCP12.1 is a recombinant VSV vector harboring mutations that
prevent its ability to form the truncated forms of the matrix protein. This promotes its
non-cytopathic phenotype in a number of cell lines including BHK21 cells. In evaluating
rNCP12.1 as a potential oncolytic virus for the treatment of malignant brain tumors, we
wanted to first establish the cell rounding phenotype in cells of glial origin as this is
associated with viral-induced cytopathic effects. In order to do so, a cell rounding assay
was performed in primary rat astrocytes (PRAs) and in two rat glioma cell lines, F98GFP and C6-GFP. Cells were infected with both wtVSV and rNCP12.1 at an MOI of 10
and cell rounding was observed at 24hpi. rNC12.1- infectedPRAs demonstrated minimal
cell rounding at 24hpi in comparison to those infected with wtVSV. This was similar to
cell rounding previously seen in BHK-21 cells. On the other hand, rNCP12.1 infection in
F98 cells caused rounding and cells became detached from the culture plate by 24hpi
comparable to wtVSV infection. C6 glioma cells demonstrated a cell rounding variant in
which the majority of cells were rounded but not detached from the plate (data not
shown). The cell rounding phenotype of rNCP12.1 infection was also determined using
an MOI of 1 versus 10 in three human glioma cell lines, U87-GFP, A172, and T98G
(Figure 3-1). As with rat glioma cells, there was variation in cell rounding. T98G
glioma cells were least sensitive to rNCP12.1 infection with very few rounded cells.
Though cells were not rounded, they did display a decrease in confluency at 24hpi in
comparison to uninfected cells (Figure 3-1E and F). Both U87-GFP (Figure 3-1A
and B) and A172 (Figure 3-1C and D) human glioma cells were highly sensitive to
rNCP12.1 infection and demonstrated wildtype like cell rounding.
We next sought to determine if the observed cell rounding phenotypes with
rNCP12.1 infection corresponded to differences in cell viability. An MTS cytotoxicity
assay was used in order to measure viability following infection at an MOI of 10 over a
time range of 6 hours to 1week (168 hours) (Figure 3-2A). In F98-GFP glioma cells,
rNCP12.1 maintained close to wildtype cytotoxicity. Viability decreased at a similar rate
to wildtype infection, dropping to 32% within 48hpi. C6-GFP glioma cells were ~90%
viable relative to uninfected cells following infection with both viruses during the first
day of infection, eventually dropping to approximately 40% by 48 hours. As expected,
cytotoxicity in PRAs showed the greatest attenuation during rNCP12.1 infection, with
cells maintaining 65-70% viability at one week post-infection. In contrast, wt-VSV
infection in PRAs displayed a similar cytotoxic profile to that observed in F98 glioma
with viability dropping to nearly 30% by 48hpi.
In addition to the lack of cell rounding, cell specific differences in viral yield were
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Figure 3-1. Cell rounding phenotype of rNCP12.1 in human glioma cells
Human glioma cell lines, (A, B) U87-GFP (C, D) A172 (E, F) T98G were infected with
either (B) rNCP12.1-dsRed or (D,F) rNCP12.1-GFP at an MOI of 10 for 1 hour at 31oC.
At 24hpi, culture medium was removed and cells were fixed with 3% paraformaldehyde.
Images were obtained by bright field and fluorescence microscopy at 10X magnification
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Figure 3-2. Characterization of rNCP12.1 in glioma cells
(A) MTS cell viability assay measuring cytotoxicity of F98-GFP glioma and primary rat
astrocytes (PRAs) following infection with either wtVSV or rNCP12.1 at an MOI of 10.
At t= 6, 12, 24, 48, 72hpi, and 1wkpi, culture medium was removed and MTS reagents
using Cell Titer Assay (Promega) were added to cells for 4 hours at 37oC. Cell viability
was calculated based on changes in absorbance at 490nm, (A490). Values are reported as
percent (%) absorbance relative to uninfected cells at the same time point. (B) Growth
Curve for rNCP12.1 versus wtVSV in PRAs and glioma cells. Astrocytes or glioma cells
(F98-GFP, C6-GFP) were infected with either wtVSV or rNCP12.1-GFP at an MOI of
10. At t=12, 24, 48, 72hpi and 1wpi, supernatants were harvested and used to determine
viral titer by standard plaque assay in BHK cells. [pfu, plaque forming units; hpi, hours
post infection; wpi, week post infection]
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observed. To determine viral yield in glial cells, one step growth curves were obtained
over the course of 1 week following infection in rat non-tumor and tumor glial cells
(Figure 3-2B). Supernatants from cells infected at an MOI of 10 were collected at
various time-points and titers were obtained using a standard plaque assay in BHK cells.
Previous studies have shown that rNCP12.1 viral yield in BHK cells is 10 fold
lower than that of wtVSV [237]. Similar to these results, rNCP12.1 yields were 10-100
fold lower than wtVSV at several time points during infection in both tumor and nontumor cell lines. However, in glioma cells, rNCP12.1 titers eventually reached wtVSV
titers by 72hpi whereas rNCP12.1 was consistently 10 fold lower throughout all time
points in primary astrocytes. We also observed that wtVSV growth in primary astrocytes
was attenuated with yields 101-104 fold lower than titers obtained from wtVSV infection
in tumor cell lines throughout the time course. Mutations in rNCP12.1 had the most
effect on viral yield in primary astrocytes with titers also ranging between 101-104 fold
lower than rNCP12.1 titers in glioma cells. There were also cell specific differences in
the rate of viral production. Though viral yields were different between wtVSV and
rNCP12.1 in PRAs, the rate of infectious particles produced over time were congruent.
Rates of viral yield in F98 cells were similar with exception of an earlier drop in yield
during rNCP12.1 infection at 48hpi compared to a drop at 72hpi with wtVSV infection.
On the other hand, consistent with results from the cell viability assay, C6 glioma cells
lagged behind in viral yield during the first 48 hours of infection in comparison to F98.
Whereas wtVSV slowly increased over 48 hours to yields similar in F98, rNCP12.1 titers
remained stagnant at approximately 2x106 pfu/mL during this same time period,
eventually increasing to wtVSV titers by 72hpi.
These results confirm those of previous studies showing variations in VSVinduced CPE and growth based on cell type [237, 358, 366, 369]. In the glial cells tested,
there was a correlation between cell rounding and cell viability, which paralleled viral
growth kinetics. Growth and cytotoxicity of rNPC12.1 in PRAs were better controlled
throughout infection whereas C6s revealed early but non-sustainable control that
ultimately ended in cell death. F98s, however, were less effective at controlling infection
and therefore were more sensitive to the cytopathic effects of rNCP12.1.
rNCP12.1 Upregulates IFN
 Expression and Increases Production of Active IFN
over wtVSV in a Cell Specific Manner
It has been shown that VSV-induced cell rounding and apoptosis are genetically
linked with inhibition of host cell gene expression during infection [245, 250-254, 275].
This inhibition is attributed to inhibition by the matrix protein at various stages of gene
expression including transcription, nucleocytoplasmic transport, and protein translation.
The expression of IFN and IFN stimulated genes are known to be greatly affected by M
protein and VS virions harboring specific mutations in matrix have defects in the
inhibition of IFN related antiviral responses [266, 289-291]. To determine if the matrix
mutant, rNCP12.1, possessed the same inability to inhibit these responses following
infection in both normal and tumor brain cells, we compared levels of IFN expression
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following infection with wtVSV and rNCP12.1 in the C6 glioma cell line compared to a
rat fibroblast cell line (FR). Using semi-quantitative reverse transcriptase-polymerase
chain reaction (RT-PCR), we first tested for presence of IFN message following
infection with either wtVSV or rNCP12.1 at an MOI of 10 at 6 and 12hpi (Figure 3-3A).
We saw that wtVSV induced very low levels of IFN expression at both time points in
FR cells while almost negligible amounts were expressed in C6 cells. rNCP12.1, on the
other hand, induced a robust expression of IFN which was present at both time points in
FR cells. IFN levels were also induced in C6 cells comparable to levels in FR cells at
6hpi however this signal decreased tremendously by 12hpi. Expression levels were
normalized to the housekeeping gene, -actin, however expression levels of -actin were
affected by infection in C6 glioma cells. As a result, all subsequent RT-PCR experiments
used Cyclophilin B as the housekeeping gene as its expression levels were not affected by
infection with wtVSV or rNCP12.1 (discussed in Appendix A). We next used
quantitative RT-PCR (qRT-PCR) to obtain more precise expression levels of IFN in FR
cells, primary astrocytes, and both glioma cell lines at 24hpi (Figure 3-3B). We found
that both wtVSV and rNCP12.1 upregulated transcription of IFN however, rNCP12.1
increased message 3x103 fold greater than wildtype in primary astrocytes. rNCP12.1 also
upregulated IFN in glioma cells ~102 fold over wildtype though these levels were
exponentially lower than levels observed in primary astrocytes.
We next determined if upregulation of message following infection corresponded
with an increase in production of active IFN through the use of an IFN bioassay. In this
assay, L929 murine cells are exposed to harvested supernatant of immuno-stimulated
cells and evaluated for inhibition of viral-induced CPE. We first tested the ability of our
bioassay to detect IFN produced by the glial cells in response to polyinosinic:
polycytidylic acid (pI:C), a synthetic dsRNA molecule used to elicit antiviral responses
predominantly through the TLR3 pathway. Cells were either treated for 6 hours with
pI:C containing media or by transfection of pI:C at increasing concentrations. After 6
hours, fresh media was added and samples were harvested at 24 hours following pI:C
treatment. Mouse embryonic fibroblasts (MEF) were used as a positive control (Figure
3-3C). Cells exposed to pI:C containing media were unable to produce detectable IFN
regardless of cell type at any concentration of pI:C. In line with what is known about
pI:C induced antiviral responses, transfection of pI:C was superior in inducing an
interferon response in all cell types tested, with the highest dose of 10g eliciting the
most robust production of IFN. PRAs produced the greatest amount of active IFN
(5.3x103 U/mL), similar to control cells, while F98 levels were less than 102 U/mL. We
then followed the induction of IFN using this predetermined dose of transfected pI:C over
a 24 hour time period in glioma cells. FR cells were used as the positive control for this
study (Figure 3-3D). Starting at 4 hours, a gradual production of biologically active IFN
in FR cells was observed with amounts greater than104 U/mL being produced by 24
hours after treatment. F98 glioma cells again produced the least amount of IFN
throughout the study with levels less than 102 U/mL throughout the time course. C6
glioma cells produced comparable amounts of active IFN to F98 glioma at earlier
timepoints with an increase in production, exceeding 102 U/mL by 24 hours.
Once the ability to produce active IFN detectable by our IFN bioassay was
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Figure 3-3. Cell and viral specific comparisons of IFN responses
(A) Semi-quantitative RT-PCR and (B) qRTPCR verifying specificity of primers in FR
and C6 cells. Cells were infected with either rNCP12.1 or wtVSV at an MOI of 10 for 1h
at 31oC. At 6 and 12hpi, cells were harvested, RNA was extracted using trizol reagent,
and extracted RNA was amplified. rNCP12.1 infection resulted in increased IFN signal
at both time points similarly in FR cells while signal increased in C6 cells at 6h with
dissipation of signal by 12hpi. Results were normalized to the housekeeping gene, actin. Of note, changes in basal levels of  -actin were observed following viral infection
C6 glioma cells, therefore expression levels of IFN 1 were unable to be normalized in
this cell line. (B) For qRT-PCR, expression levels were normalized to Cyclophilin B
gene. Values are presented as means of duplicates with standard errors. (C) IFN activity
following treatment with (C, D) pI:C or (E) virus. (C) Cells were either treated with
various amounts (g) of pI:C in culture media or with transfected pI:C using
lipofectamine 2000 (Invitrogen). At 24h after treatment, supernatant was collected and
used for detection of IFN activity using an IFN bioassay in L929 murine cells. Values
obtained are based on comparisons to antiviral activity of the rat IFN (rIFN) standard for
each bioassay. IFN activity is expressed in units (U)/mL. (D) Detection of IFN activity
following treatment of 10g transfected pI:C at t =2.5, 4, 6, 12, 18, 24 hours post
transfection. There is a gradual increase in IFN activity starting at 4 hours posttreatment, extending to 24 hours. (E) Detection of IFN activity following viral infection.
Cell lines were infected with wtVSV or rNCP12.1-GFP at an MOI of 10 for 1h at 31oC.
At several time points following infection (t= 6, 12, 18, 24hpi), supernatants were
collected and residual virus was removed by ultrafiltration using Amicon filters
(Millipore). Virus free supernatant was then used to detect IFN activity. (F) Ratio of
IFN gene expression: IFN activity. Using data obtained from qRT-PCR and IFN
bioassay described above, a combined graph was constructed revealing cellular and viral
differences in the translation of IFN message into biologically active IFN.
pI:C= polyinosinic:polycytidylic acid; Level of significance denoted by “*” to “****”
from low to very high significance, respectively.
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confirmed, we tested the supernatant from virally infected glial cells for presence of
active IFN to determine if upregulation of IFN message corresponded with IFN activity.
Supernatant of virally stimulated cells was harvested from 6-24hpi and residual
virus was separated by ultra-filtration so that IFN activity could be determined more
accurately using the IFN bioassay (Figure 3-3E). We found that wtVSV infection did
not result in detectable levels of IFN in the FR control cell line or in any glioma cell line,
however a low amount of 6.25U/mL IFN was detected at 24hpi in the primary astrocytes.
Therefore, though wtVSV induced the synthesis of IFN message, this did not
significantly translate into active protein in the glial cell lines. This observation is
consistent with results from a number of studies that suggest matrix protein inhibits IFN
responses at multiple levels of gene expression including nucleocytoplasmic transport of
mRNA and protein translation. On the other hand, the rNCP12.1 matrix mutant
stimulated the production of biologically active IFN in control cells, primary astrocytes,
and glioma cell lines. FR cells produced copious amounts of IFN with levels totaling
2.56x104U/mL at 24hpi, comparable to induction of IFN gene expression in these cells.
In comparison, though rNCP12.1-induced expression of IFN was 10 fold higher in
primary astrocytes than FR cells, they produced a maximum of 1.6x103 U/mL of IFN at
24hpi, 16 fold less than FR cells. Not surprisingly, glioma cells produced active IFN
during rNCP12.1 infection. F98-GFP produced the least active IFN at 24hpi (1.3x102
U/mL) while C6s produced approximately 8 fold more IFN than F98 at the same time
point despite its lower induction of IFN transcription. In addition, IFN levels in C6s
remained steady, maintaining 800U/mL of IFN over all time points. This steady state of
IFN produced by C6 cells corresponds to the stagnant viral yield and delayed viralinduced cytotoxicity by rNCP12.1 infection over the same time period. In comparison to
primary astrocytes, this amount was approximately 16 fold higher at the earliest time
point tested (6hpi) however IFN production in PRAs, eventually increased to surpass C6
levels by 18hpi. These results suggest that not only is the quantity of active IFN
produced important in eliciting a protective antiviral state in infected cells during viral
replication but the ability to amplify IFN signaling is important as well.
IFN
 Gene Expression Does Not Correlate with Production of Active IFN in
Primary Rat Astrocytes
Based on a recent review by Vogel and Marcotte, 40% of the variability in protein
synthesis can be attributed to the abundance of mRNA. The other 60% is due to posttranscriptional events such as protein stability or regulatory mechanisms of translation
[370]. Generally, message in mammalian cells is less stable and is produced at a much
lower rate than proteins. The average rate of synthesis of transcripts has been shown to
be approximately two mRNA per hour compared to dozens of protein
molecules/mRNA/h [370]. This rate tends to vary based on cell type, protein of interest
(metabolic proteins versus proteins involved in transcriptional regulation), and cellular
conditions. Nevertheless, most studies use mRNA abundance as a means of predicting
the likelihood of detecting its coded protein. In our studies, all three parameters appear to
play a role in the correlation between mRNA abundance and protein activity. It must be
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noted, however, that these studies do not aim to correlate mRNA message with the total
amount of protein produced but rather to the amount of active protein produced under
variable conditions. A comparison of IFN gene expression to production of active IFN
following mutant and wildtype infection revealed notable cell and viral specific
differences in the ability to elicit the IFN mediated antiviral pathway. In each cell type,
though wtVSV induced gene expression of IFN over non-infected cells, this did not
correlate with production of active IFN. rNCP12.1 however induced expression of IFN
which translated to active IFN, though still not according to the expected rate of
synthesis. Interestingly, this deviation was more pronounced in primary astrocytes.
Whereas the ratio of active IFN to message corresponded to approximately 1:10 in the
control cell line and in both glioma cell lines, values were more disproportionate in
primary astrocytes with a ratio closer to 1:103 at 24hpi (Figure 3-3F).
In evaluating the IFN response from this perspective, these results not only
reinforce the influence of the matrix protein in the antiviral response pathway but they
also confirm that a number of variables effect adherence to the rate of production of
mRNA to protein. We specifically see the effects of cell type as primary astrocytes
produced much lower amounts of active IFN relative to its level of induction of gene
expression following rNCP12.1 infection. Despite this disparity, PRAs demonstrated a
greater response to the active IFN produced which was evident not only in cell viability
but in the production of infectious virus over time. On the other hand, though C6 glioma
cells produced detectable amounts of active IFN following rNCP12.1 infection that
correlated more with the induction of IFN gene expression, these cells responded less to
IFN which was also evident in cell viability, cell rounding, and viral growth kinetics.
Primary Astrocytes Are Highly Sensitive to the Anti-Viral Effects of IFN While
Glioma Cells Are Not
In order to determine if differences in the ability to produce IFN correlated with
IFN sensitivity in glial cell lines, we performed a protection assay in which cells were
pretreated with escalating doses of rat IFN (r IFN) (0-1000 units) for 24 hours then
infected with wtVSV at an MOI of 3. At 24hpi, cells were stained by
immunofluorescence to detect VSV nucleocapsid (N). Response to interferon was graded
by the gross detection of staining in IFN treated versus untreated cells. Protection was
defined as samples with less than 50% VSV-N positive cells (Table 3-1).
Primary astrocytes were protected starting at 3.125 U of IFN. C6s were also
protected from viral infection but at higher doses of IFN, starting close to 100U. F98s,
however, were not protected from viral infection even at the highest dose of 1000 units
(Table 3-1 and Figure 3-4). These results suggest the glioma cell lines are less sensitive
to the antiviral effects of IFN and confirm the results of previous studies that the level of
IFN sensitivity can vary among tumor cell types even when derived from the same
histological cell of origin [358, 371].
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Table 3-1.
Cell
Type
PRA
C6
F98

Sensitivity to antiviral effects of IFN
IFN (U)
High Dose

Low Dose

1000

250

125

62.5

+
+
-

+
+
-

+
+
-

+
-

100 50

+
+
-

+
-

25

+
-

12.5 6.25 3.125 2.562 1.562

+
-

+
-

+
-

+
-

-

Note: +, protection (<50% cells positive for N protein staining); -, no protection (>50%
cells positive for N protein staining).
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Figure 3-4. Representative fluorescence micrographs showing infection of cells
with wtVSV following IFN pre-treatment
(A) C6-GFP, (B) F98-GFP, and (C) Primary rat astrocytes were pre-treated with various
doses of IFN then infected with wtVSV at an MOI of 3. Cells were then labeled with
anti-VSV N antibody conjugated to Rhodamine at 24hpi and visualized by fluorescence
microscopy at 10X magnification.
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As the above experiments have demonstrated, matrix mutations in rNCP12.1 alter
its ability to cause cell rounding and apoptosis in normal cells, which appears to be
correlated with its ability to promote IFN gene expression and, ultimately, IFN
production. On the other hand, these defects reveal a spectrum of phenotypes in tumor
cells of glial origin with F98 displaying a high IFN resistance, high CPE phenotype and
C6 glioma cells displaying a more intermediate IFN resistance with an intermediate CPE
phenotype.
IFN Activity Following rNCP12.1 Infection Is Associated with Induction of ISGs in
Primary Astrocytes While Glioma Cells Vary in Their Ability to Elicit Downstream
IFN Responses
In order to evaluate involvement of specific elements of the IFN pathway and
how they correlate with cytopathic effects and IFN production in tumor cells, we
surveyed the expression of interferon stimulated genes by qRT-PCR at 24 hours
following viral infection using the cell fraction collected from the previous IFN bioassay
studies. Key ISGs that have been shown to be elevated following exposure to IFN and/or
viral infection were considered [289, 333, 371, 372]. According to data obtained by
Stojdl et al [289], expression of ISGs are time specific following VSV infection and this
expression may vary depending on alterations in the matrix protein. For instance,
primary transcriptional responders appear during early infection (3-6hpi). These include
ISG15 and IFN and are dependent on factors that bind interferon stimulated response
elements (ISRE) in the IFN promoter region such as IRF3 and NFB. IRF-1 and RIG-I
have been shown in separate studies to be upregulated early in infection and may
therefore be considered primary transcriptional responders. In addition, these two ISGs
have been shown to be constitutively active in a number of cell lines including astrocytes
[310, 372] and are directly upregulated by viral infection even in the absence of
interferon [310, 373]. Mx-1/2, GBP-1, and Plscr-1 are considered secondary
transcription responders, appearing 6-12 hpi. These responders are dependent on the
activity of ISGF3, a heterotrimer formed by IRF9, Stat 1, and Stat2 as has been
described. Lastly, responders such as IFN4 appear latest in infection, usually after 12
hours. These genes are known as tertiary transcription responders and are dependent on
IRF7 for their activation [289]. Other studies, however, consider IFN4 an immediate
early response gene, showing upregulation as early as 4hpi even in the absence of active
protein synthesis [374]. Nevertheless, expression of secondary responders is inhibited by
wtVSV infection whereas mutants defective in inhibition of host gene expression
promote expression of these responders. By blocking this step, wtVSV consequently
inhibits the transcription of tertiary responders as well.
As expected, rNCP12.1 induced the expression of all ISGs over wildtype in
primary astrocytes, similar to induction in FR cells (Figure 3-5A-F). Of the ISGs tested,
only plscr1 was not significantly induced by infection and no significant differences in
expression levels were observed between wtVSV and rNCP12.1 (Figure 3-5F). Glioma
cell lines were more variable in their ISG expression. F98 glioma cells are both resistant
to IFN and unable to produce amounts of active IFN that would be protective against
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Figure 3-5. Differences in interferon stimulated genes (ISGs) following viral
infection with wtVSV or rNCP12.1-GFP
(A) IFN4, (B) Ddx-58 (RIG-I), (C) IRF-1, (D) Mx1/Mx2, (E) GBP-1, (F) Plscr-1. Cells
were infected at an MOI of 10 for 1 hour at 31oC. Cells were then harvested, RNA was
extracted, amplified, and quantified using qRTPCR at 24 hours of infection. Expression
levels are normalized to the cellular Cyclophilin B gene and are presented as means of
duplicates ± SD. Expression levels vary based on gene tested (see y axis for different
scales)
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viral infection. In parallel,the induction of most ISGs tested was lowest in F98s
following infection compared to other cell types. rNCP12.1 upregulated all secondary
ISG responders significantly over wtVSV (Figure 3-5D-F). Interestingly, plscr1, a
secondary responder that was not induced in the other cell lines, was expressed
approximately 10 fold higher after rNCP12.1 infection relative to wtVSV in F98 and to
expression in the other cell lines (Figure 3-5F). In addition, expression of the primary
responder, IRF1, and tertiary responder, IFN4, were induced by both viruses at similar
levels in the glioma cell lines. C6 glioma cells, having a more intermediate resistance to
IFN, also varied in ISG expression. Both GBP1 and Mx1/2, secondary ISGs, were
induced by rNCP12.1 infection similar to induction in PRAs although the induction of
GBP1 was not significant. Like PRAs, these cells were low in their induction of plscr1
with both wtVSV and rNCP12.1 (Figure 3-5D-F). Unexpectedly, IRF1 induction did not
follow the pattern of higher induction with rNCP12.1 infection. Rather, wtVSV induced
IRF-1 expression 2.5 fold higher than rNCP12.1 (Figure 3-5C). Another primary
responder, Ddx58, had a greater induction in C6s after rNCP12.1 infection with
expression approximately 2.5 fold higher than rNCP12.1 infection in primary astrocytes
(Figure 3-5B). These data are represented by a heat map depicted in Figure 3-6.
rNCP12.1 Alters the Temporal Expression of Ddx-58 (RIG-I) in Glial Cells
Ddx58 or RIG-I is important in the detection of viral RNA and therefore in
eliciting IFN mediated antiviral responses during infection. In addition, it is a known
ISG that is upregulated early during infection. Ddx-58 is also a known activator of NFB
[372] that has been implicated as a determinant in resistance to the apoptotic effects of
IFN. Like IRF-1, Ddx-58 was found to be constitutively expressed in primary human
astrocytes with increased levels following wtVSV infection reaching optimal expression
by 4hpi then falling back to baseline by 8hpi [372]. Our results demonstrate that Ddx-58
expression is low but slightly elevated at 24 hours following wtVSV infection in both rat
fibroblasts and primary rat astrocytes (Figure 3-5B). Both glioma cells showed higher
expression following wtVSV infection with C6 expression 50 fold higher than uninfected
cells. There was an even greater rise in expression in both glioma and normal cells
following rNCP12.1 infection with levels more than 100 fold higher in all cell types over
uninfected cells. As with wtVSV infection, rNCP12.1 induced expression of Ddx58 in
C6 glioma that was double the levels of induction in other cell types. In comparison to
results by Furr et al [372], our results showed that Ddx58 expression was still elevated
however at low levels even at 24hpi and this expression was greatly enhanced by the
matrix mutations found in rNCP12.1. We also see that in C6 glioma, which
demonstrated stagnant viral yield, fixed cell viability, and unwavering levels of active
IFN during the first 24-48 hours of rNCP12.1 infection, Ddx58 levels are highly elevated
even more so than normal cells. It could be that the upregulation of Ddx58 in these cells
is involved in delaying apoptosis during the first 2 days of infection via downstream Ddx58 stimulated effectors.
Though there are obvious host specific differences in IFN responses following
rNCP12.1 infection, the overall inability of glioma cells to produce a sustainable antiviral
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Heatmap Key

Figure 3-6. Heat map representation of IFN stimulated gene (ISG) expression in
normal and tumor glial cells following viral infection
N/A= not available for comparison
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IFN response in comparison to the protective antiviral responses elicited in normal cells
contributes to the oncolytic capacity of this vector. Based on these differences, we next
evaluated the oncolytic activity of rNCP12.1 in an in vivo model of intracranial glioma.
Efficacy of rNCP12.1 in an Immunocompetent Intracranial Model of Glioma
Intracranial Administration of rNCP12.1 Is Safe Relative to wtVSV in Non-Tumor
Bearing Animals
The mortality and morbidity caused by VSV infection varies based on immune
status of host as well as mode of administration. This has been studied using
experimental murine models in which intranasal administration of VSV leads to a less
fatal encephalitic disease whereas intracranial administration of virus usually results in a
fatal disease marked by severe neurological symptoms within 2 weeks post-infection
[219, 351, 375]. Younger animals are more susceptible to viral neurotoxicity; however,
attenuated strains of VSV demonstrate mild disease regardless of age. Hence, we wanted
to first determine mortality and morbidity in animals receiving rNCP12.1 intracranially
relative to wildtype. This was carried out in an immunocompetent non-tumor bearing
model. On day zero, six week old Wistar rats weighing ~250-350 grams were given an
intracranial injection of 109 pfu rNCP12.1-GFP or wtVSV-GFP. Along with survival,
weight trends were followed throughout the study. Animals were sacrificed at day 15
post-infection or when criteria for euthanasia were met. As expected, we found that wtVSV caused severe neurotoxicity with all animals succumbing to infection by 8 days
post-infection. On the other hand, neurotoxicity of rNCP12.1 was attenuated with
animals surviving to the end of the study. In addition, average weight of rNCP12.1infected animals progressed at a comparable rate to animals receiving only viral vehicle
(Tris-Saline + 10% sucrose, TN sucrose) (data not shown). Based on these studies we
concluded that rNCP12.1 could safely be administered intracranially for the treatment of
glioma in this rat model.
rNCP12.1 Decreases Tumor Load in a Dose Dependent Manner Without Causing
Morbidity in an Intracranial Model of C6-GFP Glioma
Our initial evaluation of the oncolytic activity of rNCP12.1 against intracranially
implanted glioma was first executed in a rat model using C6-GFP glioma cells in the
immunocompetent Wistar rat. This model was chosen as previous studies by our lab
demonstrated in vitro proof-of-principle of the oncolytic activity of a replication
restricted rVSV vector in a co-culture of C6 glioma with normal CNS cells from various
brain structures [354]. On day zero, cells were implanted intracranially as described and
allowed to grow for three days. At three days post tumor implantation, animals were
given varying doses of intratumorally injected virus. Animals were then euthanized at 15
days post infection in order to assess differences in tumor size based on fluorescence
from GFP expressing tumor compared to animals treated with viral vehicle (TN-sucrose).
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Tumor sizes were measured from cryo-sections by circumscribing the tumor area defined
by GFP fluorescence using NIH ImageJ software as described in Chapter 2.
Measurements based on fluorescence were compared to those obtained by H&E staining
of tissue and found to be indistinguishable (data not shown).
We found that tumor size inversely correlated with dose of VSV. The highest
dose tested of 108 pfu demonstrated the greatest decrease in tumor load of 82% relative to
vehicle treated tumors while the lowest dose of 105 pfu resulted in 15% tumor load
reduction (Figure 3-7A). Surprisingly, three of five animals treated with 108 pfu had
nearly undetectable tumors. In addition, weight trends were followed in animals
receiving the highest dose of rNCP12.1 (107 and 108 pfu). Weights decreased
accordingly in all groups following tumor implantation but gradually increased over the
next few days before virus administration. On the day following treatment, all animals
decreased in weight with animals receiving a higher dose of virus decreasing the most
over the first 24 hours of infection (5.2g versus 1.2g in vehicle only). The animals in this
treatment group also experienced an extended duration of weight decline seen on day 5,
whereas, an increase in weight was observed in the other two groups at this time point.
However, by day six, average weights of all groups rose at similar rates though animals
receiving the highest dose of virus had an overall lower average weight at each time
point. Despite this, no group experienced more than a 5% decrease in weight during the
study and by day 15, all animals had gained at least 50 grams over their pre-tumor
implantation weight (Figure 3-7B). Together, these results suggest that one dose of
rNCP12.1 does not cause significant morbidity or mortality as all animals survived to the
end of the study with an overall increase in weight over time. Therefore this oncolytic
virus appeared to be safe for administration in the brains of tumor bearing animals. In
addition, we concluded a single dose of rNCP12.1 was effective at reducing tumor
growth in a dose-dependent manner when given intracranially in the C6 glioma bearing
Wistar rat model.
Comparison of the F98 Glioma/ Fischer Rat Model
Because C6 gliomas are derived from outbred Wistar rat, they have been shown to
be immunogenic in inbred rats causing tumors to often regress spontaneously by 4 weeks
post-implantation. As a result, this model, though appropriate for short term studies, is
not appropriate for studies in which long term survival would be determined [376, 377].
Therefore, the syngeneic F98 glioma/ Fischer rat model was used for the remainder of
our studies. The F98 glioma cell line was chemically induced by giving the mutagenic
alkylating agent, ethylnitrosourea (ENU), to pregnant Fischer rats resulting in offspring
harboring spontaneous brain tumors [378, 379]. F98 tumors are refractory to most
therapies and demonstrate an invasive pattern of growth. As few as 10-100 tumor cells
are capable of developing into an aggressive tumor and, with an engraftment rate of
>90% following intracranial administration, this model is considered a reliable
experimental model capable of mimicking human disease [376, 380]. Further, time of
progression from implantation to adverse neurological changes caused by tumor mass
effect is short, occurring in about 2 weeks post-implantation. Therefore this model is
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Figure 3-7. Dose-dependent reduction of C6 tumors after rNCP12.1 treatment
C6-GFP glioma bearing adult Wistar rats were inoculated with a single dose of
intratumoral (i.t.) virus on day 3 post tumor implantation (pti). Four treatment groups
included a single injection of rNCP12.1-GFP at 105, 106, 107, or 108 pfu (n=5). Animals
were euthanized at day 15 pti and tumor load was determined based on tumor
measurements from fluorescence images using NIH ImageJ software. (A) Tumor size is
represented by percent (%) reduction compared to control tumors. (B) Weight trends of
animals treated in higher dose (107 and 108 pfu) of rNCP12.1 compared to animals in
control (vehicle) group. Weights at each time point are an average of those obtained for
each treatment group. Unpublished data from Himangi Jayakar and Qihong Zhou, 2005.
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effective at allowing us to study survival as well as the possible immunological responses
elicited against virus and/or against tumor as a result of viral treatment.
We carried out a comparative study of tumor anatomy and histology between the
C6-Wistar rat model and F98-Fischer rat model. F98 glioma cell line was previously
transduced with the pFB retrovirus expressing GFP (pFB-GFP) to allow visualization of
tumor. As described, either 105 C6 glioma cells or F98 glioma cells were implanted
intracranially in Wister or Fischer rat, respectively. On day 15, post-tumor implantation,
animals were euthanized and brains were harvested for analysis of tumor load following
H&E staining and fluorescence microscopy for visualization of GFP expressing tumors.
Representative images in Figure 3-8 demonstrate the gross and microscopic features of
these tumors. While C6 gliomas are less aggressive and more immunogenic, forming a
well-demarcated tumor mass at 15 days following implantation (Figure 3-8A-C), F98
gliomas are more infiltrative and tend to invade surrounding normal tissue much like
high-grade human gliomas (Figure 3-8D-F).
We next sought to determine the growth kinetics of implanted F98 tumors to
gauge changes in tumor size over several time points and the reproducibility of
establishing tumors following implantation (Figure 3-9A). 105 cells were implanted
intracranially as decribed and animals were euthanized at 3, 6, 9, and 15 days post tumor
implantation. Brains were harvested and assessed for tumor load based on GFP
expression of F98 glioma cells. We found that establishment of tumors were
reproducible at each time point and that tumor size gradually increased as expected over
time. Measure of morbidity was determined not only by weight trends throughout the
study but also by changes in neurological function as assessed by the rat coma scale
(described in Chapter 2). In this study, average weight of animals never dropped below
10% of starting weight (Figure 3-9B) and neuroscores ranged between 9.5-11 with the
lowest scores occurring at day 12 (Figure 3-9C). This range of neuroscores is expected
as tumor load usually begins to cause neurological dysfunction within 2 weeks of
implantation. As experienced in this study, there are often additional neurological signs
and symptoms not measurable with the rat coma scale that may occur. These additional
neurological signs, when observed, range from changes in grooming to staggering during
ambulation (ataxia). Based on symptomology, animals may require euthanasia even
when neuroscores and weights are within normal limits. An explanation of these
additional symptoms that are considered in criteria for euthanasia can be found in
Chapter 2.
Intracranial Administration of rNCP12.1 Is Safe but Results in a Non-Durable
Reduction of Tumor Load in the F98 Glioma Model
With reproducibility of tumor implantation and growth established, we next tested
the oncolytic activity of rNCP12.1 against F98 glioma in vivo in order to determine if the
antitumor activity we observed in our in vitro studies translated into the intracranial
animal model. Because the highest dose tested in C6-Wistar model of 108 pfu was well
tolerated and most effective, we decided to increase the dose to 109 pfu for subsequent
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Figure 3-8. Comparison of the C6 and F98 rat intracranial glioma models
Coronal sections of brain tissue harboring (A-C) C6 and (D-F) F98 intracranial gliomas
in Wistar and Fischer rats, respectively. (A, D) H&E stained sections taken at 1.25X
magnification. Brain tissue in the right hemisphere reveals increased cellular infiltration
and a tumor mass that is causing compression of the ventricles and a midline shift toward
the contralateral side of the brain. (B&E) Fluorescence microscopy illuminating the GFP
(green) expressing tumor. (C, F) Fluorescence confocal microscopy at 60X
magnification of both C6 (C) and F98 (F) gliomas within brain tissue.
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Figure 3-9. Tumor progression of F98-GFP glioma in Fischer rat over time
(A) Fischer rat were implanted with 100,000 cells resuspended in 20L of PBS on day
zero. Animals were sacrificed every three days for 15 days in order to determine tumor
load by GFP expressing tumor cells (See inset fluorescence micrographs). (B) Weight
trends and (C) Neuroscores measured every three days before euthanasia (n=3).
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studies. As described in Chapter 2, F98-GFP gliomas were implanted in six week old
male Fischer rat and allowed to grow for three days at which point one intratumoral
injection of 109 pfu rNCP12.1-GFP was administered (Figure 3-10).
At 15 days following tumor implantation, the first group of rNCP12.1 treated
animals (n=9) was sacrificed and brains were harvested and assessed for tumor size. We
found that at 15 days post infection, tumor size was 66% smaller (p< 0.0013) than
vehicle-treated controls (Figure 3-11A). Representative fluorescence micrographs are
seen in Figure 3-11Bi, iii). Morbidity at time of sacrifice was minimal as determined by
weight trends (Figure 3-12A) and neuroscore (Figure 3-12C). Weight trends following
tumor implantation and up to one day post-treatment were as expected based on similar
findings observed during the previous dose escalation study in Wistar rats. By 48 hours
post-infection, weight trends in vehicle treated animals continued to increase and on
average animals weighed approximately 20g more than starting weights (day 0). On the
other hand, virally treated animals continued to decline in weight up to 4 days postinfection at which point weights plateaued and slightly increased at several time points
until the end of the study. At the most, weight of virally treated animals decreased 15.5%
(day 11) of starting weight but never exceeded a 20% decline. Neuroscores for both
vehicle only and rNCP12.1 treated animals ranged between 10 and 11 with the most
common decrease in score attributed to changes in spontaneous movement.
Another group of treated animals (n=9) were used to determine survival. These
animals were allowed to live until criteria for euthanasia were met based on effects of
viral treatment, weight trends, and/or tumor load. Based on log rank analysis of the
Kaplan-Meier survival curve comparing vehicle treated to rNCP12.1 treated animals,
there was a small yet significant difference in survival in animals receiving virus
(p=0.0063) (Figure 3-12E). Median survival of virus-treated animals was 29 days
compared to 23 days in those treated with vehicle. Despite the remarkable decrease in
tumor size due to rNCP12.1 treatment observed at 15 days post tumor implantation, at the
time of sacrifice, tumors were not significantly different than vehicle-treated animals,
displaying only an 11% decrease in tumor load (Figure 3-11A and Bii, iv).
Immunohistochemical analysis of cryosections from an animal in the acute group
was performed. H&E stain shows areas of hypercellularity marked by necrotic tissue
with infiltrating blood cells possibly marking areas where tumor became hemorrhagic
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Figure 3-10. Timeline for the single rNCP12.1- GFP injection study in Fischer rat
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Figure 3-11. Comparisons of tumor properties in animals treated with a single i.t
injection of rNCP12.1-GFP
Comparison of tumor load as a percentage of tumor load in uninfected animals in animals
from the (A) acute arm of study sacrificed at 15 days following tumor implantation;
(p=0.0013) and survival arm, sacrificed when criteria for euthanasia were met (p=0.2829,
ns). (B) Representative fluorescence micrographs demonstrating tumor size in (i) acute
control animals (ii) acute virus-treated animals (iii) survival control animals (iv) survival
virus-treated animals. (C) Micrographs of brain tissue from a treated animal in the acute
arm, demonstrating patterns of inflammation and of viral infection relative to tumor. (i)
H&E stain (ii) Fluorescence; F98-GFP tumor cells (green); Virus (Red). (D) Additional
labeled tissue samples from the same animal illustrating tumor (green), virus (red), and
GFAP astrocytic marker (Blue) (i) left (untreated) hemisphere (ii) 10X magnification of
right (treated) hemisphere, (iii) 20X magnification (iv) 40X magnification.
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Figure 3-12. Measures of morbidity of animals treated with a single i.t. injection of
rNCP12.1-GFP
Weight trends of animals in the (A) acute and (B) survival arms. Neuroscores of animals
in (C) acute and (D) survival arms. (E) Kaplan-Meier survival analysis demonstrating a
significant difference in survival between virus-treated animals and controls. Statistical
data performed using Log-rank (Mantel-Cox) test; P= 0.0063.
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due to leaky tumor associated blood vessels (Figure 3-11Ci). In correlation, staining of
virus for VSV-N using a rhodamine-conjugated antibody demonstrated areas of increased
GFP expression near the surface of the brain with positive rhodamine (red) labeling
intraparenchymally (Figure 3-11Cii). Additional tissue was double labeled for detection
of the astrocytic marker, GFAP (glial fibrillary acidic protein) (blue) and virus (red). The
uninfected hemisphere is shown for comparison and demonstrates the normal presence of
GFAP astrocytic marker in the area of the subventricular zone (Figure 3-11Di). Staining
of tissue in the right hemisphere reveals GFP expressing tumor with GFAP present within
the tumor as well as surrounding normal tissue. Additionally, we see virus present
specifically within the tumor mass (Figure 3-11Dii, iv) with some evidence of viral
presence in the immediate surrounding normal tissue (Figure 3-11Div).
Morbidity based on weight trends (Figure 3-12B) and neuroscores (Figure
3-12D) were also followed in the survival arm. Weights in the survival study were
followed for all animals throughout the study but only weights up to medium survival for
both groups were plotted. Trends following tumor implantation and up to one day, post
treatment, were consistent with the previously described studies. Unlike in the acute
study, weights in survival study animals began increasing by day 2 post-treatment and at
day 16, weights of virally treated animals had surpassed those of control animals. They
continued to increase for several more days while weights of control animals decreased
until animals were sacrificed. Though delayed, weight trends of virally treated animals
eventually decreased by day 19 and continued declining until animals were euthanized.
Although weights never declined >20% of starting weight in either group, the decreasing
trend correlated with progression to death in each group. Neuroscores remained between
10-11 for all animals in both groups up to day 15. Scores were not recorded following
this time point.
One Intracranial Dose of rNCP12.1 Induces Both Innate and Adaptive Immune
Responses in F98 Glioma Bearing Rats by 15 Days Post-Infection
As discussed, immune responses play a very important role in the success of viral
therapies. A balance between protecting the host from adverse viral effects and allowing
optimal viral replication in order to kill tumor and elicit long term anti-tumor responses
must exist. To this end, the immune system is often referred to as a double-edged sword
in that oncolytic potential is maximized by both inhibition and promotion of various
features of immunity. For example, previous studies showed that promoting IFN
responses aids in protection of normal cells [289, 344], yet blocking IFN responses
through the use of IFN pathway inhibitors such as rapamycin, can prolong viral activity
allowing a longer therapeutic window [193]. The same is said for adaptive immune
responses, particularly neutralizing antibodies that help clear virus for protection of the
infected host while limiting the duration of antitumor activity.
In the present studies, we evaluated serum collected by transcardiac method from
animals treated with 1x109pfu rNCP12.1 in the acute study at the time of sacrifice. These
results were also compared to sera from F98 tumor bearing animals of a subsequent study
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in which a single intracranial injection of a slightly higher dose (2x109pfu) of rNCP12.1
was administered. Innate (IFN; Figure 3-13A) activity was determined using the
described IFN bioassay. An adaptive (anti-rNCP12.1 antibodies; Figure 3-13B and C)
response was determined by the presence of circulating antibodies using Western blot
analysis and a neutralizing antibody assay. Antibodies were detected in the sera and were
mostly directed against VSV glyocoprotein (G) as well as matrix (M), which are the two
major antigens that give antibody responses during VSV infection. The anti-G response
produces neutralizing antibody and is protective against infection in animals. Some antiN antibodies were observed but with a lower signal than those directed against the other
viral antigens. Anti-rNCP12.1 neutralizing antibodies (nAbs) were detected using a
neutralizing assay in which sera of infected animals was treated at 56oC for 35 minutes in
order to inactivate any residual virus [344]. Serial dilutions (1:2 to 1:1000) of heatinactivated sera was combined with 200 pfu of wtVSV inoculum and incubated together
for 45 minutes at 37oC to allow potential binding of antibody and viral antigen.
Serum/inoculum mix was then applied to BHK cells to determine the dilution at which
50% inhibition of CPE was observed relative to fetal bovine serum/inoculum (negative
control). Neutralization is plotted as the inverse of the dilution required for 50%
inhibition of infection at 24 hours post-treatment. The positive control is a polyclonal
antibody developed in rabbits following immunization with intact UV- inactivated virus
(TN-1). It is the antibody used by our lab for neutralization experiments and in the
detection of VSV proteins for other molecular techniques. The dilution of TN-1 needed
for 50% inhibition was 1:800 therefore the titer plotted in the neutralization assay is 800.
Similar to in vitro studies, rNCP12.1 induces systemic production of detectable
IFN in vivo. Regardless of dose, IFN activity ranged from 2-4x102 U/mL. One of the 4
animals in the lower dose group displayed ~10 fold lower IFN activity than other
animals. When compared to the nAb detection assay, nAb against rNCP12.1 were
consistently present in almost all treated animals with titers ranging between 600-1000,
with some animals having even greater neutralizing activity than the positive control.
Not surprisingly, the one animal with the least detected IFN activity also expressed the
lowest titer of anti-rNCP12.1 nAb signifying a possible error in delivery of initial dose of
virus. All sera was evaluated for presence of virus using our standard plaque assay in
BHKs and no infectious virus was detected in any samples (data not shown).
From these results, we conclude that in the first 2 weeks of treatment, an obvious
decrease in tumor load is experienced in animals receiving one intratumoral dose of 109
pfu rNCP12.1. These results were accompanied by low morbidity as seen by weight
trends and neurological scoring as well as induction of both peripheral innate (IFN) and
adaptive (nAb) immune responses. Nonetheless, reduction in tumor load was not
sustainable though it did result in a significant yet minor prolongation in survival of
treated animals. Gliomas eventually recurred at an accelerated rate with tumors of virustreated animals being comparable in size to those treated with vehicle only.

107

Figure 3-13. Detection of immune responses at day 15 in animals treated with a
single injection of rNCP12.1
(A) IFN activity as measured by the IFN bioassay (units (U)/ mL). Detection of antiVSV antibodies in sera of treated animals by (B) Western Blot analysis confirming
presence of circulating antibodies directed against VSV antigens. Serum was diluted to
1:100 for each tested sample. R6F, diluted at 1:5000, was used as the positive control. It
is a polyclonal antibody developed in rabbits immunized with detergent disrupted
wtVSV. Negative (untreated) control was serum from tumor-bearing animals not treated
with virus. (C) Detection of anti-VSV neutralizing antibodies (nAb) in sera of treated
animals using a neutralizing assay. Neutralizing titer was determined as the dilution of
sample needed for 50% inhibition of wtVSV. TN-1, a polyclonal antibody developed in
rabbits immunized with intact UV inactivated virus, served as the positive control. TN-1
requires at least a dilution of 1:800 for 50% inhibition of wtVSV induced CPE therefore
the nAb titer is 800
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Evaluation of Various Methods of Viral Administration on Safety and Efficacy of
rNCP12.1 as an Oncolytic Treatment for Intracranial Glioma
As demonstrated, components of both innate and adaptive immunity are elicited
in response to rNCP12.1 infection in vivo. Due to this phenomenon, a number of delivery
methods have been proposed as potential ways of enhancing effectiveness of viral
therapy. These methods are based on their ability to either shield virus from the immune
system or modulate the immune system by suppressing certain aspects of immunity long
enough to achieve optimal oncolysis. Other methods consider the role of the tumor
microenvironment in hindering spread of virus. This includes, but is not limited to,
increases in pressure caused by the tumor mass and associated inflammation that can
prevent infusion of virus within the tumor as well as sequestration of virus by
components of the extracellular matrix [178-181]. In the following studies, we have
tested a number of delivery methods and their effects on efficacy of treatment and safety
as seen through weight trends, neuroscore, and overall survival, taking into account the
role of both tumor microenvironment as well as components of the immune system.
Constant Infusion of rNCP12.1 over Time by Infusion Pumps Is Not a More
Effective Method of Viral Delivery
Taking into account the effects of the microenvironment on the oncolytic efficacy
of viral therapy, we tested the use of subcutaneously implanted micro-osmotic pumps
(Alzet Model 1003D) in their ability to reduce tumor by infusing a small yet constant
dose of virus over time. These implantable pumps are loaded with a pre-determined
concentrated volume of therapy and implanted subcutaneously where they deliver a
continuous flow (1L/hour) of therapeutic agent over a limited time frame (three days).
Considering our therapeutic agent of choice is a virus with a potency that is sensitive to
temperature and time, we first performed a stability study in which we tested changes in
initial titers of virus over 3 days at 37oC. Alzet pumps containing 5x1010 pfu/mL
rNCP12.1 were incubated at 37oC for three days. Viral titers were tested at t=0, 4, 8, and
24 hours then every 24 hours for the next 2 days using our standard plaque assay in BHK
cells. We found that viral activity decreased approximately 10 fold every 24 hours for
the first two days eventually dropping to no infectious virus by three days under the
specified conditions (Figure 3-14). Though this temperature is an estimate of body
temperature in the animal model and is likely lower given the superficial implantation
site of the pumps, these results provided an idea of changes in virus concentration that
should be expected during the study. We therefore assume that our delivered virus by the
end of the first day of infusion would be approximately10 fold lower than the loading
dose with day two titers being 100 fold lower. In addition, it is likely that no infectious
virus would be infused by the end of day three.
Next, we evaluated this delivery system using our oncolytic virus in an
immunocompetent F98 glioma model. Fischer rats were implanted with F98 glioma cells
on day zero as described. At five days post-implantation, animals were given a single
dose of rNCP12.1 by intratumoral injection. On the same day as injection, Alzet pumps
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Figure 3-14. Stability of rNCP12.1 during the use of Alzet infusion pumps
A starting titer of 5x1010pfu of rNCP12.1 was added to Alzet pumps then incubated for
three days at 37oC. Titers were performed at t=0, 4, 8, 24, 48, 72 hours in order to
determine viral stability over time. Titers decreased 10 fold every day for two days with
no infectious virus detected at the end of the study
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containing varying doses of rNCP12.1 were secured subcutaneously and allowed to
infuse virus at a rate of 1L/hour (24L/day) from days 5-8 (Table 3-2; Figure 3-15A).
Animals were followed carefully with weights and neuroscore checked every three days
until criteria for euthanasia were met.
We observed a non-significant (p= 0.5932) 27% decrease in tumor size of animals
receiving the medium dose of virus versus 18% decrease in low dose and 4% decrease in
high dose treated animals as compared to control animals (no vehicle). Interestingly,
animals receiving vehicle only displayed the highest decrease in tumor load with tumors
reduced by 34% by the end of the study (Figure 3-16A). Representative micrographs of
tumors are shown in Figure 3-16B. Weight trends (Figure 3-16C) and neuroscores
(Figure 3-16D) were measured every three days with more frequent checks if additional
signs of distress were observed.
Specifically, weight trends compared to the previous study were much more
affected. Control animals not receiving any vehicle demonstrated expected trends in
weight with a slight fall after tumor implantation followed by a rise and then subsequent
fall as animals started to experience effects of tumor burden. Animals receiving vehicle
only displayed similar trends in weight as control animals, though at an approximately 15
grams lower weight at each time point. Virus treated animals all displayed a continuous
decline in weight following therapy until time of sacrifice. Animals receiving low dose
lost less weight than animals in the other two groups with weight at time of sacrifice
approximately 27% lower than starting weight. Neuroscores using the RCS on average
were lower compared to scores of animals that received only one intratumoral injection
of rNCP12.1. Animals in the high dose group surprisingly maintained a neuroscore
between 10-11 whereas scores averaged approximately 9-10 by the end of the study for
all groups including control animals. Low and medium dosed animals experienced the
most neurological decline with neuroscores ranging from 9.0 to 9.5 during the last few
days of life. As we saw with a single injection, tumors were not significantly different
between treated and untreated animals however unlike animals that received one injection
of virus, survival was not significantly different between the treated groups nor were they
significantly different from control (Figure 3-16E). The only significant difference in
survival was observed by comparing survival of control animals that received vehicle and
animals receiving the lowest dose of rNCP12.1 (Figure 3-16F). Median survival was 21
days and 27 days, respectively. Though animals receiving vehicle only had the smallest
tumors on average, they also had the lowest overall survival (Table 3-3).
In summary, continuous infusion after initial injection of rNCP12.1 did not
enhance anti-tumor activity or survival. There was no significant difference in tumor size
based on dosing of initial injection or infusion. Survival was not enhanced compared to
control animals. However it appears that animals receiving vehicle had an overall lower
survival that was significantly different from animals treated with low dose virus. The
infusion method appeared to have a negative effect on morbidity and animals in the study
had an overall lower average weight and neuroscore than observed in previous studies not
using this method. In conclusion, this method of delivery was not effective at enhancing
tumor reduction and in improving morbidity in treated animals.
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Table 3-2.

Description of treatment groups in Alzet pump study

Treatment Group

Injection Dose
8

Overall Pump Infusion
Dose
7

Low

4x10 pfu

1.6x10 pfu

Medium

1x10 pfu

4x10 pfu

2.5x10 pfu

1x10 pfu

High

9

9

Figure 3-15. Timeline for Alzet pump delivery study
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7
8

Figure 3-16. Comparison of tumor load in animals treated with varying doses of
rNCP12.1 delivered by Alzet pump infusion
At day five, post-tumor implantation, animals were given one i.t. injection of rNCP12.1
at varying doses per group. On the same day, Alzet pumps were implanted and infusion
of virus occurred over three days. Animals were sacrificed when criteria for euthanasia
were met. (A) There was no significant difference in size of tumors between treated and
untreated (p = 0.5932). Level of significance determined by One Way ANOVA using
mean values of exact tumor size (mm2). (B) Representative fluorescence micrographs of
each group demonstrating GFP expressing tumor. Morbidity of animals as determined by
(C) Weight trends and (D) Neuroscore. (E) Kaplan-Meier survival analysis
demonstrating a significant difference in survival. Statistical data performed using Logrank (Mantel-Cox) test; P= 0.0140. (F) Kaplan-Meier survival analysis demonstrating a
significant difference in survival between Control (vehicle) animals and Low Dose
animals; P= 0.0073. Statistical data performed using Log-rank (Mantel-Cox) test
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Table 3-3.
Summary of survival for animals treated in Alzet pump study relative
to vehicle control
Treatment Group*
Control
Control (Vehicle)
Low
Medium
High

Median Survival (Days)
23.5
21
27
23.5
25

Significant
Survival
(vs Control-Vehicle)
No
-
Yes
No
No

*Control-tumors implanted on day 0 with no further surgeries; Vehicle Controlimplanted tumors on day 0 with injection of viral vehicle only (TN-sucrose) on day 5
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Switching Serotype Enhances Survival and Prolongs Tumor Reduction in F98
Glioma Bearing Animals
In an effort to overcome the effects of the adaptive immune system, specifically
of neutralizing antibodies, on viral therapy, we performed a study in which we
administered two separate doses of rNCP12.1, intratumorally. As previously discussed,
VSV has two major serotypes, New Jersey and Indiana. The glycoprotein of these
serotypes possess only 50% amino acid sequence homology therefore infection of one
serotype should not protect against subsequent infection with the other serotype. For the
initial dose, all treated animals received rNCP12.1, Indiana serotype G protein (GI). For
the second dose, animals received either the same rNCP12.1 (GI) or rNCP12.1 having a
G protein from the New Jersey serotype (GNJ). Hence, group Ind/Ind received two
injections of the same serotype and Group Ind/NJ received the New Jersey serotype for
the second injection. The timeline of the study is depicted in Figure 3-17 with a
description of dosing in Table 3-4. There were two separate groups based on time of
sacrifice, an acute study to determine tumor load at 15 days post-tumor implantation and
a second group sacrificed when euthanasia criteria were met. At 15 days post-tumor
implantation, tumors from animals in both treated groups were found to be 63-65%
smaller than tumors from animals receiving vehicle only (p=0.0149) (Figure 3-18A).
Representative tumor images are shown in Figure 3-18B-G. Morbidity as determined by
weight trends (Figure 3-19A) and neuroscores (Figure 3-19B) were assessed throughout
the 15 days. Animals receiving treatment regardless of serotype experienced near
identical weight trends with the largest decrease in weight of approximately 30%
experienced at 12 days post-tumor implantation followed by a 25% increase in weight by
day 15. Control animals displayed a gradual decline with weights at sacrifice
approximately 15% lower than starting weight. All animals maintained a neuroscore of
11 in the first 15 days (data not shown). Past 15 days post-implantation, tumors were
reduced in size though non-significantly (Figure 3-18A). Of note, animals in the Ind/NJ
treatment arm had 54% smaller tumors than control animals whereas, tumors in the
Ind/Ind treatment arm were 19% reduced. Weights were more varied later in the study
with Ind/Ind animals weighing ~15-25 grams more than animals in the Ind/NJ group
(Figure 3-19B). The largest decrease in weight of 22% of the starting weight in the
Ind/NJ group was observed at day 15, post-tumor implantation, and the largest decrease
of 13.4% in the Ind/Ind group observed at day 12. Neuroscores were again maintained at
11 during the first 15 days with scores dropping as low as 7 and 8 by the time of sacrifice
in Ind/Ind treated animals and Ind/NJ treated animals respectively (Figure 3-19C). For
both treatment groups, there was an identical and significant increase in survival with
median survival of 24 days compared to median survival of 20 days in control animals
(Figure 3-19D).
From these studies we conclude that double injections of rNCP12.1 administered
at a 5 day interval significantly decreased tumor load with minimal morbidity by 15 days
some morbidity demonstrated by neurological deficits toward the very end of the study.
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Figure 3-17. Time line of Indiana/New Jersey double injection study

Table 3-4.
Description of treatment groups in Indiana/New Jersey double
injection study
Treatment Group
Ind/Ind
Ind/NJ

1.

1.


Serotype
Indiana
Indiana
Indiana
New Jersey
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Dose
109 pfu for ALL injections

Figure 3-18. Evaluation of animals treated with Indiana/Indiana versus
Indiana/New Jersey double injection
On day five, post-tumor implantation, animals were given one i.t. injection of 109 pfu of
rNCP12.1I-GFP. On day 10 post-tumor implantation, animals were given a second
injection of a 109 pfu dose of either rNCP12.1I-GFP or rNCP12.1NJ-GFP. Animals were
either sacrificed at day 15 post-tumor implantation (acute arm) or when euthanasia
criteria were met (survival arm). (A) Comparison of tumor load demonstrated
significantly smaller tumors in both treated groups (p=0.0149) for animals sacrificed at
day 15. However, there was no significant difference in the size of tumors in treated
animals of the survival arm relative to control (p= 0.1329), though tumors of animals
receiving a serotype switch for the second injection did have 54% smaller tumors.
Representative fluorescence micrographs of animals in acute arm receiving (B) no
treatment, (C) two doses of Indiana serotype, or (D) one dose of Indiana serotype and one
dose of New Jersey serotype and animals in the survival arm receiving (E) no treatment,
(F) two doses of Indiana serotype, or (G) one dose of Indiana serotype and one dose of
New Jersey. Levels of significance were determined by One Way ANOVA using mean
values of exact tumor size (mm2).
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Figure 3-19. Morbidity of animals treated in the Indiana/Indiana versus
Indiana/New Jersey double injection study
Morbidity of animals in acute arm as determined by (A) Weight trends. Morbidity of
animals in survival arm as determined by (B) Weight trends and (C) Neuroscore
(D) Kaplan-Meier analysis of survival demonstrating a significant difference in both
treated groups relative to control (vehicle); P < 0.0001. Statistical data performed using
Log-rank (Mantel-Cox) test.
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Administration of rNCP12.1 by Tumor “Carrier Cells” as a Potential Method of
Delivering Virus for the Treatment of Intracranial Glioma
Infected tumor carrier cells are unable to form intracranial glioma
In order to determine if infected tumor cells maintained the ability to form tumors
intracranially, we infected F98 glioma cells in vitro at an MOI of 0.1 or 10. At one hour
post-infection, cells were harvested and combined with uninfected cells at a ratio of 1:1
or 1:10 (infected: uninfected). Accordingly, 4 different treatment arms (Group 1-4) were
prepared and tested (1. MOI of 1 at 1:1 infected: uninfected cells; 2. MOI of 1 at 1:10
infected: uninfected cells; 3. MOI of 10 at 1:1 infected: uninfected cells; 4. MOI of 10 at
1:10 infected: uninfected cells) (Table 3-5). On day zero, 105 cells prepared for each
treatment group were intracranially implanted in Fischer rats. Weight trends and
neuroscores were assessed daily for morbidity, and at 15 days after implanting cells,
animals were sacrificed and brains were harvested and processed for further analyses of
tumor load and presence of virus (Figure 3-20).
We found that only implanted cells that were never infected in vitro (control)
developed into visible tumors while all animals receiving pre-infected cells (PC) did not
have visible tumors based on detection of GFP expressing cells (Figure 3-21A). All
animals experienced a similar drop in weight, one day post tumor implantation of ~10%
which gradually increased in all groups except control animals and animals of the Group
1 treatment arm. Control animals continued to decline in weight until day 7 post
implantation at which point weights increased until the end of the study. Group 1
animals maintained a steady weight following their initial drop on day one postimplantation (Figure 3-21B). Neuroscores were stable with an RCS of 11 throughout the
study for all groups except animals in treatment Group 1 with scores averaging between
9.5-10 during the second half of the study (Figure 3-21C).
From these results, we concluded that implantation of pre-infected tumor cells lost
tumorigenicity as a result of viral infection. Furthermore, following exposure to infected
tumor cells, non-infected cells became infected also losing their ability to form tumors.
Animals tolerated this treatment well without significant morbidity. This pilot study
provided the information needed to next evaluate infected tumor cells as vehicles for
oncolytic rNCP12.1 viral treatment.
Pre-infected tumor cell carriers cause tumor load reduction with moderate
morbidity at early time points with later time points inconclusive
To test the efficacy and safety of using pre-infected tumor cells as carriers for
virus in our glioma model, we first established F98-GFP gliomas in 6 week old male
Fischer rats as described. On day four post-implantation, F98-GFP cells were infected in
vitro at an MOI of 3. At 1 hour post-infection, 103 cells were harvested and re-suspended
in 10mL PBS vehicle. These cells were injected into the previous injection site used for
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Table 3-5.
Description of treatment groups in evaluation of pre-infected tumor
cell implantation study
Treatment Group
1
2
3
4

MOI
0.1
10

Ratio
Infected: Uninfected
1:1
1:10
1:1
1:10

# of Cells Implanted
105 cells/10L
vehicle (PBS)

Figure 3-20. Timeline for evaluation of pre-infected tumor cell implantation study
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Figure 3-21. Evaluation of tumor implantation by rNCP12.1-GFP pre-infected F98
glioma
At day zero, F98 glioma cells were infected in vitro at an MOI of 0.1 or 10 and cells were
harvested and combined with uninfected cells at a ratio of 1:1 or 1:10, infected:
uninfected. 105 cells were prepared for each treatment group and intracranially implanted
and on day 15, animals were sacrificed. (A) Comparison of tumor load. Only animals
receiving vehicle only treated glioma cells (control) formed detectable tumors. Morbidity
of animals as determined by (B) weight trends and (C) neuroscore.

124

125

tumor implantation (Figure 3-22). For comparison, several animals received
intratumoral injections of rNCP12.1 virus only (free virus, FV) similar to previous studies
(Table 3-6). Control animals received 10L PBS vehicle only. Tumor sizes were
calculated using ImageScope (Aperio ePathology Solutions) and were based on
measurements obtained from H&E stained tissue as well as fluorescence from GFP
expressing tumors (Figure 3-23B-O). Up to 15 days post-treatment, PC treated tumor
growth significantly lagged behind that of control with tumor growth reduced by as much
as 69% during the first 10 days after treatment (p=0.013) (Figure 3-23A). By day 15, PC
treated tumors were identical in size to control tumors while FV-treated tumors were
reduced in size by 29%. On day 20, all tumors had decreased in size including control
tumors however in comparison to control, PC-treated tumors were 63% smaller than
controls and the FV-treated tumor was 68% smaller, though not significantly.
Interestingly, one animal that received pre-infected cells had no evidence of residual
tumor at this time point (Figure 3-23L). Unfortunately, after day 20, tumors were unable
to be analyzed as a consequence of tissue processing for this study. Whereas animals in
all previous studies underwent perfusion with 4% paraformaldehyde, animals in this
study were perfused with normal saline in order to preserve tissue for qRT-PCR studies
therefore brain samples were extremely fragile during cutting of tissue. Weight trends
were also assessed and found to be similar to previous studies in the first week posttumor implantation (Figure 3-23P). Control animals maintained the greatest average
weights with weights increasing until the end of the study whereas FV treated animals
also experienced a gradual increase in weight though at a slower rate than in controls. On
the other hand, weight trends in PC-treated animals gradually decreased until the end of
study with average weights dropping approximately 30% from starting weights.
Neuroscores were stable early in the study with most animals maintaining a score of 11
for both control and treatment groups (Figure 3-23F). Neuroscores later in the study
were lower for control and PC-treated animals, decreasing to 9 by day 25 post-treatment.
Infectious virus can be recovered from brain tissue of PC-treated animals
One advantage of using carrier cells includes the ability to not only shield virus
from the immune system, but carrier cells also serve as in vivo “factories” of virus,
amplifying treatment even after initial dose is given. To determine the presence of
replicating virus in the CNS and in the periphery during treatment, several samples were
collected at various time-points before euthanasia. Samples included sera, cerebrospinal
fluid (CSF), and brain tissue. Brain tissue was homogenized in PBS and all samples were
then centrifuged to remove cellular debris. Only cell-free supernatants were used in the
detection of virus. One hundred microliters of each sample was added to cultured BHK
cells for 1 hour at 31oC. Samples were then removed and warm agar containing D5 was
applied. At 24-36hpi, agar was removed and cells were fixed and stained to detect VSV
nucleocapsid using a Rhodamine conjugated anti-VSV N monoclonal antibody. At three
days post-treatment, infectious virus was recovered from homogenized brain tissue of PC
treated animals (Figure 3-24A). Surprisingly, no virus was recovered after day three,
however on day 24 and 25, infectious virus was again recovered from homogenized brain
tissue (Figure 3-24B and C). Virus was not recovered from sera or CSF of PC-treated
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Figure 3-22. Timeline of rNCP12.1-GFP pre-infected cell study

Table 3-6.
study

Description of treatment groups in rNCP12.1-GFP pre-infected cell

Treatment Group
Pre-infected cells (PC)
Free virus (FV)

Dose of rNCP12.1-GFP
1000 cells infected at MOI of 3
9

10 pfu free virus
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Figure 3-23. Evaluation of rNCP12.1-GFP pre-infected F98 cells as treatment in
rat intracranial model of glioma
On day four post-tumor implantation, F98 cells were infected with rNCP12.1-GFP in
vitro at an MOI of 3 and 1000 infected cells were injected intratumorally. Animals were
euthanized at t=3, 6, 10, 15, 20, 25 days post-treatment. (A) Comparison of tumor load
demonstrated smaller tumors in PC-treated animals reaching significant levels at day 10
(p=0.01326). By day 15, PC-treated tumors reached the size of control tumors. FVtreated tumor was 29% smaller than controls, though not significantly. On day 20, PCtreated tumors regressed in size with tumors 63% smaller than controls while the FVtreated tumor was 68% smaller but not significantly. Representative H&E and
fluorescence micrographs of (B, D, F, H, K, M) control versus (C, E, G, I, L, N) PCtreated and (J, O) FV treated animals on (B,C) day 3, (D,E) day 6, (F,G) day 10, (H,I,J)
day 15, (K-O) day 20. Images were taken at 0.4X magnification using ImageScope
(Aperio ePathology Solutions). Morbidity of animals was determined by (P) Weight
trends and (Q) Neuroscore.
§
, average tumor size of animals sacrificed at day 18 and day 20 post-treatment
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Figure 3-23. Continued
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Figure 3-23. Continued
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Figure 3-24. Detection of virus in PC- and FV- treated animals
Brain tissue and sera of treated animals were collected and used to recover infectious
virus particles. Supernatant from homogenized brain tissue of animals treated with preinfected cells contained infectious virus particles at (A) day 3, (B) day 24, (C) day 25.
Virus was recovered from serum of the FV-treated animal at (D) day 15. Images on the
left are merges of fluorescence and bright field and images on the right are gray scale
fluorescence micrographs. All images were taken at 10X magnification. Additional
brain tissue was used for immunofluorescence staining for the detection of virus, tumor,
and the astrocytic marker, GFAP. Representative fluorescence micrographs of (E-H) PCand (I-K) FV-treated animals show expression of GFAP (blue) localized to GFPexpressing tumor cells (green) and surrounding normal tissue. (E-G) Virus (red) in PCtreated tumors, at day three appears to be highly localized in an area surrounding the
needle track within tumor tissue co-expressing GFP and GFAP. At day 15, (I-K) FVtreated tumors show virus within areas of GFP-expressing tumor. (E) Brain tissue of the
untreated, non-tumor bearing hemisphere is included in order to appreciate non-specific
background of green fluorescence. (H) Image of whole brain slice showing non-specific
background of green fluorescence in the left hemisphere relative to GFP expressing
tumor located in the right hemisphere.
E, F- 10X magnification; G, I- 20X magnification; H= 0.4X magnification; J, K- 40X
magnification
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animals at any time point. Cryo-sections of brain tissue were also used for
immunohistochemical analysis in the detection of GFAP and VSV-nucleocapsid. GFP
expression was again used as a marker for tumor. The astrocytic marker, GFAP, was
observed in multiple areas of the brain, localized both within tumor and in areas devoid
of tumor. At day three post-treatment, brain tissue from PC-treated animals was positive
for viral antigen. Increased VSV expression was observed in areas that correlated with
high GFP expressing tumor. This area was surrounded by a GFAP positive/GFP negative
(astrocytic/ non- tumor) tissue, which could correspond with normal astrocytic tissue
or non-GFP expressing tumor (Figure 3-24F and G). Figure 3-24F shows that infected
tumor is specifically located along the needle track, an artifact of tumor implantation.
This suggests that rNCP12.1-infected cells were capable of migrating to areas of tumor to
allow spread of virus within pre-established tumor. As we have seen from previous
experiments, pre-infected cells lose the capacity to form tumors in vivo therefore infected
cells at 3 days post-treatment are likely from previous implantation and not from
treatment. Normal uninfected tissue of the left hemisphere is shown in Figure
3-24E and H for comparison.
At day 15, on the other hand, virus was only recovered from serum of the FVtreated animal and no virus was detected in the CSF or homogenized brain tissue (Figure
3-24D). Immunohistochemical analysis of cryosections from this same animal also
demonstrated GFAP positive cells within tumor and surrounding normal tissue (Figure
3-24I-K). In addition, virus was also localized within tumor and not surrounding normal
tissue.
Innate and adaptive antiviral immune responses were not increased
following carrier cell delivery
Sera and CSF were also used to determine activity of both innate and acquired
immunity. Using the IFN bioassay, we found that systemic IFN activity was not elevated
relative to controls following treatment with pre-infected cells at any time-point. For
comparison, IFN activity in serum of the FV treated animal at day 15 was elevated
though not to levels observed in previous experiments (Figure 3-25A). CSF samples
were also tested for presence of active IFN in the CNS, which resulted in no detectable
IFN regardless of treatment (data not shown). In addition, neutralizing activity was
tested using the previously described neutralization assay (Figure 3-25B and C). A
control animal sacrificed on day 15 and one PC-treated animal sacrificed on day 20 were
compared to levels of neutralizing antibody in the sera of FV-treated animals. Only
animals receiving free virus demonstrated neutralizing activity with titers of 1000, the
same as titers confirmed in the single injection study.
In sum, the use of rNCP12.1 pretreated F98 glioma cells as a therapeutic vehicle
in our rat glioma model demonstrated significant tumor load reduction. At early timepoints, it appears tumor growth was delayed relative to controls yet when tumors became
more active, evident by an increase in tumor load, viral replication increased causing a
second peak in tumor load reduction and viral presence at later time-points. Furthermore,

134

Figure 3-25. Evaluation of innate and adaptive immune responses following
treatment with pre-infected tumor cells
(A) Sera from 1-2 animals at various time points were collected and IFN activity
determined by the IFN bioassay. Pre-infected F98 cells did not induce peripheral IFN
activity in contrast to animals that received free virus. (B) Presence of neutralizing
antibodies was first tested using Western blot analysis and sera of FV-treated animals
only were found to have detectable antibodies directed against VSV G and M. (C)
Neutralizing activity was evaluated using a neutralizing assay in which sera was serially
diluted 2 fold and tested for the inhibition of VSV infection in BHK cells. Neutralizing
titer was calculated as the inverse of the dilution found to cause inhibition of infection.
+ control, TN-1 (rabbit polyclonal antibody formed against intact UV-inactivated virus,
nAb titer- of 800).
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infection appeared to be localized therefore infectious virus was not present in the CSF or
serum of treated animals. Not surprising, this translated to a lack of antiviral immune
responses as seen by low IFN levels and absence of circulating nAbs. On the other hand,
we demonstrated that direct injection of free virus elicits a robust antiviral response as
seen by increased IFN levels relative to untreated animals and presence of nAb in the
periphery. This immune response was directed against infectious virus recovered from
the systemic circulation but not from brain tissue at 15 days following treatment. Despite
elicited systemic immune responses, virus was still localized to areas of tumor and not
normal tissue even at 15 days post infection, which corresponded with lower (though
non-significant) tumor load at both 15 and 20 days post-treatment.
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CHAPTER 4.

DISCUSSION

Glioblastoma multiforme is one of the most destructive of adult tumors.
Prognosis is poor even when patients receive all possible therapies. Patients that are not
suitable for surgical management, tend to do poorly and chemo-radiation alone may only
extend life weeks to months at best resulting in a 2-year survival of only 10-18% [9, 381].
Median survival of patients with GBM continues to be approximately one year, even
considering advancements of modern medicine. Long-term survivors (greater than 3 year
survival) eventually succumb to disease as tumors typically recur and with a resistant
phenotype, non-amenable to surgical or pharmacological therapy [1, 7, 382]. This shifts
the focus of therapy from cure to comfort care as end of life issues become more critical.
Not surprisingly, a push for therapies that have the potential to extend survival while
maintaining a satisfactory quality of life have become an important focus for cancer
researchers and medical practitioners of neuro-oncology, neurological surgery, and
palliative care. Specifically, oncolytic viruses have moved more into the spotlight as
potential therapies for cancer in general but also as a unique therapeutic agent in the
treatment of high-grade gliomas. Multiple viruses along the vast spectrum of viral
classes have been evaluated and have shown promise in both pre-clinical and clinical
studies (reviewed in [63, 383, 384]). Ideal characteristics of oncolytic viruses being
considered as therapy for GBM should include a specificity to infect tumor while
maintaining the ability to and preference for replication and cytolysis in these cells over
those of normal tissues. This is often challenging in the CNS especially considering the
sensitive nature of neuronal tissue to damage and infection. Additionally, viruses that are
naturally oncolytic often maintain the ability to infect surrounding normal tissues. Unlike
non-biological therapies, viruses endure unique challenges that hinder their transition
from cell culture and pre-clinical models to human patients. These challenges often
involve balancing safety with optimal therapeutic efficacy, therefore, it is not surprising
that understanding the immune responses elicited during and by viral therapy may help
address these obstacles.
We have developed a novel viral therapy derived from a naturally selected noncytopathic variant of vesicular stomatitis virus [237, 366]. VSV, an RNA virus of the
order Mononegavirales is no newcomer to pre-clinical studies, and its selectivity has
been tested in a number of different tumor models including breast, prostate, melanoma,
liver, and brain [294, 358, 359, 361, 371, 385, 386]. VSV specificity for tumor stems
from the role of the matrix protein, particularly through its ability to inhibit host gene
expression especially of genes related to antiviral responses. Matrix binds at the nuclear
pore complex (NPC) preventing the movement of message into the cytoplasm where it
would be used to synthesize protein [275, 278]. Many tumor cells are vulnerable to these
mutants due to inherent defects in their antiviral IFN responses rendering them unable to
fight off viral infection while normal cells with intact IFN pathways are protected [289,
291, 292]. A number of matrix variants have been tested including those that have been
genetically engineered to express defective matrix proteins to those that have developed a
natural selection for growth in specific tumor cells [285, 289, 354, 355, 371].
Nevertheless, it is the inability to inhibit the innate IFN antiviral responses that is the
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main focus of tumor oncolysis. In addition to tumor specificity, other characteristics
make VSV a suitable candidate for treatment of GBM. These include its quick
replication cycle, ability to grow to high titers in most cell lines, broad tropism, and ease
of genetic manipulation for the insertion of foreign genes or of mutations of VSV genes
that help attenuate viral infection in normal cells [207, 291, 343, 344]. We have shown
that our novel matrix mutant, rNCP12.1, possesses these characteristics. Specifically,
viral growth and cytopathic effects represented by cell rounding vary between normal and
tumor cells as well as between histologically identical tumor cells of different cell lines.
Primary astrocytes have a more attenuated growth pattern with rNCP12.1 as well as
wtVSV in comparison to growth in rat glioma cells however this mutant produced 10 fold
less virus relative to wildtype. Cytotoxicity was also attenuated and primary astrocytes
infected with rNCP12.1 had minimal cell rounding. On the other hand, in the majority of
glioma cell lines, differences, though minimal, in growth of rNCP12.1 relative to
wildtype virus were most noticeable in C6 earlier during infection with titers lagging
behind but eventually catching up to wildtype titers at later timepoints. Human glioma
cell lines also varied in their sensitivity to rNCP12.1 infection. For instance U87, known
to have chromosomal aberrations in the IFN-I gene, is extremely sensitive to rNCP12.1
infection, with cells forming large syncytia indicative of membrane fusion that is
characteristic of VSV infection in vitro. T98G human glioma cells, on the other hand,
have an intact IFN signaling which correlated with an overall resistance to rNCP12.1
infection evident by minimal expression of viral antigen and almost negligible cell
rounding.
With these results in mind, we were, naturally curious about the IFN activity in
cells of our rat glioma model in order to determine if in fact IFN activity or lack thereof
corresponded with cytopathic attenuation. Using semi-quantitative RT-PCR to check for
the presence of IFN mRNA, we observed an induction of IFN following wtVSV
infection in rat fibroblasts, though at extremely low levels whereas rNCP12.1 elicited a
robust signal for IFN message at both 6 and 12hpi. IFN signal following wtVSV
infection in C6 rat glioma was negligible while rNCP12.1 increased IFN expression to
levels comparable to that found in rNCP12.1 infected rat fibroblasts; however, expression
was not sustained and substantially dissipated by 12hpi. Quantitative analysis provided
even stronger evidence of differences between normal and tumor cells to elicit IFN
responses. Though wtVSV induced some level of expression in all cell types, rNCP12.1
caused a much greater level of induction. This induction extended into tumor cell lines,
as well, though at exponentially lower levels than normal cells. These results in most
studies would be interpreted as corresponding to equivalent levels of protein synthesis.
In order to determine whether expression levels indeed translated into active protein, we
tested for the presence of biologically active IFN levels as seen by antiviral activity in the
supernatant of infected cells and we found that wtVSV caused production of very low
amounts of active IFN only in primary astrocytes. Robust antiviral IFN activity however
was observed in normal rat fibroblasts infected with rNCP12.1. These levels gradually
increased over time showing that normal astrocytes like rat fibroblasts are able to amplify
signal with time. Not surprisingly, IFN activity was also observed in tumor cells
however they lacked the ability to consistently amplify signal (C6, F98) or to elicit a
robust production of IFN early during infection (F98).
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Generally, mRNA accounts for less than half of protein abundance and it is
suggested that the ratio of mRNA abundance to that of protein leans more toward a
higher prevalence of protein. This ratio is sensitive to cellular conditions and often
depends on the specific role a protein plays in cellular activity [370]. Nonetheless, it is
assumed that if a specific gene transcript is detected, likely the corresponding protein will
be detected also. An interesting observation from these data was the imbalance between
gene expression and protein activity in each cell line with mRNA abundance being more
prominent than protein activity. More specifically, there appeared to be much tighter
regulation on the production of active IFN by the primary astrocytes. There are a number
of potential levels of regulation that could account for this divergence. As we know,
VSV matrix protein inhibits nucleocytoplasmic transport (NCT) of message [278]. This
is evident in our results with wtVSV, however mutants should be defective in their
binding at the NPC therefore allowing transcripts to be exported from the nucleus. This
in fact appears to be true, however, there may be a difference in sensitivity to this
inhibition that is cell specific. For instance, a lower level, relative to other cells tested, of
matrix binding to NPCs may be all that is required in astrocytes to block NCT.
Regulation of post-transcriptional events including increased stability of IFN transcripts
might also be at play. Several studies have indeed addressed mechanisms that affect the
stability of IFN transcripts following infection. Johnsen et al demonstrated that IFN
transcripts possess a 3’ untranslated region that contains sequences involved in
controlling mRNA stability. During infection or in the presence of synthetic inducers of
the antiviral pathway such as pI:C, IFN transcripts become more stable, enhancing
production of protein during infection, which increases the likelihood of a protective
antiviral state [387]. It is possible that at this time point we are observing the effects of
more stable mRNA in combination with continued cellular control over translation.
Interference at the translational and posttranslational level is also a possibility. These
could include alterations in the half-life of protein due to increased degradation or protein
stability as well as post-translational modifications rendering the protein inactive.
From these results, the question becomes, whether or not more is better; is
overabundance of active IFN necessarily biologically relevant? Considering astrocytes
are a vital component of the cellular network in the central nervous system, it is not
surprising that there would be a tighter control over the availability of biologically active
IFN. In fact, outside of its role in antiviral responses, IFNs are also important in cell
survival serving as a major inducer of apoptotic responses [23, 330]. In comparison to
neuronal cells, astrocytes do maintain some level of competency to proliferate and are the
most important CNS cell that responds to brain trauma by proliferating in a process
known as gliosis [388, 389]. Despite this proliferative capacity, uncontrolled promotion
of cell death would be detrimental therefore controlling IFN could serve as a survival
mechanism in the face of infection. A better understanding of the mechanisms involved
in controlling IFN activity in primary astrocytes could aid in addressing these points.
Future studies might first test whether control of active protein produced is the same as
control of total protein in astrocytes. This can be done by ELISA analysis to quantify
total protein concentration of IFN. If total protein adheres to the same pattern, it might be
worthwhile to determine whether there is a noticeable gradient of mRNA from the
nucleus to the cytoplasm as this would point more toward NCT as a cause for the
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disproportion between gene expression and protein activity.
IFN defects can happen at multiple points in the antiviral response pathway from
the production of IFN to IFN sensitivity [331-333]. Therefore, it is possible that even
though certain cells may not produce active IFN, they may in fact retain the ability to
respond to IFN. This response is evident by the promotion of downstream interferon
stimulated genes (ISGs) that amplify the IFN pathway, promoting the protection of cells
during viral infection. We next tested the sensitivity of cells to exogenous IFN as
determined by their ability to inhibit virus propagation in cell culture and found that
primary astrocytes are highly sensitive to antiviral effects of IFN with protection
observed at IFN levels <5 U/mL. On the other hand, glioma cells showed variable levels
of sensitivity with F98 being completely resistant and C6 glioma having a more
intermediate level of sensitivity requiring higher levels of exogenous IFN to create
protection (summarized in Table 4-1). Generally speaking, cells that respond to IFN but
do not produce IFN may likely have defects that are concentrated upstream of IFNAR
activity. On the other hand, cells that produce IFN but are not able to respond to IFN
may harbor more defects downstream of IFN binding to its respective receptor, such as in
JAK/STAT signaling.
The focus has mostly been on whether individual cell types alone could elicit
protective IFN responses by an endogenous pool of induced IFN. Endogenous levels
become more important in cell culture however, in a living system, we must take both
pools of IFN into account, IFN produced by that specific cell population and IFN
produced by surrounding cells of different types. Hence, the combination of these data,
which includes IFN production by cells correlated with viral titers and cell specific viral
induced CPE versus protection by exogenous IFN suggest that they are both important.
In adding to the above studies, we also performed more in depth analysis of IFN
Table 4-1.

Summary of in vitro results of VSV in normal and tumor glial cells

Measurable
Response to
Infection
Cell Rounding
Cell Viability

PRA

C6



wt vs. NCP12.1






Viral Yield





IFN
transcription*
IFN bioactivity*
















wt vs. NCP12.1




F98















 wt vs. NCP12.1
























Note: Scale of + to ++++ signifies lowest to highest for each measure of response to
infection; -, negligible
* IFN transcription and bioactivity are relative to control cells (FR, rat fibroblasts)
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responses as determined by induction of specific ISGs, several of which have been
studied more than others as responders of VSV infection. Van den pol and associates
tested the stimulation of genes in several human glioma cell lines (U87, U118, U373,
A172, M059) as well as in primary glioma tissue compared to normal brain tissue and
found that their glioma-adapted VSV mutant, VSV-rp30a (MOI of 2) and treatment with
exogenous IFN (100U/mL) both demonstrated significant increases in expression levels
of IFN and MxA 6h post treatment [371]. Another key study by Barber and associates
involving some of the first engineered attenuated matrix variants of VSV (AV1 and AV2)
showed that wtVSV blocks transcription at the level of secondary ISG responders such as
GBP1 and MxA while mutants allow, and actually, induce expression levels of the same
transcripts [289]. Expression of these ISGs goes on to activate tertiary responders (e.g
IFN4), which augment antiviral activity. This study tested ISG responses in an ovarian
carcinoma cell until 12hpi. Though our studies veered from the above studies in tumor
cell type (human glial versus ovarian carcinoma versus rat glial), time post infection
(6hpi versus 12hpi versus 24hpi) and specific mutant virus (vsv-rp30 versus AV1 and
AV2 versus rNCP12.1), overall, we observed increases in expression levels by our
mutant in comparison to wildtype. Several differences in our results included that we did
not see a total inhibition of secondary interferon responders however our study was
carried out 12 hours after those showing inhibition and therefore it is possible that these
responders eventually did become expressed as cells began to overcome the block of
wtVSV. Several individual ISGs were also noted to not follow the expected increases
after mutant infection in our study. Altogether, our non-tumor cell line, primary rat
astrocytes, followed a pattern of ISG induction almost identical to that of control rat
fibroblasts whereas glioma cell lines varied from this pattern and even from each other.
Whether these differences affect rNCP12.1 related oncolysis of glioma cells will require
additional studies. At any rate, though specific interpretation of the intricacies of these
patterns is beyond the scope of the project, several ISGs are worth mentioning in detail.
RIG-I, for instance, is an important component of antiviral signaling through its
role as a pattern recognition receptor. Particularly, RIG-I has been shown to be
indispensible in the activation of antiviral IFN activity in fibroblasts after VSV infection,
with RIG-I knockout cells having up to 100 fold higher viral titers than normal cells
[306]. RIG-I is constitutively active and has been shown to be most elevated in
astrocytes at 4hpi returning to basal levels by 8hpi [372]. Our analysis of expression
levels in astrocytes supported this as both PRAs and FR cells had very low levels at 24h
following wtVSV infection. In contrast, both glioma cell lines demonstrated a notable
elevation following wild-type infection at the same time point. Even more, expression in
all cell types following rNCP12.1 was significantly elevated at 24hpi. Though it is
unknown whether this expression at 24hpi is due to a delayed induction of RIG-I or
rather a constant, prolonged induction, it is of note that this contradicts what is known
about RIG-I activity this late in infection. Many cells display autonomous control of
RIG-I activity, specifically by a splice variant, which is upregulated during viral infection
or following exposure to Type I IFN [390]. This splice variant is determined at the
transcriptional level and amplification of RNA in cells treated with IFN or after viral
infection shows both wildtype and variant bands. RIG-I responses have been shown to
be inhibited by the heterodimer formation of the RIG-I splice variant with the wildtype
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form as a negative feedback mechanism to protect cells from unbalanced production of
IFN [390, 391]. Our results specifically showed that wtVSV and rNCP12.1 induction of
RIG-I was highest in C6 glioma but not normal cells. Therefore, future studies might
address whether this variant is present in our glioma cell lines specifically in C6 cells
thus possibly causing the observed levels of IFN gene expression and ultimately IFN
activity. In addition, evaluation of RIG-I expression levels at earlier time points might
reveal whether rNCP12.1 prolongs RIG-I expression or whether expression is actually
delayed.
Expression of plscr1 was also notable following infection. This ISG is known to
affect survival and terminal differentiation of myeloid cell lines [326]. The ability of
plscr-1 to attach and insert into the cell plasma membrane is interesting as plscr1 contains
the PPXY N-terminus motif just as is found in the N-terminus of VSV matrix, which has
been shown to interact with SH3 and WW domains found in a host of cellular proteins.
Moreover, depending on post-translation palmitoylation, plscr-1 migrates to the nucleus
where it binds to DNA as a regulator of transcription, therefore IFN-induced gene
expression. It may be possible that, during VSV infection, especially events during the
replication cycle such as assembly and budding where matrix is associated with the cell
membrane, competition for similar cellular proteins might occur between matrix and
plscr1 during viral infection. Except for F98 levels, our studies revealed very low
expression in all other cell types regardless of infecting virus. F98 glioma demonstrated
10 fold higher expression levels of plscr1 following rNCP12.1 infection. Therefore,
aside from results in F98 cells, expression levels in all other cell lines are in contrast to
those observed by Barber et al in which plscr1 expression was inhibited by wtVSV but
induced starting at 6hpi with attenuated VSV strains [289]. It is possible that like RIG-I,
some cells especially non-tumor cells regulate the overexpression of plscr1 whereas F98
cells are unable to, especially considering their role in effecting sensitivity to viral
infection. Additionally, it is possible that plscr1 levels were indeed elevated at earlier
time points and, like RIG-I, should decrease back to lower basal levels at later time
points. Therefore, evaluation of plscr 1 expression at earlier time points leading up to
24hpi would allow us to determine which is more likely. It would also be of interest to
see if in fact there are differences in localization of plscr1 as a result of VSV infection
particularly of displacement of plscr1 from the cell membrane by competition with matrix
for binding of cellular proteins and whether this relationship correlates with IFN activated
responses.
Lastly, IRF-1, an inducer and effector of the IFN pathway, is known to be directly
upregulated in response to VSV infection, even in the absence of IFN [392]. IRF-1 levels
are observed during states of cell cycle arrest as well as during apoptosis. IRF-1
increases expression not only of Type I IFN but also of a subset of ISGs including Mx1
and 2, GBP1, OAS, PKR, and RIG-I [310]. Sgorbissa et al demonstrated that U87 and
T98G, two human glioma cell lines that lie on the opposite ends of the IFN spectrum,
expressed biphasic elevations of IRF1 following treatment with IFN at 6h and later at
24h [331]. IRF1 expression went on to induce expression of TRAIL, a known activator
of apoptosis, in T98G cells but not in U87. In our studies, glioma cells expressed similar
levels of IFN4 regardless of infecting virus. IRF-1 expression also demonstrated this
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same non-specific pattern in F98 as well with wtVSV inducing almost identical levels of
expression as rNCP12.1. This demonstrated that the expected elevations in IRF1
expression following mutant infection was not observed in F98 glioma and that the
relationship between IFN4 and IRF1 induction was still intact. On the other hand, IRF1
levels showed a switch in expression with wtVSV inducing a higher expression over
rNCP12.1 in C6 glioma even more so than increases in expression following rNCP12.1 in
normal cells. This may be that IFN independent induction of IRF1 following wtVSV
infection in C6 cells is more important following wtVSV than in other cell types.
Obviously, a thorough explanation for these results would require additional
studies in order to determine the meaning of these patterns of induction and how they
relate to the overall IFN phenotype of each cell line. In combination with IFN activity
and protection assays, unique cell specific IFN phenotypes are revealed and could
possibly serve as predictors of cells that may likely respond to VSV oncolytic therapy.
As we moved from in vitro studies into an immunocompetent animal model of
glioma, we saw positive tumor response to rNCP12.1 therapy even after only a single
injection of virus. This tumor reduction, though highly significant was not sustainable
and tumors eventually recurred at an expedited rate over untreated animals so much that
at the time of euthanasia, tumors were virtually the same size as animals that never
received virus. Similar results have been observed in other studies particularly testing
naturally oncolytic viruses like VSV. In their evaluation of Semliki Forest Virus as
treatment for glioma, Maatta et al demonstrated that when using an immunocompetent
model for systemically administered OV, tumor growth is inhibited early during
treatment resulting in significantly smaller tumors than controls; however, treated tumors
do eventually catch up to the size of untreated tumors at an accelerated pace. On the
other hand, immunocompromised animals lacking an intact antibody response did not
demonstrate this type of recurrence [393]. Non-published data from the same group,
observed that in a different immunocompetent syngeneic model of glioma, SFV was
more effective at the same dose of virus suggesting that specific tumor model
characteristics play an important role in therapeutic efficacy [394]. Nonetheless, our
evaluation of host innate and adaptive immune responses following intratumoral
rNCP12.1 confirmed an obvious increase in both IFN and in VSV neutralizing activity.
Specifically, neutralizing activity was observed at time points that coincide with natural
progression of immune responses against VSV [395].
The cause for accelerated tumor recurrence in the presence of heightened immune
responses is likely multi-factorial. As we stated, injury to normal brain tissue can
activate proliferation of normal astrocytes. It is possible that whatever factors trigger this
response can be a cause of increased growth of astrocytic tumors as well. Changes in the
tumor microenvironment caused by virus may additionally serve as a factor and several
studies have revealed key changes that occur with viral therapies. For instance,
Kurozumi et al showed that oncolytic viral infection promoted enhanced leakage of
vessels when administered intratumorally even over the pro-angiogenic responses already
encouraged by the tumor itself. Enhanced tumor perfusion opens the flood gates for the
movement of antiviral immune responders capable of inactivating virus therefore
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decreasing viral effect [396]. Another possible cause of enhanced growth could be due to
tumor-acquired resistance to virus. With chemotherapeutic agents, resistance to therapy
is a common occurrence during treatment of highly malignant brain tumors. It is possible
that these cells are also capable of acquiring resistance to viral therapy in the same
manner. In addition, cells have been known to acquire a tolerance to virus. As a matter
of fact, many of the attenuated strains of VSV were discovered during persistent
infections [356, 357]. Previous studies in our lab have demonstrated the ability of VSV
to establish persistent infections in cell culture. This was even demonstrated in several
studies involving the F98 glioma cell line (data not shown). Persistence of infectious
virus in our tumor model would likely terminate oncolysis, therefore, increasing the
possibility of tumor proliferation.
To test whether controlling immune mediated neutralization of virus could
enhance tumor reduction and decrease or possibly inhibit later accelerated tumor growth,
we performed another evaluation of intratumoral rNCP12.1 but by administering two
separate injections. Two treatment arms were designed, one group receiving 2 injections
of the same serotype (Ind/Ind) and the other receiving 2 injections, one from Indiana
serotype and the other from New Jersey serotype (Ind/ NJ) of VSV. It is generally
accepted that neutralizing activity against one serotype does not cross react with the
other. More accurately, cross reactivity of one serotype over another was found rather to
be dependent upon several factors: route of administration; amount of viral antigen
present; co-administration with immune adjuvants. Live virus given into the peritoneal
cavity only activates non-cross reactive antibodies whereas intravenous virus or virus
given at high levels especially over a prolonged period of time (e.g. persistent infection)
activates antibody with an assymetrical cross reactivity. This means that antibodies
produced by the New Jersey serotype are more cross reactive to Indiana than are Indiana
antibodies against the New Jersey serotype [397]. To our knowledge, no studies have
shown whether an assymetric cross reactivity exists when virus is administered in the
CNS. Based on our results, 2 doses of rNCP12.1 were just as effective at reducing tumor
as one injection at earlier time points (up to 15 days). Differences at later time points
showed that animals treated with the same serotype experienced a robust recurrence of
tumor while tumors of animals receiving a switch in serotype for the second dose
maintained smaller tumors until the time of euthanasia. Survival of both animals was
identical. It was not determined in this experiment whether neutralizing antibodies were
produced in response to virus or whether these responses possessed cross reactivity
between serotypes. In addition, each injection was given 5 days apart, day 5 post-tumor
implantation for the first injection and day 10 for the second injection. Therefore,
presence of a substantial neutralizing antibody population likely had not occurred. Future
studies should aim to determine the time course of nAb production from virus
administration to neutralizing activity in order to optimize anti-tumor effect from the
second dose of therapy.
As mentioned before, the immune system is a double-edged sword in which
immune responses activated by virus can also serve as key anti-tumor effectors that
contribute to what is known as the bystander effect seen during therapy. This means that
non-infected tumor cells are killed by enhanced anti-tumor immunity triggered by an
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upregulation of immune mediators that, before viral infection, were not strong enough in
their response to eliminate tumor. The other side of the sword involves the early
elimination of viral treatment in an effort to protect the infected host. By amplifying the
signal of danger to surrounding immune cells, viruses are able to disrupt the state of
immune tolerance created by tumors and even increase visibility of tumor associated
antigens (TAAs) that otherwise would go unnoticed [398].
Several studies have suggested the use of carrier cells as a mobile manufacturer of
virus, shielding its product from immune regulators during transit. As tumor cells should
retain susceptibility to infection, viral dose would theoretically be amplified during
transit, as they home to sites of tumor attracted by their preferred tumor niche [197, 399].
One such study tested a combination of immunosuppressants with cell carriers of an
oncolytic poxvirus in the treatment of a peritoneal carcinomatosis mouse model. MC38,
autologous murine colon carcinoma cells were used as carriers. This therapy not only
enhanced survival but also promoted recovery of virus from tumor tissue confirming the
continued replication of virus within tumor even at eight days post treatment [400]. We
tested the use of autologous F98 glioma cells as vehicles for rNCP12.1 in the treatment of
glioma in our immunocompetent Fischer rat model. Tumors responded to treatment
significantly as demonstrated by a reduction in tumor load until day 15 at which point
treated tumors were equal in size to those of control animals. Though comparisons of
tumor size following this time point were unable to be determined due to quality of tissue
samples, of note, at day 20, one animal showed complete regression of tumor while tissue
of other animals demonstrated areas of high cellular infiltrate on H&E that did not
correlate with GFP expression on fluorescence microscopy. In addition, analyses of
immune responses proved that carrier cells were effective in their ability to shield virus
from potential antiviral responses. There was an absence of neutralizing antibody in the
serum of PC-treated animals even at 20 days post-treatment, despite recovery of virus
from brain tissue at the same time point. This was opposite of what was observed in FVtreated animals which were positive for IFN and neutralizing antibodies in the periphery.
Virus in these animals was not recovered from brain tissue but rather from systemic
circulation. It appears from these results as well as of previous experiments that
neutralizing antibody directly correlates with the size of tumor and that the concept of
“the more, the better” pertaining to IFN activity during viral treatment may not
necessarily be a marker for predicting effective response to therapy (See Table 4-2 for
summary of in vivo experiments).
Another theory that has been proposed concerning autologous tumor carrier cells
is that they could possibly initiate or encourage anti-tumor activity. A number of very
successful therapies are based on this possibility including monoclonal antibodies that are
directed against specific tumor proteins or those of the tumor microenvironment (i.e.
VEGF, Her2). As a preliminary study, we evaluated immune recognition of tumor cells
by testing for the presence of anti-tumor antibodies. Using Western blot analysis, we
analyzed serum for the presence of systemic antibodies that may have been produced
against F98 specific tumor antigens during treatment (See Appendix A). Results revealed
a pattern of tumor antigen recognition that was specific to FV- versus PC-treated animals.
The majority of antigens more immunogenic in FV-treated animals were antigens that
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Table 4-2.
Summary of in vivo experiments of rNCP12.1 in the syngeneic F98
glioma/ Fischer rat model
Study
Treatment
Single injection:
9
10 pfu rNCP12.1 GFP

Acute, A
or
Tumor Load  ?
Survival,
(%)
S
A
Yes (65%)

Significant
Survival ?

Median
Survival

N/A

N/A

S

No

Yes

23 (C) vs.
29 (Tx)

Single injection w/
Alzet Pump:
High Dose, HD;
Medium Dose, MD;
Low Dose, LD

S

No

Yes
(CV vs LD)

21 (CV) vs.
27 (LD)

Double Injection/
Serotype Switch:
9
10 pfu rNCP12.1 (I/I)
9
and 10 pfu rNCP12.1
(I/NJ)

A

Yes
(63%, I/I;
65%, I/NJ)

N/A

N/A

S

No
(54%, I/NJ)

Yes

21 (C) vs. 24
(I/I and I/NJ)

Pre-infected Tumor
Cell Carriers:
103 cells infected at
MOI of 3

N/A*

Yes** (69%)

N/A

N/A

*This experiment was a time course in which animals were sacrificed at 3-5 day
intervals.
**Tumor load was significantly decreased up to 10 days following treatment; Later time
points will need to be repeated
N/A, not applicable; Tx, treated; C, control; CV, control with vehicle; LD, low dose; I/I,
Indiana/ Indiana; I/NJ; Indiana/ New Jersey
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were not recognized in the other treatment groups whereas most antigens that were more
immunogenic in PC-treated animals were also immunogenic in the other groups though at
much higher levels of reactivity. Of note, the greatest level of tumor antigen recognition
was observed at day 15 following treatment for both FV- and PC-treated animals. These
preliminary data are encouraging and more in depth analysis into the importance of these
immunogenic antigens could provide a platform for more sophisticated
immunotherapeutic adjuvants for the treatment of high-grade brain tumors.
In summary, we have revealed unique cell specific patterns of gene expression in
various cell types that must be taken into account in order to determine if rNCP12.1
would be an optimal therapy in that system. Just as every high-grade glioma does not
respond as anticipated to temozolamide (TMZ), the standard chemotherapeutic agent for
GBM, there is a subset of tumors especially sensitive to TMZ based on mutations in the
DNA repair enzyme, MGMT. Therefore a pre-determined molecular signature can be
extremely helpful in making sure that a particular treatment will have optimal effect as an
anti-tumor agent. Similarly, determination of proposed IFN phenotypes that are defined
by the ability of cells to produce IFN and respond to IFN, evident by the ability to
upregulate the expression of particular ISGs as well as to create an antiviral state
following exposure to exogenous IFN, could prove to be just as important in determining
whether a specific tumor is right for rNCP12.1 therapy (Figure 4-1). The push for a less
histologically oriented and more molecular signature based classification system of
gliomas stems from the importance of these molecular signatures on therapeutic
outcomes. Supporting evidence for this concept as it relates to VSV oncolytic therapy is
evident in several studies that confirmed differences in response to viral therapy based on
IFN expression profiles. One such study involved the evaluation of another RNA virus,
Semliki Forest virus (SFV) as a cancer therapeutic in several cancer models including
melanoma and glioma. GL261 and CT-2A glioma cells were shown to be producers of
and responders to IFN and therefore were protected against in vitro infection with SFV.
When pre-infected GL261 were implanted intracranially, these cells retained the ability to
form aggressive intracranial tumors in immunocompetent mice [401]. On the other hand,
a study by Ruotsalainen et al demonstrated the IFN resistant cell line CT26 were highly
susceptible to SFV infection in a syngeneic model of colon carcinoma. This is not to say
that VSV based OVs would not work in the face of IFN sensitive cells [401]. As Alain et
al have shown, tumor models responsive to IFN benefit from the addition of adjuvant
immunomodulatory therapies such as rapamycin which inhibits IFN activity. They
demonstrate in this study that though rapamycin decreases the production of IFN, levels
of IFN produced are still able to protect normal tissue resulting in a significant increase in
survival over virus alone [193].
As oncolytic viruses continue down the road to clinical studies, it is important to
remember that in vitro results as compelling as they may be are not always relevant in
living models. As is the case of rNCP12.1 viral therapy, neutralizing activity proved to
be as important if not more to IFN phenotype in the potential to reach optimal efficacy in
vivo. In addition the ability to enhance anti-tumor activity may prove to be the most
important factor related to long-term outcome measures resulting from viral therapy.
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Figure 4-1. Interferon phenotypes of glial cells in response to rNCP12.1 infection
In summary, these normal and tumor rat glial cells have unique IFN phenotypes. These
phenotypes can be described as either (A) IFN sensitive in which cells sufficiently
produce and respond to exogenous IFN, (B) IFN intermediate in which cells
insufficiently produce IFN at levels unable to create an antiviral state and they respond to
exogenous IFN at much higher levels than are needed to protect normal cells. It is
unknown whether this protective state is sustainable past 24 hours, (C) IFN resistant cells
that insufficiently produce and respond to exogenous IFN.

149

LIST OF REFERENCES
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.

Krex, D., et al., Long-term survival with glioblastoma multiforme. Brain, 2007.
130(Pt 10): p. 2596-606.
Brat DJ, e.a., Pseudopalisades in glioblastoma are hypoxic, express extracellular
matrix proteases, and are formed by an actively migrating cell population. Cancer
Res 2004. 64: p. 8.
Louis DN, e.a., The 2007 WHO Classification of Tumours of the Central Nervous
System. Acta Neuropathol 2007. 114: p. 13.
Dolecek TA, P.J., Stroup NE, and Kruchko C, CBTRUS Statistical Report:
Primary Brain and Central Nervous System Tumors Diagnosed in the United
States in 2005–2009. Neuro-Oncology 2012. 14: p. 50.
Ohgaki H, K.P., Epidemiology and etiology of gliomas. Acta Neuropathol, 2005.
109: p. 16.
Goodenberger ML, J.R., Genetics of adult glioma. Cancer Genet 2012. 205: p. 9.
Wen PY, K.S., Malignant gliomas in adults. N Engl J Med 2008. 359: p. 16.
Sanai, N., et al., An extent of resection threshold for newly diagnosed
glioblastomas. J Neurosurg, 2011. 115(1): p. 3-8.
Bloch O, e.a., Impact of extent of resection for recurrent glioblastoma on overall
survival. J Neurosurg 2012. 117: p. 7.
Walker, M.D., et al., Evaluation of BCNU and/or radiotherapy in the treatment of
anaplastic gliomas. A cooperative clinical trial. J Neurosurg, 1978. 49(3): p. 33343.
Johnson, D.R. and S.M. Chang, Recent medical management of glioblastoma.
Adv Exp Med Biol, 2012. 746: p. 26-40.
Stupp, R., et al., Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med, 2005. 352(10): p. 987-96.
Louis, D.N., E.C. Holland, and J.G. Cairncross, Glioma classification: a
molecular reappraisal. Am J Pathol, 2001. 159(3): p. 779-86.
Shirahata M, e.a., Using gene expression profiling to identify a prognostic
molecular spectrum in gliomas. Cancer Sci, 2009. 100: p. 8.
Verhaak, R.G., et al., Integrated genomic analysis identifies clinically relevant
subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1,
EGFR, and NF1. Cancer Cell, 2010. 17(1): p. 98-110.
Wuchty S, e.a., Gene pathways and subnetworks distinguish between major
glioma subtypes and elucidate potential underlying biology. Journal of
Biomedical Informatics, 2006. 43: p. 8.
Markoa NF, T.S., Gene H. Barnett GH, Weil R Genomic expression patterns
distinguish long-term from short-term glioblastoma survivors: A preliminary
feasibility study. Genomics, 2003. 91: p. 12.
van den Boom J, e.a., Characterization of gene expression profiles associated
with glioma progression using oligonucleotide-based microarray analysis and
real-time reverse transcription-polymerase chain reaction. Am J Pathol 2003.
163: p. 11.

150

19.

20.
21.
22.
23.
24.
25.
26.
27.
28.
29.

30.
31.
32.
33.
34.
35.
36.
37.
38.

Heyman M, e.a., Deletions of the short arm of chromosome 9, including the
interferon-alpha/-beta genes, in acute lymphocytic leukemia. Studies on loss of
heterozygosity, parental origin of deleted genes and prognosis. Int J Cancer,
1993. 54: p. 6.
Heyman, M., et al., Interferon system defects in malignant T-cells. Leukemia,
1994. 8(3): p. 425-34.
Fountain, J.W., et al., Homozygous deletions within human chromosome band
9p21 in melanoma. Proc Natl Acad Sci U S A, 1992. 89(21): p. 10557-61.
James CD, e.a., Chromosome 9 Deletion Mapping Reveals Interferon  and
Interferon -1 Gene Deletions in Human Glial Tumors. Cancer Res 1991. 51: p.
5.
Olopade O, e.a., Molecular Analysis of Deletions of the Short Arm of
Chromosome 9 in Human Gliomas. Cancer Res 1992. 52: p. 7.
Bello MJ, e.a., Molecular and cytogenetic analysis of chromosome 9 deletions in
75 malignant gliomas. Genes Chromosomes Cancer 1994. 9: p. 9.
Serrano M, H.G., Beach D, A new regulatory motif in cell cycle control causing
specific inhibition of cyclin D/CDK4. Nature, 1993. 366: p. 4.
Cairns, P., et al., Rates of p16 (MTS1) mutations in primary tumors with 9p loss.
Science, 1994. 265(5170): p. 415-7.
Okamoto, A., et al., Mutations and altered expression of p16INK4 in human
cancer. Proc Natl Acad Sci U S A, 1994. 91(23): p. 11045-9.
Hartwell, L., Defects in a cell cycle checkpoint may be responsible for the
genomic instability of cancer cells. Cell, 1992. 71(4): p. 543-6.
He, J., J.J. Olson, and C.D. James, Lack of p16INK4 or retinoblastoma protein
(pRb), or amplification-associated overexpression of cdk4 is observed in distinct
subsets of malignant glial tumors and cell lines. Cancer Res, 1995. 55(21): p.
4833-6.
Nishikawa, R., et al., Loss of P16INK4 expression is frequent in high grade
gliomas. Cancer Res, 1995. 55(9): p. 1941-5.
Taha, M., et al., Extra-cranial metastasis of glioblastoma multiforme presenting
as acute parotitis. Br J Neurosurg, 2005. 19(4): p. 348-51.
Rajagopalan, V., et al., Bone marrow metastases from glioblastoma multiforme--A
case report and review of the literature. J Neurooncol, 2005. 72(2): p. 157-61.
Seo, Y.J., et al., Extraneural metastasis of glioblastoma multiforme presenting as
an unusual neck mass. J Korean Neurosurg Soc, 2012. 51(3): p. 147-50.
Nagpal, S., The role of BCNU polymer wafers (Gliadel) in the treatment of
malignant glioma. Neurosurg Clin N Am, 2012. 23(2): p. 289-95, ix.
Chamberlain, M.C., Treatment options for glioblastoma. Neurosurg Focus, 2006.
20(4): p. E19.
Allhenn, D., M.A. Boushehri, and A. Lamprecht, Drug delivery strategies for the
treatment of malignant gliomas. Int J Pharm, 2012. 436(1-2): p. 299-310.
Mrugala, M.M., J.E. Adair, and H.P. Kiem, Outside the box--novel therapeutic
strategies for glioblastoma. Cancer J, 2012. 18(1): p. 51-8.
Rich, J.N., et al., Phase II trial of gefitinib in recurrent glioblastoma. J Clin
Oncol, 2004. 22(1): p. 133-42.

151

39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.

Franceschi, E., et al., Gefitinib in patients with progressive high-grade gliomas: a
multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia
(GICNO). Br J Cancer, 2007. 96(7): p. 1047-51.
Prados, M.D., et al., Phase-1 trial of gefitinib and temozolomide in patients with
malignant glioma: a North American brain tumor consortium study. Cancer
Chemother Pharmacol, 2008. 61(6): p. 1059-67.
http://www.iressa.com.
Mok, T.S., et al., Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med, 2009. 361(10): p. 947-57.
Akhavan, D., T.F. Cloughesy, and P.S. Mischel, mTOR signaling in glioblastoma:
lessons learned from bench to bedside. Neuro Oncol, 2010. 12(8): p. 882-9.
Salphati, L., et al., Targeting the PI3K pathway in the brain--efficacy of a PI3K
inhibitor optimized to cross the blood-brain barrier. Clin Cancer Res, 2012.
18(22): p. 6239-48.
Thomas, A.A., M.S. Ernstoff, and C.E. Fadul, Immunotherapy for the treatment of
glioblastoma. Cancer J, 2012. 18(1): p. 59-68.
D'Costa, S.M., et al., Vaccinia H5 is a multifunctional protein involved in viral
DNA replication, postreplicative gene transcription, and virion morphogenesis.
Virology, 2010. 401(1): p. 49-60.
http://clinicaltrials.gov/show/NCT00589875.
Pulkkanen, K.J. and S. Yla-Herttuala, Gene therapy for malignant glioma:
current clinical status. Mol Ther, 2005. 12(4): p. 585-98.
Duarte, S., et al., Suicide gene therapy in cancer: where do we stand now? Cancer
Lett, 2012. 324(2): p. 160-70.
http://clinicaltrials.gov/show/NCT01156584.
Tambuyzer, B.R., P. Ponsaerts, and E.J. Nouwen, Microglia: gatekeepers of
central nervous system immunology. J Leukoc Biol, 2009. 85(3): p. 352-70.
Heimberger, A.B. and J.H. Sampson, Immunotherapy coming of age: what will it
take to make it standard of care for glioblastoma? Neuro Oncol, 2011. 13(1): p.
3-13.
Hickey, W.F., B.L. Hsu, and H. Kimura, T-lymphocyte entry into the central
nervous system. J Neurosci Res, 1991. 28(2): p. 254-60.
Cserr, H.F., C.J. Harling-Berg, and P.M. Knopf, Drainage of brain extracellular
fluid into blood and deep cervical lymph and its immunological significance.
Brain Pathol, 1992. 2(4): p. 269-76.
Jackson, C., et al., Challenges in immunotherapy presented by the glioblastoma
multiforme microenvironment. Clin Dev Immunol, 2011. 2011: p. 732413.
Murphy, A.M. and S.D. Rabkin, Current status of gene therapy for brain tumors.
Transl Res, 2013. 161(4): p. 339-54.
Parker, J.N., et al., Engineered herpes simplex virus expressing IL-12 in the
treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A, 2000.
97(5): p. 2208-13.
Ryu, C.H., et al., Gene therapy of intracranial glioma using interleukin 12secreting human umbilical cord blood-derived mesenchymal stem cells. Hum
Gene Ther, 2011. 22(6): p. 733-43.
http://www.abedia.com/wiley/record_detail.php?ID=1552.

152

60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.

Ohgaki, H., Genetic pathways to glioblastomas. Neuropathology, 2005. 25(1): p.
1-7.
D'Avenia, P., et al., Tp53-gene transfer induces hypersensitivity to low doses of Xrays in glioblastoma cells: a strategy to convert a radio-resistant phenotype into a
radiosensitive one. Cancer Lett, 2006. 231(1): p. 102-12.
Lang, F.F., et al., Phase I trial of adenovirus-mediated p53 gene therapy for
recurrent glioma: biological and clinical results. J Clin Oncol, 2003. 21(13): p.
2508-18.
Parker, J.N., et al., Oncolytic viral therapy of malignant glioma.
Neurotherapeutics, 2009. 6(3): p. 558-69.
Vaha-Koskela, M.J., J.E. Heikkila, and A.E. Hinkkanen, Oncolytic viruses in
cancer therapy. Cancer Lett, 2007. 254(2): p. 178-216.
Parato, K.A., et al., Recent progress in the battle between oncolytic viruses and
tumours. Nat Rev Cancer, 2005. 5(12): p. 965-76.
Thorne, S.H., T. Hermiston, and D. Kirn, Oncolytic virotherapy: approaches to
tumor targeting and enhancing antitumor effects. Semin Oncol, 2005. 32(6): p.
537-48.
Cattaneo, R., et al., Reprogrammed viruses as cancer therapeutics: targeted,
armed and shielded. Nat Rev Microbiol, 2008. 6(7): p. 529-40.
Nguyen, T.L., et al., The emergence of combinatorial strategies in the
development of RNA oncolytic virus therapies. Cell Microbiol, 2009. 11(6): p.
889-97.
Kelly, E. and S.J. Russell, History of oncolytic viruses: genesis to genetic
engineering. Mol Ther, 2007. 15(4): p. 651-9.
Hammill, A.M., J. Conner, and T.P. Cripe, Oncolytic virotherapy reaches
adolescence. Pediatr Blood Cancer, 2010. 55(7): p. 1253-63.
Dock, G., Rabies virus vaccination in a patient with cervical carcinoma.
American Jouranl of Medical Sciences, 1904. 127: p. 563.
DePace, N., Sulla scomparsa di un enorme cancro vegetante del collo dell’utero
senza cura chirurgica. Ginecologia, 1912. 9: p. 82-89.
Southam, C.M. and A.E. Moore, Clinical studies of viruses as antineoplastic
agents with particular reference to Egypt 101 virus. Cancer, 1952. 5(5): p. 102534.
Huebner, R.J., et al., Studies on the use of viruses in the treatment of carcinoma of
the cervix. Cancer, 1956. 9(6): p. 1211-8.
Zielinski, T. and E. Jordan, [Remote results of clinical observation of the
oncolytic action of adenoviruses on cervix cancer]. Nowotwory, 1969. 19(3): p.
217-21.
Georgiades, J., et al., Research on the oncolytic effect of APC viruses in cancer of
the cervix uteri; preliminary report. Biul Inst Med Morsk Gdansk, 1959. 10: p.
49-57.
Asada, T., Treatment of human cancer with mumps virus. Cancer, 1974. 34(6): p.
1907-28.
Hoster, H.A., R.P. Zanes, Jr., and E. Von Haam, Studies in Hodgkin's syndrome;
the association of viral hepatitis and Hodgkin's disease; a preliminary report.
Cancer Res, 1949. 9(8): p. 473-80.

153

79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.

92.
93.

94.
95.
96.

dos Reis, M., et al., Charting the host adaptation of influenza viruses. Mol Biol
Evol, 2011. 28(6): p. 1755-67.
Lynch, J.P., 3rd, M. Fishbein, and M. Echavarria, Adenovirus. Semin Respir Crit
Care Med, 2011. 32(4): p. 494-511.
de Gruijl, T.D. and R. van de Ven, Chapter six--Adenovirus-based
immunotherapy of cancer: promises to keep. Adv Cancer Res, 2012. 115: p. 147220.
Steele, T.A., Recent developments in the virus therapy of cancer. Proc Soc Exp
Biol Med, 2000. 223(2): p. 118-27.
Asadi-Moghaddam, K. and E.A. Chiocca, Gene- and viral-based therapies for
brain tumors. Neurotherapeutics, 2009. 6(3): p. 547-57.
Ganly, I., et al., A phase I study of Onyx-015, an E1B attenuated adenovirus,
administered intratumorally to patients with recurrent head and neck cancer. Clin
Cancer Res, 2000. 6(3): p. 798-806.
Shen, Y., et al., Analyses of single-amino-acid substitution mutants of adenovirus
type 5 E1B-55K protein. J Virol, 2001. 75(9): p. 4297-307.
Geoerger, B., et al., Oncolytic activity of the E1B-55 kDa-deleted adenovirus
ONYX-015 is independent of cellular p53 status in human malignant glioma
xenografts. Cancer Res, 2002. 62(3): p. 764-72.
Heise, C., et al., ONYX-015, an E1B gene-attenuated adenovirus, causes tumorspecific cytolysis and antitumoral efficacy that can be augmented by standard
chemotherapeutic agents. Nat Med, 1997. 3(6): p. 639-45.
Fueyo, J., et al., Preclinical characterization of the antiglioma activity of a
tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl
Cancer Inst, 2003. 95(9): p. 652-60.
Lamfers, M.L., et al., Potential of the conditionally replicative adenovirus Ad5Delta24RGD in the treatment of malignant gliomas and its enhanced effect with
radiotherapy. Cancer Res, 2002. 62(20): p. 5736-42.
http://clinicaltrials.gov/show/NCT01582516.
Chiocca, E.A., et al., A phase I open-label, dose-escalation, multi-institutional
trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the
peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol
Ther, 2004. 10(5): p. 958-66.
Kanai, R., et al., Effect of gamma34.5 deletions on oncolytic herpes simplex virus
activity in brain tumors. J Virol, 2012. 86(8): p. 4420-31.
Cassady, K.A., M. Gross, and B. Roizman, The second-site mutation in the herpes
simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of
protein synthesis by blocking the phosphorylation of eIF-2alpha. J Virol, 1998.
72(9): p. 7005-11.
Harrow, S., et al., HSV1716 injection into the brain adjacent to tumour following
surgical resection of high-grade glioma: safety data and long-term survival. Gene
Ther, 2004. 11(22): p. 1648-58.
http://www.virttu.com/clinical-studies
Sundaresan, P., et al., Attenuated, replication-competent herpes simplex virus type
1 mutant G207: safety evaluation in mice. J Virol, 2000. 74(8): p. 3832-41.

154

97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.

108.
109.
110.
111.
112.
113.
114.
115.

Mineta, T., et al., Attenuated multi-mutated herpes simplex virus-1 for the
treatment of malignant gliomas. Nat Med, 1995. 1(9): p. 938-43.
Mineta, T., S.D. Rabkin, and R.L. Martuza, Treatment of malignant gliomas using
ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex
viral mutant. Cancer Res, 1994. 54(15): p. 3963-6.
Markert, J.M., et al., Phase Ib trial of mutant herpes simplex virus G207
inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther, 2009.
17(1): p. 199-207.
http://clinicaltrials.gov/show/NCT00028158.
http://clinicaltrials.gov/show/NCT00157703.
Rhode, S.L., 3rd, Replication process of the parvovirus H-1. II. Isolation and
characterization of H-1 replicative form DNA. J Virol, 1974. 13(2): p. 400-10.
Gerson SL, L.E., ed. Translational Approaches from Preclinical Studies to
Clinical Implementation. 2nd ed. Parvovirus Vectors for the Gene Therapy of
Cancer, ed. J.K.a.C.S. Wong. 2002, Academic Press. 53-71.
Rommelaere, J., et al., Oncolytic parvoviruses as cancer therapeutics. Cytokine
Growth Factor Rev, 2010. 21(2-3): p. 185-95.
Di Piazza, M., et al., Cytosolic activation of cathepsins mediates parvovirus H-1induced killing of cisplatin and TRAIL-resistant glioma cells. J Virol, 2007. 81(8):
p. 4186-98.
Geletneky, K., et al., Regression of advanced rat and human gliomas by local or
systemic treatment with oncolytic parvovirus H-1 in rat models. Neuro Oncol,
2010. 12(8): p. 804-14.
Geletneky, K., et al., Phase I/IIa study of intratumoral/intracerebral or
intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in
patients with progressive primary or recurrent glioblastoma multiforme:
ParvOryx01 protocol. BMC Cancer, 2012. 12: p. 99.
Elankumaran, S., et al., Type I interferon-sensitive recombinant newcastle disease
virus for oncolytic virotherapy. J Virol, 2010. 84(8): p. 3835-44.
Freeman, A.I., et al., Phase I/II trial of intravenous NDV-HUJ oncolytic virus in
recurrent glioblastoma multiforme. Mol Ther, 2006. 13(1): p. 221-8.
Fiola, C., et al., Tumor selective replication of Newcastle disease virus:
association with defects of tumor cells in antiviral defence. Int J Cancer, 2006.
119(2): p. 328-38.
http://clinicaltrials.gov/show/NCT01174537.
Coffey, M.C., et al., Reovirus therapy of tumors with activated Ras pathway.
Science, 1998. 282(5392): p. 1332-4.
Figova, K., J. Hrabeta, and T. Eckschlager, Reovirus - possible therapy of cancer.
Neoplasma, 2006. 53(6): p. 457-62.
Yang, W.Q., et al., Efficacy and safety evaluation of human reovirus type 3 in
immunocompetent animals: racine and nonhuman primates. Clin Cancer Res,
2004. 10(24): p. 8561-76.
Russell, S.J., RNA viruses as virotherapy agents. Cancer Gene Ther, 2002. 9(12):
p. 961-6.

155

116.
117.
118.
119.
120.
121.
122.

123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.

Forsyth, P., et al., A phase I trial of intratumoral administration of reovirus in
patients with histologically confirmed recurrent malignant gliomas. Mol Ther,
2008. 16(3): p. 627-32.
http://clinicaltrials.gov/show/NCT00528684.
Tatsuo, H., et al., SLAM (CDw150) is a cellular receptor for measles virus.
Nature, 2000. 406(6798): p. 893-7.
Naniche, D., et al., Human membrane cofactor protein (CD46) acts as a cellular
receptor for measles virus. J Virol, 1993. 67(10): p. 6025-32.
Galanis, E., Therapeutic potential of oncolytic measles virus: promises and
challenges. Clin Pharmacol Ther, 2010. 88(5): p. 620-5.
Haralambieva, I., et al., Engineering oncolytic measles virus to circumvent the
intracellular innate immune response. Mol Ther, 2007. 15(3): p. 588-97.
Myers, R., et al., Toxicology study of repeat intracerebral administration of a
measles virus derivative producing carcinoembryonic antigen in rhesus macaques
in support of a phase I/II clinical trial for patients with recurrent gliomas. Hum
Gene Ther, 2008. 19(7): p. 690-8.
http://clinicaltrials.gov/show/NCT00390299.
Goetz, C., et al., Oncolytic poliovirus against malignant glioma. Future Virol,
2011. 6(9): p. 1045-1058.
Ochiai, H., et al., Treatment of intracerebral neoplasia and neoplastic meningitis
with regional delivery of oncolytic recombinant poliovirus. Clin Cancer Res,
2004. 10(14): p. 4831-8.
de Breyne, S., et al., Direct functional interaction of initiation factor eIF4G with
type 1 internal ribosomal entry sites. Proc Natl Acad Sci U S A, 2009. 106(23): p.
9197-202.
Goetz, C. and M. Gromeier, Preparing an oncolytic poliovirus recombinant for
clinical application against glioblastoma multiforme. Cytokine Growth Factor
Rev, 2010. 21(2-3): p. 197-203.
Gromeier, M., L. Alexander, and E. Wimmer, Internal ribosomal entry site
substitution eliminates neurovirulence in intergeneric poliovirus recombinants.
Proc Natl Acad Sci U S A, 1996. 93(6): p. 2370-5.
Gromeier, M., et al., Intergeneric poliovirus recombinants for the treatment of
malignant glioma. Proc Natl Acad Sci U S A, 2000. 97(12): p. 6803-8.
Toyoda, H., et al., Oncolytic treatment and cure of neuroblastoma by a novel
attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res,
2007. 67(6): p. 2857-64.
http://clinicaltrials.gov/show/NCT01491893.
Maetzig, T., et al., Gammaretroviral vectors: biology, technology and
application. Viruses, 2011. 3(6): p. 677-713.
Tai, C.K., et al., Single-shot, multicycle suicide gene therapy by replicationcompetent retrovirus vectors achieves long-term survival benefit in experimental
glioma. Mol Ther, 2005. 12(5): p. 842-51.
Ostertag, D., et al., Brain tumor eradication and prolonged survival from
intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic
retroviral replicating vector. Neuro Oncol, 2012. 14(2): p. 145-59.

156

135.
136.

137.
138.
139.
140.

141.
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.

Perez, O.D., et al., Design and selection of Toca 511 for clinical use: modified
retroviral replicating vector with improved stability and gene expression. Mol
Ther, 2012. 20(9): p. 1689-98.
Rainov, N.G., A phase III clinical evaluation of herpes simplex virus type 1
thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical
resection and radiation in adults with previously untreated glioblastoma
multiforme. Hum Gene Ther, 2000. 11(17): p. 2389-401.
http://clinicaltrials.gov/show/NCT01470794.
Zemp, F.J., et al., Oncolytic viruses as experimental treatments for malignant
gliomas: using a scourge to treat a devil. Cytokine Growth Factor Rev, 2010.
21(2-3): p. 103-17.
Garber, K., China approves world's first oncolytic virus therapy for cancer
treatment. J Natl Cancer Inst, 2006. 98(5): p. 298-300.
Miller, C.R., et al., Differential susceptibility of primary and established human
glioma cells to adenovirus infection: targeting via the epidermal growth factor
receptor achieves fiber receptor-independent gene transfer. Cancer Res, 1998.
58(24): p. 5738-48.
Li, Y., et al., Loss of adenoviral receptor expression in human bladder cancer
cells: a potential impact on the efficacy of gene therapy. Cancer Res, 1999. 59(2):
p. 325-30.
Barnett, B.G., C.J. Crews, and J.T. Douglas, Targeted adenoviral vectors.
Biochim Biophys Acta, 2002. 1575(1-3): p. 1-14.
Zhang, Y. and J.M. Bergelson, Adenovirus receptors. J Virol, 2005. 79(19): p.
12125-31.
Arduino, P.G. and S.R. Porter, Herpes Simplex Virus Type 1 infection: overview
on relevant clinico-pathological features. J Oral Pathol Med, 2008. 37(2): p. 10721.
Lu, Y., et al., Binding of the influenza virus NS1 protein to double-stranded RNA
inhibits the activation of the protein kinase that phosphorylates the elF-2
translation initiation factor. Virology, 1995. 214(1): p. 222-8.
Markert, J.M., et al., Conditionally replicating herpes simplex virus mutant, G207
for the treatment of malignant glioma: results of a phase I trial. Gene Ther, 2000.
7(10): p. 867-74.
Bloom, M.E., et al., Analysis of parvovirus infections using strand-specific
hybridization probes. Virus Res, 1989. 14(1): p. 1-25.
Maxwell, I.H., K.L. Terrell, and F. Maxwell, Autonomous parvovirus vectors.
Methods, 2002. 28(2): p. 168-81.
Herrero, Y.C.M., et al., Parvovirus H-1 infection of human glioma cells leads to
complete viral replication and efficient cell killing. Int J Cancer, 2004. 109(1): p.
76-84.
Seal, B.S., D.J. King, and H.S. Sellers, The avian response to Newcastle disease
virus. Dev Comp Immunol, 2000. 24(2-3): p. 257-68.
Knipe, D.a.h.P., ed. Fields' Virology. 4th ed. Reoviruses and their replication, ed.
N.M.a.S. LA. 2001, Lippincott-Raven Press: Philadelphia. 1679-1728.
Moss, W.J. and D.E. Griffin, Measles. Lancet, 2012. 379(9811): p. 153-64.

157

153.
154.
155.
156.
157.
158.
159.
160.
161.
162.
163.
164.
165.
166.
167.
168.
169.
170.
171.

Okwo-Bele, J.M. and T. Cherian, The expanded programme on immunization: a
lasting legacy of smallpox eradication. Vaccine, 2011. 29 Suppl 4: p. D74-9.
Centers for Disease, C. and Prevention, Progress toward measles elimination-region of the Americas, 2002-2003. MMWR Morb Mortal Wkly Rep, 2004.
53(14): p. 304-6.
Noyce, R.S., et al., Tumor cell marker PVRL4 (nectin 4) is an epithelial cell
receptor for measles virus. PLoS Pathog, 2011. 7(8): p. e1002240.
Noyce, R.S. and C.D. Richardson, Nectin 4 is the epithelial cell receptor for
measles virus. Trends Microbiol, 2012. 20(9): p. 429-39.
Jurianz, K., et al., Complement resistance of tumor cells: basal and induced
mechanisms. Mol Immunol, 1999. 36(13-14): p. 929-39.
Ulasov, I.V., et al., CD46 represents a target for adenoviral gene therapy of
malignant glioma. Hum Gene Ther, 2006. 17(5): p. 556-64.
Fabre-Lafay, S., et al., Nectin-4 is a new histological and serological tumor
associated marker for breast cancer. BMC Cancer, 2007. 7: p. 73.
Takano, A., et al., Identification of nectin-4 oncoprotein as a diagnostic and
therapeutic target for lung cancer. Cancer Res, 2009. 69(16): p. 6694-703.
Derycke, M.S., et al., Nectin 4 overexpression in ovarian cancer tissues and
serum: potential role as a serum biomarker. Am J Clin Pathol, 2010. 134(5): p.
835-45.
Koga, R., et al., Measles virus-induced immunosuppression in SLAM knock-in
mice. J Virol, 2010. 84(10): p. 5360-7.
Aylward, B. and R. Tangermann, The global polio eradication initiative: lessons
learned and prospects for success. Vaccine, 2011. 29 Suppl 4: p. D80-5.
Knipe, D., Howley PM, ed. Fields' Virology. 4 ed. Picornaviridae: the viruses and
their replication, ed. R. VR. Vol. 1. 2001, Lippincott, WIlliams and Wilkins:
Philadelphia. 685-772.
Masson, D., et al., Overexpression of the CD155 gene in human colorectal
carcinoma. Gut, 2001. 49(2): p. 236-40.
Campbell, S.A., et al., Genetic determinants of cell type-specific poliovirus
propagation in HEK 293 cells. J Virol, 2005. 79(10): p. 6281-90.
Neplioueva, V., et al., Tissue type-specific expression of the dsRNA-binding
protein 76 and genome-wide elucidation of its target mRNAs. PLoS One, 2010.
5(7): p. e11710.
Goetz, C., et al., MAPK signal-integrating kinase controls cap-independent
translation and cell type-specific cytotoxicity of an oncolytic poliovirus. Mol
Ther, 2010. 18(11): p. 1937-46.
Horie, H., et al., Analysis of the accumulation of mutants in Sabin attenuated
polio vaccine viruses passaged in Vero cells. Vaccine, 2001. 19(11-12): p. 14569.
Wimmer, E., C.U. Hellen, and X. Cao, Genetics of poliovirus. Annu Rev Genet,
1993. 27: p. 353-436.
Braoudaki, M. and F. Tzortzatou-Stathopoulou, Tumorigenesis related to
retroviral infections. J Infect Dev Ctries, 2011. 5(11): p. 751-8.

158

172.
173.
174.
175.
176.
177.
178.
179.
180.
181.
182.
183.
184.
185.
186.
187.
188.

Howe, S.J., et al., Insertional mutagenesis combined with acquired somatic
mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J
Clin Invest, 2008. 118(9): p. 3143-50.
Stein, S., et al., Genomic instability and myelodysplasia with monosomy 7
consequent to EVI1 activation after gene therapy for chronic granulomatous
disease. Nat Med, 2010. 16(2): p. 198-204.
Hacein-Bey-Abina, S., et al., Insertional oncogenesis in 4 patients after
retrovirus-mediated gene therapy of SCID-X1. J Clin Invest, 2008. 118(9): p.
3132-42.
Miller, D.G., M.A. Adam, and A.D. Miller, Gene transfer by retrovirus vectors
occurs only in cells that are actively replicating at the time of infection. Mol Cell
Biol, 1990. 10(8): p. 4239-42.
Hein, A., et al., Effects of adoptive immune transfers on murine leukemia virusinfection of rats. Virology, 1995. 211(2): p. 408-17.
Lun, X., et al., Myxoma virus virotherapy for glioma in immunocompetent animal
models: optimizing administration routes and synergy with rapamycin. Cancer
Res, 2010. 70(2): p. 598-608.
Wojton, J. and B. Kaur, Impact of tumor microenvironment on oncolytic viral
therapy. Cytokine Growth Factor Rev, 2010. 21(2-3): p. 127-34.
Cheng, J., et al., Human matrix metalloproteinase-8 gene delivery increases the
oncolytic activity of a replicating adenovirus. Mol Ther, 2007. 15(11): p. 198290.
McKee, T.D., et al., Degradation of fibrillar collagen in a human melanoma
xenograft improves the efficacy of an oncolytic herpes simplex virus vector.
Cancer Res, 2006. 66(5): p. 2509-13.
Muldoon, L.L., et al., Chemotherapy delivery issues in central nervous system
malignancy: a reality check. J Clin Oncol, 2007. 25(16): p. 2295-305.
Green, N.K. and L.W. Seymour, Adenoviral vectors: systemic delivery and tumor
targeting. Cancer Gene Ther, 2002. 9(12): p. 1036-42.
Liu, R., R.L. Martuza, and S.D. Rabkin, Intracarotid delivery of oncolytic HSV
vector G47Delta to metastatic breast cancer in the brain. Gene Ther, 2005. 12(8):
p. 647-54.
Vlachaki, M.T., et al., Impact of preimmunization on adenoviral vector expression
and toxicity in a subcutaneous mouse cancer model. Mol Ther, 2002. 6(3): p. 3428.
Miest, T.S., et al., Envelope-chimeric entry-targeted measles virus escapes
neutralization and achieves oncolysis. Mol Ther, 2011. 19(10): p. 1813-20.
Lorence, R.M., et al., Complete regression of human neuroblastoma xenografts in
athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst,
1994. 86(16): p. 1228-33.
Power, A.T., et al., Carrier cell-based delivery of an oncolytic virus circumvents
antiviral immunity. Mol Ther, 2007. 15(1): p. 123-30.
Green, N.K., et al., Extended plasma circulation time and decreased toxicity of
polymer-coated adenovirus. Gene Ther, 2004. 11(16): p. 1256-63.

159

189.
190.
191.
192.
193.
194.
195.
196.
197.
198.
199.
200.
201.
202.
203.
204.

Sistigu, A., et al., Immunomodulatory effects of cyclophosphamide and
implementations for vaccine design. Semin Immunopathol, 2011. 33(4): p. 36983.
Peng, K.W., et al., Using clinically approved cyclophosphamide regimens to
control the humoral immune response to oncolytic viruses. Gene Ther, 2013.
20(3): p. 255-61.
Ikeda, K., et al., Oncolytic virus therapy of multiple tumors in the brain requires
suppression of innate and elicited antiviral responses. Nat Med, 1999. 5(8): p.
881-7.
Qiao, J., et al., Cyclophosphamide facilitates antitumor efficacy against
subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res,
2008. 14(1): p. 259-69.
Alain, T., et al., Vesicular stomatitis virus oncolysis is potentiated by impairing
mTORC1-dependent type I IFN production. Proc Natl Acad Sci U S A, 2010.
107(4): p. 1576-81.
Lun, X., et al., Efficacy and safety/toxicity study of recombinant vaccinia virus
JX-594 in two immunocompetent animal models of glioma. Mol Ther, 2010.
18(11): p. 1927-36.
Cole, C., et al., Tumor-targeted, systemic delivery of therapeutic viral vectors
using hitchhiking on antigen-specific T cells. Nat Med, 2005. 11(10): p. 1073-81.
Coukos, G., et al., Use of carrier cells to deliver a replication-selective herpes
simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian
cancer. Clin Cancer Res, 1999. 5(6): p. 1523-37.
Raykov, Z., et al., Carrier cell-mediated delivery of oncolytic parvoviruses for
targeting metastases. Int J Cancer, 2004. 109(5): p. 742-9.
Komarova, S., et al., Mesenchymal progenitor cells as cellular vehicles for
delivery of oncolytic adenoviruses. Mol Cancer Ther, 2006. 5(3): p. 755-66.
Thaci, B., et al., Pharmacokinetic study of neural stem cell-based cell carrier for
oncolytic virotherapy: targeted delivery of the therapeutic payload in an
orthotopic brain tumor model. Cancer Gene Ther, 2012. 19(6): p. 431-42.
Platten, M., W. Wick, and M. Weller, Malignant glioma biology: role for TGFbeta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech,
2001. 52(4): p. 401-10.
Grauer, O.M., et al., CD4+FoxP3+ regulatory T cells gradually accumulate in
gliomas during tumor growth and efficiently suppress antiglioma immune
responses in vivo. Int J Cancer, 2007. 121(1): p. 95-105.
Okada, H., et al., Immunotherapeutic approaches for glioma. Crit Rev Immunol,
2009. 29(1): p. 1-42.
Dunn, G.P., L.J. Old, and R.D. Schreiber, The immunobiology of cancer
immunosurveillance and immunoediting. Immunity, 2004. 21(2): p. 137-48.
Sinkovics, J.G. and J.C. Horvath, Natural and genetically engineered viral agents
for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp
(Warsz), 2008. 56 Suppl 1: p. 3s-59s.

160

205.

206.
207.
208.
209.
210.
211.
212.
213.
214.
215.
216.
217.
218.
219.
220.
221.
222.
223.
224.

Batliwalla, F.M., et al., A 15-year follow-up of AJCC stage III malignant
melanoma patients treated postsurgically with Newcastle disease virus (NDV)
oncolysate and determination of alterations in the CD8 T cell repertoire. Mol
Med, 1998. 4(12): p. 783-94.
Steiner, H.H., et al., Antitumor vaccination of patients with glioblastoma
multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin
Oncol, 2004. 22(21): p. 4272-81.
Rose, J.K. and M.A. Whitt, Rhabdoviridae: The viruses and their replication, in
Field's Virology, D. Knipe and P.M. Howley, Editors. 2001, Lippincott Williams
& Wilkins: Philadelphia. p. 1221-1244.
Kinnunen, P.M., et al., Epidemiology and host spectrum of Borna disease virus
infections. J Gen Virol, 2013. 94(Pt 2): p. 247-62.
Bourhy, H., B. Kissi, and N. Tordo, Molecular diversity of the Lyssavirus genus.
Virology, 1993. 194(1): p. 70-81.
Albertini, A.A., R.W. Ruigrok, and D. Blondel, Rabies virus transcription and
replication. Adv Virus Res, 2011. 79: p. 1-22.
Hanson, R.P., Discussion of the natural history of vesicular stomatitis. Am J
Epidemiol, 1968. 87(2): p. 264-6.
Rodriguez, L.L., Emergence and re-emergence of vesicular stomatitis in the
United States. Virus Res, 2002. 85(2): p. 211-9.
Vernon, S.D., L.L. Rodriguez, and G.J. Letchworth, Vesicular stomatitis New
Jersey virus glycoprotein gene sequence and neutralizing epitope stability in an
enzootic focus. Virology, 1990. 177(1): p. 209-15.
Letchworth, G.J., L.L. Rodriguez, and J. Del cbarrera, Vesicular stomatitis. Vet J,
1999. 157(3): p. 239-60.
http://www.aphis.USDA.gov.
http://www.aphis.usda.gov/vs/nahss/equine/vsv/.
Howerth, E.W., et al., Experimental vesicular stomatitis in swine: effects of route
of inoculation and steroid treatment. J Vet Diagn Invest, 1997. 9(2): p. 136-42.
Bruno-Lobo, M., et al., Pathogenesis of vesicular stomatitis virus infection in the
infant hamster and mouse. An Microbiol (Rio J), 1968. 15: p. 53-68.
Cornish, T.E., et al., Pathogenesis of experimental vesicular stomatitis virus (New
Jersey serotype) infection in the deer mouse (Peromyscus maniculatus). Vet
Pathol, 2001. 38(4): p. 396-406.
Ozduman, K., et al., Peripheral immunization blocks lethal actions of vesicular
stomatitis virus within the brain. J Virol, 2009. 83(22): p. 11540-9.
Wilks, C.R. and J.A. House, Susceptibility of various animals to the
vesiculoviruses Isfahan and Chandipura. J Hyg (Lond), 1986. 97(2): p. 359-68.
Marriott, A.C., Complete genome sequences of Chandipura and Isfahan
vesiculoviruses. Arch Virol, 2005. 150(4): p. 671-80.
Ogino, T. and A.K. Banerjee, An unconventional pathway of mRNA cap formation
by vesiculoviruses. Virus Res, 2011. 162(1-2): p. 100-9.
Coll, J.M., Synthetic peptides from the heptad repeats of the glycoproteins of
rabies, vesicular stomatitis and fish rhabdoviruses bind phosphatidylserine. Arch
Virol, 1997. 142(10): p. 2089-97.

161

225.
226.
227.
228.
229.
230.
231.
232.

233.
234.
235.
236.
237.
238.
239.
240.
241.
242.

Albertini, A.A., et al., Molecular and cellular aspects of rhabdovirus entry.
Viruses, 2012. 4(1): p. 117-39.
Coil, D.A. and A.D. Miller, Phosphatidylserine is not the cell surface receptor for
vesicular stomatitis virus. Journal of Virology, 2004. 78(20): p. 10920-6.
Bloor, S., et al., Endoplasmic reticulum chaperone gp96 is essential for infection
with vesicular stomatitis virus. Proc Natl Acad Sci U S A, 2010. 107(15): p. 69705.
Mire, C.E., J.M. White, and M.A. Whitt, A spatio-temporal analysis of matrix
protein and nucleocapsid trafficking during vesicular stomatitis virus uncoating.
PLoS Pathog, 2010. 6(7): p. e1000994.
Ge, P., et al., Cryo-EM model of the bullet-shaped vesicular stomatitis virus.
Science, 2010. 327(5966): p. 689-93.
Pfeiffer, S., S.D. Fuller, and K. Simons, Intracellular sorting and basolateral
appearance of the G protein of vesicular stomatitis virus in Madin-Darby canine
kidney cells. J Cell Biol, 1985. 101(2): p. 470-6.
Jayakar, H.R., E. Jeetendra, and M.A. Whitt, Rhabdovirus assembly and budding.
Virus Research, 2004. 106(2): p. 117-132.
Brown, E.L. and D.S. Lyles, A novel method for analysis of membrane
microdomains: vesicular stomatitis virus glycoprotein microdomains change in
size during infection, and those outside of budding sites resemble sites of virus
budding. Virology, 2003. 310(2): p. 343-58.
Bergmann, J.E. and P.J. Fusco, The M protein of vesicular stomatitis virus
associates specifically with the basolateral membranes of polarized epithelial
cells independently of the G protein. J Cell Biol, 1988. 107(5): p. 1707-15.
Pornillos, O., J.E. Garrus, and W.I. Sundquist, Mechanisms of enveloped RNA
virus budding. Trends Cell Biol, 2002. 12(12): p. 569-79.
Hale, B.G., et al., The multifunctional NS1 protein of influenza A viruses. J Gen
Virol, 2008. 89(Pt 10): p. 2359-76.
Blackford, A.N. and R.J. Grand, Adenovirus E1B 55-kilodalton protein: multiple
roles in viral infection and cell transformation. J Virol, 2009. 83(9): p. 4000-12.
Jayakar, H.R. and M.A. Whitt, Identification of two additional translation
products from the matrix (M) gene that contribute to vesicular stomatitis virus
cytopathology. J Virol, 2002. 76(16): p. 8011-8.
Gaudier, M., Y. Gaudin, and M. Knossow, Crystal structure of vesicular
stomatitis virus matrix protein. EMBO J, 2002. 21(12): p. 2886-92.
Gomez-Puertas, P., et al., Influenza virus matrix protein is the major driving force
in virus budding. J Virol, 2000. 74(24): p. 11538-47.
Timmins, J., et al., Vesicular release of ebola virus matrix protein VP40.
Virology, 2001. 283(1): p. 1-6.
Jayakar, H.R., K.G. Murti, and M.A. Whitt, Mutations in the PPPY motif of
vesicular stomatitis virus matrix protein reduce virus budding by inhibiting a late
step in virion release. J Virol, 2000. 74(21): p. 9818-27.
Black, B.L., et al., The role of vesicular stomatitis virus matrix protein in
inhibition of host-directed gene expression is genetically separable from its
function in virus assembly. J Virol, 1993. 67(8): p. 4814-21.

162

243.
244.
245.
246.
247.
248.
249.
250.
251.
252.
253.

254.
255.
256.
257.
258.

Connor, J.H., M.O. McKenzie, and D.S. Lyles, Role of residues 121 to 124 of
vesicular stomatitis virus matrix protein in virus assembly and virus-host
interaction. J Virol, 2006. 80(8): p. 3701-11.
Mire, C.E. and M.A. Whitt, The protease-sensitive loop of the vesicular stomatitis
virus matrix protein is involved in virus assembly and protein translation.
Virology, 2011. 416(1-2): p. 16-25.
Coulon, P., et al., Genetic evidence for multiple functions of the matrix protein of
vesicular stomatitis virus. J Gen Virol, 1990. 71 ( Pt 4): p. 991-6.
Lyles, D.S., et al., Complementation of M gene mutants of vesicular stomatitis
virus by plasmid-derived M protein converts spherical extracellular particles into
native bullet shapes. Virology, 1996. 217(1): p. 76-87.
Justice, P.A., et al., Membrane vesiculation function and exocytosis of wild-type
and mutant matrix proteins of vesicular stomatitis virus. J Virol, 1995. 69(5): p.
3156-60.
Harty, R.N., et al., A proline-rich motif within the matrix protein of vesicular
stomatitis virus and rabies virus interacts with WW domains of cellular proteins:
implications for viral budding. J Virol, 1999. 73(4): p. 2921-9.
Flamand, A. and D.H. Bishop, Primary in vivo transcription of vesicular
stomatitis virus and temperature-sensitive mutants of five vesicular stomatitis
virus complementation groups. J Virol, 1973. 12(6): p. 1238-52.
Blondel, D., G.G. Harmison, and M. Schubert, Role of matrix protein in
cytopathogenesis of vesicular stomatitis virus. J Virol, 1990. 64(4): p. 1716-25.
Melki, R., Y. Gaudin, and D. Blondel, Interaction between tubulin and the viral
matrix protein of vesicular stomatitis virus: possible implications in the viral
cytopathic effect. Virology, 1994. 202(1): p. 339-47.
Kopecky, S.A. and D.S. Lyles, The cell-rounding activity of the vesicular
stomatitis virus matrix protein is due to the induction of cell death. J Virol, 2003.
77(9): p. 5524-8.
Lyles, D.S. and M.O. McKenzie, Activity of vesicular stomatitis virus M protein
mutants in cell rounding is correlated with the ability to inhibit host gene
expression and is not correlated with virus assembly function. Virology, 1997.
229(1): p. 77-89.
Black, B.L. and D.S. Lyles, Vesicular stomatitis virus matrix protein inhibits host
cell-directed transcription of target genes in vivo. J Virol, 1992. 66(7): p. 405864.
Raux, H., et al., The matrix protein of vesicular stomatitis virus binds dynamin for
efficient viral assembly. J Virol, 2010. 84(24): p. 12609-18.
Gu, C., et al., Direct dynamin-actin interactions regulate the actin cytoskeleton.
EMBO J, 2010. 29(21): p. 3593-606.
Koyama, A.H., Induction of apoptotic DNA fragmentation by the infection of
vesicular stomatitis virus. Virus Res, 1995. 37(3): p. 285-90.
Gadaleta, P., M. Vacotto, and F. Coulombie, Vesicular stomatitis virus induces
apoptosis at early stages in the viral cycle and does not depend on virus
replication. Virus Res, 2002. 86(1-2): p. 87-92.

163

259.
260.
261.
262.
263.

264.
265.
266.
267.
268.
269.
270.

271.
272.
273.

Kopecky, S.A., M.C. Willingham, and D.S. Lyles, Matrix protein and another
viral component contribute to induction of apoptosis in cells infected with
vesicular stomatitis virus. J Virol, 2001. 75(24): p. 12169-81.
Kurilla, M.G., H. Piwnica-Worms, and J.D. Keene, Rapid and transient
localization of the leader RNA of vesicular stomatitis virus in the nuclei of
infected cells. Proc Natl Acad Sci U S A, 1982. 79(17): p. 5240-4.
McGowan, J.J., S.U. Emerson, and R.R. Wagner, The plus-strand leader RNA of
VSV inhibits DNA-dependent transcription of adenovirus and SV40 genes in a
soluble whole-cell extract. Cell, 1982. 28(2): p. 325-33.
Kurilla, M.G. and J.D. Keene, The leader RNA of vesicular stomatitis virus is
bound by a cellular protein reactive with anti-La lupus antibodies. Cell, 1983.
34(3): p. 837-45.
Dunigan, D.D., S. Baird, and J. Lucas-Lenard, Lack of correlation between the
accumulation of plus-strand leader RNA and the inhibition of protein and RNA
synthesis in vesicular stomatitis virus infected mouse L cells. Virology, 1986.
150(1): p. 231-46.
Clinton, G.M., et al., The matrix (M) protein of vesicular stomatitis virus
regulates transcription. Cell, 1978. 15(4): p. 1455-62.
Lyles, D.S., L. Puddington, and B.J. McCreedy, Jr., Vesicular stomatitis virus M
protein in the nuclei of infected cells. J Virol, 1988. 62(11): p. 4387-92.
Ferran, M.C. and J.M. Lucas-Lenard, The vesicular stomatitis virus matrix protein
inhibits transcription from the human beta interferon promoter. J Virol, 1997.
71(1): p. 371-7.
Weck, P.K. and R.R. Wagner, Inhibition of RNA synthesis in mouse myeloma
cells infected with vesicular stomatitis virus. J Virol, 1978. 25(3): p. 770-80.
Ahmed, M. and D.S. Lyles, Effect of vesicular stomatitis virus matrix protein on
transcription directed by host RNA polymerases I, II, and III. J Virol, 1998.
72(10): p. 8413-9.
Yuan, H., B.K. Yoza, and D.S. Lyles, Inhibition of host RNA polymerase IIdependent transcription by vesicular stomatitis virus results from inactivation of
TFIID. Virology, 1998. 251(2): p. 383-92.
Yuan, H., S. Puckett, and D.S. Lyles, Inhibition of host transcription by vesicular
stomatitis virus involves a novel mechanism that is independent of
phosphorylation of TATA-binding protein (TBP) or association of TBP with TBPassociated factor subunits. J Virol, 2001. 75(9): p. 4453-8.
Connor, J.H. and D.S. Lyles, Inhibition of host and viral translation during
vesicular stomatitis virus infection. eIF2 is responsible for the inhibition of viral
but not host translation. J Biol Chem, 2005. 280(14): p. 13512-9.
Connor, J.H. and D.S. Lyles, Vesicular stomatitis virus infection alters the eIF4F
translation initiation complex and causes dephosphorylation of the eIF4E binding
protein 4E-BP1. J Virol, 2002. 76(20): p. 10177-87.
Whitlow, Z.W., J.H. Connor, and D.S. Lyles, New mRNAs are preferentially
translated during vesicular stomatitis virus infection. J Virol, 2008. 82(5): p.
2286-94.

164

274.
275.
276.
277.
278.
279.
280.
281.
282.
283.
284.
285.
286.
287.
288.
289.

Glodowski, D.R., J.M. Petersen, and J.E. Dahlberg, Complex nuclear localization
signals in the matrix protein of vesicular stomatitis virus. J Biol Chem, 2002.
277(49): p. 46864-70.
von Kobbe, C., et al., Vesicular stomatitis virus matrix protein inhibits host cell
gene expression by targeting the nucleoporin Nup98. Mol Cell, 2000. 6(5): p.
1243-52.
Enninga, J., et al., Role of nucleoporin induction in releasing an mRNA nuclear
export block. Science, 2002. 295(5559): p. 1523-5.
Petersen, J.M., L.S. Her, and J.E. Dahlberg, Multiple vesiculoviral matrix proteins
inhibit both nuclear export and import. Proc Natl Acad Sci U S A, 2001. 98(15):
p. 8590-5.
Faria, P.A., et al., VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway.
Mol Cell, 2005. 17(1): p. 93-102.
Rajani, K.R., et al., Complexes of vesicular stomatitis virus matrix protein with
host Rae1 and Nup98 involved in inhibition of host transcription. PLoS Pathog,
2012. 8(9): p. e1002929.
Pauszek, S.J., R. Allende, and L.L. Rodriguez, Characterization of the full-length
genomic sequences of vesicular stomatitis Cocal and Alagoas viruses. Arch Virol,
2008. 153(7): p. 1353-7.
Martin-Serrano, J., T. Zang, and P.D. Bieniasz, HIV-1 and Ebola virus encode
small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate
egress. Nat Med, 2001. 7(12): p. 1313-9.
Nagashima, S., et al., A PSAP motif in the ORF3 protein of hepatitis E virus is
necessary for virion release from infected cells. J Gen Virol, 2011. 92(Pt 2): p.
269-78.
Obiang, L., et al., Phenotypes of vesicular stomatitis virus mutants with mutations
in the PSAP motif of the matrix protein. J Gen Virol, 2012. 93(Pt 4): p. 857-65.
Irie, T., et al., Functional analysis of late-budding domain activity associated with
the PSAP motif within the vesicular stomatitis virus M protein. J Virol, 2004.
78(14): p. 7823-7.
Irie, T., et al., Modifications of the PSAP region of the matrix protein lead to
attenuation of vesicular stomatitis virus in vitro and in vivo. J Gen Virol, 2007.
88(Pt 9): p. 2559-67.
Irie, T., et al., Cytopathogenesis of vesicular stomatitis virus is regulated by the
PSAP motif of M protein in a species-dependent manner. Viruses, 2012. 4(9): p.
1605-18.
Lun, X., et al., Effects of intravenously administered recombinant vesicular
stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J Natl
Cancer Inst, 2006. 98(21): p. 1546-57.
Petersen, J.M., et al., The matrix protein of vesicular stomatitis virus inhibits
nucleocytoplasmic transport when it is in the nucleus and associated with nuclear
pore complexes. Mol Cell Biol, 2000. 20(22): p. 8590-601.
Stojdl, D.F., et al., VSV strains with defects in their ability to shutdown innate
immunity are potent systemic anti-cancer agents. Cancer Cell, 2003. 4(4): p. 26375.

165

290.
291.
292.
293.
294.
295.
296.
297.
298.
299.
300.
301.
302.
303.
304.
305.
306.
307.
308.
309.
310.

Ahmed, M., et al., Ability of the matrix protein of vesicular stomatitis virus to
suppress beta interferon gene expression is genetically correlated with the
inhibition of host RNA and protein synthesis. J Virol, 2003. 77(8): p. 4646-57.
Lichty, B.D., et al., Vesicular stomatitis virus: re-inventing the bullet. Trends Mol
Med, 2004. 10(5): p. 210-6.
Stojdl, D.F., et al., Exploiting tumor-specific defects in the interferon pathway
with a previously unknown oncolytic virus. Nat Med, 2000. 6(7): p. 821-5.
Lichty, B.D., et al., Vesicular stomatitis virus: a potential therapeutic virus for the
treatment of hematologic malignancy. Hum Gene Ther, 2004. 15(9): p. 821-31.
Balachandran, S. and G.N. Barber, Vesicular stomatitis virus (VSV) therapy of
tumors. IUBMB Life, 2000. 50(2): p. 135-8.
Steinhoff, U., et al., Antiviral protection by vesicular stomatitis virus-specific
antibodies in alpha/beta interferon receptor-deficient mice. J Virol, 1995. 69(4):
p. 2153-8.
Stark, G.R., et al., How cells respond to interferons. Annu Rev Biochem, 1998.
67: p. 227-64.
Hardy, M.P., et al., Characterization of the type I interferon locus and
identification of novel genes. Genomics, 2004. 84(2): p. 331-45.
Randall, R.E. and S. Goodbourn, Interferons and viruses: an interplay between
induction, signalling, antiviral responses and virus countermeasures. J Gen Virol,
2008. 89(Pt 1): p. 1-47.
Theofilopoulos, A.N., et al., Type I interferons (alpha/beta) in immunity and
autoimmunity. Annu Rev Immunol, 2005. 23: p. 307-36.
Takaoka, A., et al., Integration of interferon-alpha/beta signalling to p53
responses in tumour suppression and antiviral defence. Nature, 2003. 424(6948):
p. 516-23.
Gerlach, N., et al., Anti-retroviral effects of type I IFN subtypes in vivo. Eur J
Immunol, 2009. 39(1): p. 136-46.
Heiber, J.F. and G.N. Barber, Evaluation of innate immune signaling pathways in
transformed cells. Methods Mol Biol, 2012. 797: p. 217-38.
Perry, A.K., et al., The host type I interferon response to viral and bacterial
infections. Cell Res, 2005. 15(6): p. 407-22.
Lund, J.M., et al., Recognition of single-stranded RNA viruses by Toll-like
receptor 7. Proc Natl Acad Sci U S A, 2004. 101(15): p. 5598-603.
Hornung, V., et al., 5'-Triphosphate RNA is the ligand for RIG-I. Science, 2006.
314(5801): p. 994-7.
Kato, H., et al., Cell type-specific involvement of RIG-I in antiviral response.
Immunity, 2005. 23(1): p. 19-28.
de Veer, M.J., et al., Functional classification of interferon-stimulated genes
identified using microarrays. J Leukoc Biol, 2001. 69(6): p. 912-20.
Schoggins, J.W., et al., A diverse range of gene products are effectors of the type I
interferon antiviral response. Nature, 2011. 472(7344): p. 481-5.
Zhou, A., et al., Interferon action in triply deficient mice reveals the existence of
alternative antiviral pathways. Virology, 1999. 258(2): p. 435-40.
Kroger, A., et al., Activities of IRF-1. J Interferon Cytokine Res, 2002. 22(1): p. 514.

166

311.

312.
313.
314.
315.
316.
317.
318.
319.
320.
321.
322.
323.
324.
325.
326.
327.
328.

Stevens, A.M. and L.Y. Yu-Lee, The transcription factor interferon regulatory
factor-1 is expressed during both early G1 and the G1/S transition in the
prolactin-induced lymphocyte cell cycle. Mol Endocrinol, 1992. 6(12): p. 223643.
Kirchhoff, S., F. Schaper, and H. Hauser, Interferon regulatory factor 1 (IRF-1)
mediates cell growth inhibition by transactivation of downstream target genes.
Nucleic Acids Res, 1993. 21(12): p. 2881-9.
Fujita, T., et al., Induction of endogenous IFN-alpha and IFN-beta genes by a
regulatory transcription factor, IRF-1. Nature, 1989. 337(6204): p. 270-2.
Tamura, T., et al., The IRF family transcription factors in immunity and
oncogenesis. Annu Rev Immunol, 2008. 26: p. 535-84.
Brien, J.D., et al., Interferon regulatory factor-1 (IRF-1) shapes both innate and
CD8(+) T cell immune responses against West Nile virus infection. PLoS Pathog,
2011. 7(9): p. e1002230.
Haller, O. and G. Kochs, Interferon-induced mx proteins: dynamin-like GTPases
with antiviral activity. Traffic, 2002. 3(10): p. 710-7.
Staeheli, P. and J. Pavlovic, Inhibition of vesicular stomatitis virus mRNA
synthesis by human MxA protein. J Virol, 1991. 65(8): p. 4498-501.
Stertz, S., et al., The antiviral potential of interferon-induced cotton rat Mx
proteins against orthomyxovirus (influenza), rhabdovirus, and bunyavirus. J
Interferon Cytokine Res, 2007. 27(10): p. 847-55.
Olszewski, M.A., J. Gray, and D.J. Vestal, In silico genomic analysis of the
human and murine guanylate-binding protein (GBP) gene clusters. J Interferon
Cytokine Res, 2006. 26(5): p. 328-52.
Kresse, A., et al., Analyses of murine GBP homology clusters based on in silico,
in vitro and in vivo studies. BMC Genomics, 2008. 9: p. 158.
Carter, C.C., V.Y. Gorbacheva, and D.J. Vestal, Inhibition of VSV and EMCV
replication by the interferon-induced GTPase, mGBP-2: differential requirement
for wild-type GTP binding domain. Arch Virol, 2005. 150(6): p. 1213-20.
MacMicking, J.D., IFN-inducible GTPases and immunity to intracellular
pathogens. Trends Immunol, 2004. 25(11): p. 601-9.
Anderson, S.L., et al., Interferon-induced guanylate binding protein-1 (GBP-1)
mediates an antiviral effect against vesicular stomatitis virus and
encephalomyocarditis virus. Virology, 1999. 256(1): p. 8-14.
Degrandi, D., et al., Extensive characterization of IFN-induced GTPases mGBP1
to mGBP10 involved in host defense. J Immunol, 2007. 179(11): p. 7729-40.
Li, M., et al., Guanylate binding protein 1 is a novel effector of EGFR-driven
invasion in glioblastoma. J Exp Med, 2011. 208(13): p. 2657-73.
Dong, B., et al., Phospholipid scramblase 1 potentiates the antiviral activity of
interferon. J Virol, 2004. 78(17): p. 8983-93.
Zhou, Q., et al., Molecular cloning of human plasma membrane phospholipid
scramblase. A protein mediating transbilayer movement of plasma membrane
phospholipids. J Biol Chem, 1997. 272(29): p. 18240-4.
Sims, P.J. and T. Wiedmer, Unraveling the mysteries of phospholipid scrambling.
Thromb Haemost, 2001. 86(1): p. 266-75.

167

329.
330.
331.
332.
333.
334.

335.
336.
337.
338.
339.
340.
341.
342.

343.
344.
345.

Sahu, S.K., et al., Phospholipid scramblases: an overview. Arch Biochem
Biophys, 2007. 462(1): p. 103-14.
Chawla-Sarkar, M., et al., Apoptosis and interferons: role of interferon-stimulated
genes as mediators of apoptosis. Apoptosis, 2003. 8(3): p. 237-49.
Sgorbissa, A., et al., Type I IFNs signaling and apoptosis resistance in
glioblastoma cells. Apoptosis, 2011. 16(12): p. 1229-44.
Haybaeck, J., et al., STAT-1 expression in human glioblastoma and peritumoral
tissue. Anticancer Res, 2007. 27(6B): p. 3829-35.
Du, Z., et al., Inhibition of type I interferon-mediated antiviral action in human
glioma cells by the IKK inhibitors BMS-345541 and TPCA-1. J Interferon
Cytokine Res, 2012. 32(8): p. 368-77.
Yoshino, A., et al., Therapeutic implications of interferon regulatory factor
(IRF)-1 and IRF-2 in diffusely infiltrating astrocytomas (DIA): response to
interferon (IFN)-beta in glioblastoma cells and prognostic value for DIA. J
Neurooncol, 2005. 74(3): p. 249-60.
Versteeg, G.A. and A. Garcia-Sastre, Viral tricks to grid-lock the type I interferon
system. Curr Opin Microbiol, 2010. 13(4): p. 508-16.
Andrejeva, J., et al., The V proteins of paramyxoviruses bind the IFN-inducible
RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc
Natl Acad Sci U S A, 2004. 101(49): p. 17264-9.
Kubota, T., et al., Mumps virus V protein antagonizes interferon without the
complete degradation of STAT1. J Virol, 2005. 79(7): p. 4451-9.
Fan, L., T. Briese, and W.I. Lipkin, Z proteins of New World arenaviruses bind
RIG-I and interfere with type I interferon induction. J Virol, 2010. 84(4): p. 178591.
Basu, D., et al., Novel influenza virus NS1 antagonists block replication and
restore innate immune function. J Virol, 2009. 83(4): p. 1881-91.
Kamitani, W., et al., Severe acute respiratory syndrome coronavirus nsp1 protein
suppresses host gene expression by promoting host mRNA degradation. Proc Natl
Acad Sci U S A, 2006. 103(34): p. 12885-90.
Kopecky-Bromberg, S.A., et al., Severe acute respiratory syndrome coronavirus
open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as
interferon antagonists. J Virol, 2007. 81(2): p. 548-57.
Brzozka, K., S. Finke, and K.K. Conzelmann, Identification of the rabies virus
alpha/beta interferon antagonist: phosphoprotein P interferes with
phosphorylation of interferon regulatory factor 3. J Virol, 2005. 79(12): p. 767381.
An, H.Y., et al., Genetically modified VSV(NJ) vector is capable of
accommodating a large foreign gene insert and allows high level gene expression.
Virus Res, 2013. 171(1): p. 168-77.
Obuchi, M., M. Fernandez, and G.N. Barber, Development of recombinant
vesicular stomatitis viruses that exploit defects in host defense to augment specific
oncolytic activity. J Virol, 2003. 77(16): p. 8843-56.
Diaz, R.M., et al., Oncolytic immunovirotherapy for melanoma using vesicular
stomatitis virus. Cancer Res, 2007. 67(6): p. 2840-8.

168

346.
347.
348.
349.
350.
351.
352.
353.
354.
355.
356.
357.
358.
359.

360.
361.

van den Pol, A.N., K.P. Dalton, and J.K. Rose, Relative neurotropism of a
recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J
Virol, 2002. 76(3): p. 1309-27.
Steinhauer, D.A. and J.J. Holland, Direct method for quantitation of extreme
polymerase error frequencies at selected single base sites in viral RNA. J Virol,
1986. 57(1): p. 219-28.
Jackson, A.C., Rabies. Neurol Clin, 2008. 26(3): p. 717-26, ix.
Kennedy, P.G., Viral encephalitis. J Neurol, 2005. 252(3): p. 268-72.
Schneider-Schaulies, J., et al., Measles virus in the CNS: the role of viral and host
factors for the establishment and maintenance of a persistent infection. J
Neurovirol, 1999. 5(6): p. 613-22.
Dal Canto, M.C. and S.G. Rabinowitz, Murine central nervous system infection
by a viral temperature-sensitive mutant: a subacute disease leading to
demyelination. Am J Pathol, 1981. 102(3): p. 412-26.
Thomsen, A.R., et al., Cooperation of B cells and T cells is required for survival
of mice infected with vesicular stomatitis virus. Int Immunol, 1997. 9(11): p.
1757-66.
Wollmann, G., P. Tattersall, and A.N. van den Pol, Targeting human
glioblastoma cells: comparison of nine viruses with oncolytic potential. J Virol,
2005. 79(10): p. 6005-22.
Duntsch, C.D., et al., Recombinant vesicular stomatitis virus vectors as oncolytic
agents in the treatment of high-grade gliomas in an organotypic brain tissue
slice-glioma coculture model. J Neurosurg, 2004. 100(6): p. 1049-59.
Wollmann, G., et al., Some attenuated variants of vesicular stomatitis virus show
enhanced oncolytic activity against human glioblastoma cells relative to normal
brain cells. J Virol, 2010. 84(3): p. 1563-73.
Francoeur, A.M., L. Poliquin, and C.P. Stanners, The isolation of interferoninducing mutants of vesicular stomatitis virus with altered viral P function for the
inhibition of total protein synthesis. Virology, 1987. 160(1): p. 236-45.
Desforges, M., et al., Different host-cell shutoff strategies related to the matrix
protein lead to persistence of vesicular stomatitis virus mutants on fibroblast
cells. Virus Res, 2001. 76(1): p. 87-102.
Ahmed, M., S.D. Cramer, and D.S. Lyles, Sensitivity of prostate tumors to wild
type and M protein mutant vesicular stomatitis viruses. Virology, 2004. 330(1): p.
34-49.
Cary, Z.D., M.C. Willingham, and D.S. Lyles, Oncolytic vesicular stomatitis virus
induces apoptosis in U87 glioblastoma cells by a type II death receptor
mechanism and induces cell death and tumor clearance in vivo. J Virol, 2011.
85(12): p. 5708-17.
Ozduman, K., et al., Systemic vesicular stomatitis virus selectively destroys
multifocal glioma and metastatic carcinoma in brain. J Neurosci, 2008. 28(8): p.
1882-93.
Jenks, N., et al., Safety studies on intrahepatic or intratumoral injection of
oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and
nonhuman primates. Hum Gene Ther, 2010. 21(4): p. 451-62.

169

362.
363.
364.
365.
366.
367.
368.
369.
370.
371.

372.
373.
374.
375.
376.
377.
378.

Naik, S., et al., Potent systemic therapy of multiple myeloma utilizing oncolytic
vesicular stomatitis virus coding for interferon-beta. Cancer Gene Ther, 2012.
19(7): p. 443-50.
http://clinicaltrials.gov/show/NCT01628640.
Guertin, D.A. and D.M. Sabatini, Defining the role of mTOR in cancer. Cancer
Cell, 2007. 12(1): p. 9-22.
Costa-Mattioli, M. and N. Sonenberg, RAPping production of type I interferon in
pDCs through mTOR. Nat Immunol, 2008. 9(10): p. 1097-9.
Jayakar, H.R., VSV M protein domains involved in assembly and
cytopathogenesis, in Microbiology2001, University of Tennessee Health Science
Center: Memphis, TN. p. 216.
Familletti, P.C., S. Rubinstein, and S. Pestka, A convenient and rapid cytopathic
effect inhibition assay for interferon. Methods Enzymol, 1981. 78(Pt A): p. 38794.
Sharma, A.K., et al., Development of a percutaneous cerebrospinal fluid
collection technique in F-344 rats and evaluation of cell counts and total protein
concentrations. Toxicol Pathol, 2006. 34(4): p. 393-5.
Ahmed, M., S. Puckett, and D.S. Lyles, Susceptibility of breast cancer cells to an
oncolytic matrix (M) protein mutant of vesicular stomatitis virus. Cancer Gene
Ther, 2010. 17(12): p. 883-92.
Vogel, C. and E.M. Marcotte, Insights into the regulation of protein abundance
from proteomic and transcriptomic analyses. Nat Rev Genet, 2012. 13(4): p. 22732.
Wollmann, G., M.D. Robek, and A.N. van den Pol, Variable deficiencies in the
interferon response enhance susceptibility to vesicular stomatitis virus oncolytic
actions in glioblastoma cells but not in normal human glial cells. J Virol, 2007.
81(3): p. 1479-91.
Furr, S.R., et al., RIG-I mediates nonsegmented negative-sense RNA virusinduced inflammatory immune responses of primary human astrocytes. Glia,
2010. 58(13): p. 1620-9.
Onoguchi, K., M. Yoneyama, and T. Fujita, Retinoic acid-inducible gene-I-like
receptors. J Interferon Cytokine Res, 2011. 31(1): p. 27-31.
Marie, I., J.E. Durbin, and D.E. Levy, Differential viral induction of distinct
interferon-alpha genes by positive feedback through interferon regulatory factor7. EMBO J, 1998. 17(22): p. 6660-9.
Bi, Z., et al., Vesicular stomatitis virus infection of the central nervous system
activates both innate and acquired immunity. J Virol, 1995. 69(10): p. 6466-72.
Barth, R.F. and B. Kaur, Rat brain tumor models in experimental neuro-oncology:
the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol, 2009.
94(3): p. 299-312.
Parsa, A.T., et al., Limitations of the C6/Wistar rat intracerebral glioma model:
implications for evaluating immunotherapy. Neurosurgery, 2000. 47(4): p. 993-9;
discussion 999-1000.
Clendenon, N.R., et al., Boron neutron capture therapy of a rat glioma.
Neurosurgery, 1990. 26(1): p. 47-55.

170

379.
380.
381.
382.
383.
384.
385.
386.
387.
388.
389.
390.
391.
392.
393.
394.
395.
396.

Barth, R.F., Rat brain tumor models in experimental neuro-oncology: the 9L, C6,
T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol, 1998. 36(1): p. 91102.
http://www.atcc.org/products/all/CRL-2397.
Nieder, C., et al., Treatment of unresectable glioblastoma multiforme. Anticancer
Res, 2005. 25(6C): p. 4605-10.
Liu, Q., et al., Molecular properties of CD133+ glioblastoma stem cells derived
from treatment-refractory recurrent brain tumors. J Neurooncol, 2009. 94(1): p.
1-19.
Wollmann, G., K. Ozduman, and A.N. van den Pol, Oncolytic virus therapy for
glioblastoma multiforme: concepts and candidates. Cancer J, 2012. 18(1): p. 6981.
Auffinger, B., A.U. Ahmed, and M.S. Lesniak, Oncolytic virotherapy for
malignant glioma: translating laboratory insights into clinical practice. Front
Oncol, 2013. 3: p. 32.
Bergman, I., et al., Treatment of implanted mammary tumors with recombinant
vesicular stomatitis virus targeted to Her2/neu. Int J Cancer, 2007. 121(2): p.
425-30.
Wollmann, G., et al., Vesicular stomatitis virus variants selectively infect and kill
human melanomas but not normal melanocytes. J Virol, 2013. 87(12): p. 6644-59.
Johnsen, I.B., et al., Toll-like receptor 3-elicited MAPK activation induces
stabilization of interferon-beta mRNA. Cytokine, 2012. 57(3): p. 337-46.
Norton, W.T., et al., Quantitative aspects of reactive gliosis: a review.
Neurochem Res, 1992. 17(9): p. 877-85.
Kawano, H., et al., Role of the lesion scar in the response to damage and repair of
the central nervous system. Cell Tissue Res, 2012. 349(1): p. 169-80.
Gack, M.U., et al., Roles of RIG-I N-terminal tandem CARD and splice variant in
TRIM25-mediated antiviral signal transduction. Proc Natl Acad Sci U S A, 2008.
105(43): p. 16743-8.
Eisenacher, K. and A. Krug, Regulation of RLR-mediated innate immune
signaling--it is all about keeping the balance. Eur J Cell Biol, 2012. 91(1): p. 3647.
Stirnweiss, A., et al., IFN regulatory factor-1 bypasses IFN-mediated antiviral
effects through viperin gene induction. J Immunol, 2010. 184(9): p. 5179-85.
Maatta, A.M., et al., Evaluation of cancer virotherapy with attenuated replicative
Semliki forest virus in different rodent tumor models. Int J Cancer, 2007. 121(4):
p. 863-70.
Vaha-Koskela, M.J., et al., Resistance to two heterologous neurotropic oncolytic
viruses, Semliki Forest virus and vaccinia virus, in experimental glioma. J Virol,
2013. 87(4): p. 2363-6.
Pinschewer, D.D., et al., Kinetics of protective antibodies are determined by the
viral surface antigen. J Clin Invest, 2004. 114(7): p. 988-93.
Kurozumi, K., et al., Effect of tumor microenvironment modulation on the efficacy
of oncolytic virus therapy. J Natl Cancer Inst, 2007. 99(23): p. 1768-81.

171

397.

398.
399.
400.
401.

Charan, S., H. Hengartner, and R.M. Zinkernagel, Antibodies against the two
serotypes of vesicular stomatitis virus measured by enzyme-linked immunosorbent
assay: immunodominance of serotype-specific determinants and induction of
asymmetrically cross-reactive antibodies. J Virol, 1987. 61(8): p. 2509-14.
Prestwich, R.J., et al., The case of oncolytic viruses versus the immune system:
waiting on the judgment of Solomon. Hum Gene Ther, 2009. 20(10): p. 1119-32.
Raykov, Z. and J. Rommelaere, Potential of tumour cells for delivering oncolytic
viruses. Gene Ther, 2008. 15(10): p. 704-10.
Guo, Z.S., et al., The combination of immunosuppression and carrier cells
significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized
host. Gene Ther, 2010. 17(12): p. 1465-75.
Ruotsalainen, J., et al., Interferon-beta sensitivity of tumor cells correlates with
poor response to VA7 virotherapy in mouse glioma models. Mol Ther, 2012.
20(8): p. 1529-39.

172

APPENDIX A. SUPPLEMENTARY FIGURES AND TABLES

Figure A-1. Expression of housekeeping genes in FR cells
The expression of several housekeeping genes was tested in order to determine the best
gene for normalization of interferon stimulated genes studies. FR cells were transfected
with pI:C. At 24 hours post-treatment, cells were harvested and total RNA was extracted
using Trizol reagent. cDNA was synthesized using M-MLV reverse transcriptase
(Invitrogen) and random hexamers as primer. Quantitative PCR was performed on the
LightCycler 480 (Molecular Resource Center, UTHSC) using Universal Probe Library
(UPL) protocol for rat gene expression (Roche) (Table A-1). Universal probes are
specific for the detection of the rat transcriptome and are labeled with fluorescein at the
5’ end and a dark quencher dye at the 3’end that allow detection by standard SYBR
Green I filters. The LightCycler 480 Taqman90 protocol was used which is preprogrammed to perform the following cycles: activation of DNA polymerase for 5
minutes at 95oC; amplification of cDNA for 40 cycles which includes 10 seconds at 95oC
denature, 20 seconds at 60oC annealing, and 10 seconds at 72oC extension; cool down for
30 seconds at 40oC. From these results, -actin was chosen as the housekeeping gene to
use in further experiments. Each experiment was done in duplicate and results are
expressed as the mean ± SD.

173

Table A-1.

qRT-PCR UPL primers for housekeeping genes
Gene

Left Primer

Right Primer

Cyclophilin B
-actin
HPRT1 (Hypoxanthine
phosphoribosyltransferase 1)
-tubulin
TBP (TATA Box binding
protein)
S5 (ribosomal protein S5)

Acgtggttttcggcaaagt
Cccgcgagtacaaccttct
Gaccggttctgtcatgtcg

Cttggtgttctccaccttcc
cgtcatccatggcgaact
acctggttcatcatcactaatcac

Cagagccattctggtggac
Cccaccagcagttcagtag
c
Gactgagaagcccggtttg

Gccagcaccactctgacc
Cattctgggtttgatcattctg

174

cttgatgtccggggtctct

UPL
Probe #
97
17
95
116
129
5

Figure A-2. Expression of Cyclophilin B in infected FR cells
Due to results observed following infection in C6 cells discussed in Chapter 3, Cyclophin
B was chosen for further testing to determine the appropriate housekeeping gene for
subsequent qRT-PCR studies. FR cells were infected with either wtVSV or rNCP12.1GFP at an MOI of 10 for one hour at 31oC. At 24 hpi, cells were harvested and qRTPCR was performed as describe on the LightCycler 480 (Molecular Resource Center,
UTHSC) using Universal Primary Library (UPL) protocol for rat gene expression
(Roche) (Table A-1). Expression levels of Cyclophilin B were consistent despite
infection. (–)RT controls demonstrated high Cp values as expected for samples not
contaminated with chromosomal DNA. Therefore, Cyclophilin B was determined to be
the most appropriate housekeeping gene for use in further qRT-PCR studies. Each
experiment was done in duplicate and results are expressed as the mean ± SD
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Figure A-3. Test of UPL primer sets for the expression of ISGs in multiple cell
lines
Non-tumor (PRA) and tumor (C6, F98) glial cell lines were treated with 10g transfected
pI:C for 4 hours. At 24 hours post-transfection, cells were harvested and total RNA was
extracted and used to quantify expression levels of several interferon stimulated genes
including IRF-1, GBP-1, and Mx1/2. qRT-PCR was performed as described on the
LightCycler 480 (Molecular Resource Center, UTHSC) using Universal Primary Library
(UPL) protocol for rat gene expression (Roche) (See Chapter 2 for description of primer
sets). Levels of expression were compared to those induced in FR rat fibroblasts.
Results were normalized to the housekeeping gene, Cyclophilin B. From these results,
we were able to confirm that the designed primer sets worked in these cell models and
that non-tumor cells demonstrate higher levels of expression for each of the ISGs tested
over glioma cell lines.
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Figure A-4. BCA protein assay of proteins derived from glial cell lysate
In order to determine the concentration of proteins derived from cell lysate of several
glial cell lines, a BCA colorimetric assay was performed according to manufacturer
instructions (BCA Protein Assay Reagent, Pierce). Cells were lysed in RIPA buffer
(25mM Tris–HCl, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate, 0.15M NaCl,
1mM EDTA) and measurements were taken by spectrophotometer at A562.
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Figure A-5. Detection of circulating anti-tumor antibodies in animals treated with
pre-infected cells versus free virus
Sera from intracranial F98 glioma bearing animals that were not treated or treated with
either pre-infected (PC) F98 tumor cells or Free Virus (FV) were collected at the time of
euthanasia as described. Cultured F98 cells from a 10cm dish were harvested and lysed
in 1mL RIPA buffer. Protein concentrations were determined using the BCA
colorimetric method against known concentrations of BSA (Pierce, Rockford, IL) as
described. For SDS-PAGE, lysates were suspended in Laemmli reducing sample buffer
and heated in 100 C sand bath for 5 minutes. Samples were then centrifuged at
15,000xg for one minute and left on the bench to come to room temperature. Ten
microliters of SeeBlue Plus2 protein standard (Invitrogen) were loaded next to 10g of
lysate and resolved on 0.75mm 9% SDSPAGE gel. Gels were transferred to PVDF
membrane which were then blocked in 5% NFDM/TTBS at room temperature for one
hour. Membranes were then cut and incubated at room temperature for two hours in sera
at 1:500 in 5% NFDM/TTBS. Membranes were washed in TTBS and then incubated at
room temperature for two hours in goat -rat secondary antibody conjugated to HRP
(Jackson Immunoresearch Laboratories) at a dilution of 1:5000. Signal was visualized
using chemiluminescence (SuperSignal West Dura, Pierce) followed by exposure to and
development of X-ray film
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APPENDIX B. STANDARDIZING THE IFN BIOASSAY AFTER VSV
INFECTION
Introduction and Purpose
A number of studies have evaluated IFN activity following infection with wtVSV
as well as with a number of VSV matrix (M) mutants that are thought to be interferon
inducers [276, 289, 291, 292]. Very often these studies determine IFN activity based on
levels of gene expression using semi-quantitative or quantitative RT-PCR [289, 371] or
by quantifying total IFN protein using methods such as ELISA [193, 289]. As we have
seen, the induction of IFN gene expression does not necessarily correlate with the amount
of biologically active IFN produced. In fact, from our results, the production of active
IFN appears to be highly regulated in non-tumor cells such as primary astrocytes
regardless of the high levels of induced IFN gene expression. In order to test for IFN
activity, we have used an IFN bioassay in which IFN in a sample is determined by its
ability to inhibit VSV-induced CPE [367]. In samples already containing infectious
virus, the IFN bioassay is impossible to interpret. Various neutralizing techniques have
been used in other studies such as acid treatment [290] or heat inactivation [344],
however, results do not take into account the effects these methods potentially have on
the stability of IFN. In the following studies, we evaluated several neutralizing methods
including acid treatment, heat neutralization, and ultracentrifugation. The following
results show the effectiveness of these methods by determining the amount of residual
infectious particles post-treatment and by testing the effect of these treatments on IFN
activity.
Materials and Methods
Cells
L929 murine fibroblasts were provided by Dr. Lawrence Pfeffer. BHK21 cells
were supplied by Dr. Michael Whitt.
Neutralization Methods
Based on the high viral progeny produced by F98 glioma cells during rNCP12.1
infection in vitro (107-109pfu/mL), we tested several methods of neutralization against
samples containing high titers of virus, specifically 108 pfu wtVSV. For each technique,
residual virus was detected by standard plaque assay on BHKs. Effects on IFN activity
were determined by comparing 200U of treated IFN with non-treated rIFN using the IFN
bioassay in L929 murine fibroblasts. rIFN units were previously determined with respect
to the international reference standard for mouse interferon alpha/beta (mouse IFN-/
(NIH).
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Neutralization by anti-VSV neutralizing antibody (TN-1)
TN-1 is a polyclonal antibody developed in rabbits immunized with intact UVinactivated wtVSV. In previous studies, 10L of TN-1 neutralized 105 pfu wtVSV (data
not shown). For these studies, 20L of TN-1 was incubated at 37oC for one hour with
108 pfu wtVSV. Residual virus was detected using a standard plaque assay on BHKs.
Heat inactivation
Virus and rIFN were both heated separately in a 56oC water bath for 30 minutes
[344].
Acid neutralization
Virus and rIFN were treated with 50L of 0.5M HCl (pH= 2) and incubated for
2h at 4 C then neutralized by adding 45-50L of 0.5M NaOH [290].
o

Combination of heat inactivation and acid neutralization
We evaluated combination treatment of heat (56oC) and acid neutralization (pH of
2) on wtVSV and IFN activity. Samples were first heated for 30 minutes then treated
with acid for 2 hours at 4oC.
20% sucrose cushion
108 pfu wtVSV was suspended in 2mL of serum free DMEM, over-layed onto a
20% sucrose cushion, and centrifuged for 35 minutes at 45,000 rpm using an AH650
rotor at 4oC. 200U IFN diluted into 2mL SF-DMEM was also spun through a 20%
sucrose cushion in the same manner.
Combination of 20% sucrose cushion and acid neutralization
108 pfu virus was treated with 0.5M HCl at a pH of 2 for 2 hours at 4oC then
brought back to neutral pH using NaOH. Acid treated samples were then spun through a
20% sucrose cushion as described.
Ultra centrifugal filtration
Virus was suspended in 1mL of SF DMEM. Samples were centrifuged in
Amicon Millipore Ultracel Filters with a pore cutoff 100,000 NMWL. This cutoff would
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ensure that viral particles would be separated from IFN in the media based on the
inability of intact virus particles to move through the membrane pores. IFN, on the other
hand, having a size of approximately 20kDa, would be able to pass freely. Samples were
spun at 5000rpm for 10 minutes at 4oC using JS 4.2 rotor. Following one spin, filtered
supernatant was titered using a standard plaque assay on BHKs. Five hundred microliters
of IFN at a concentration of 1U/L was also filtered as described.
Results
Following treatment with TN-1, no residual virus was detected by plaque assay at
24hpi however between 36-48 hours, multiple plaques began to form. Heat inactivation
resulted in no remaining infectious virions for one sample and 2 pfu/mL in another,
however, IFN activity was decreased 4 fold relative to the untreated IFN standard.
Plaque analysis of acid treated virus resulted in a titer of 3.1x103 pfu/mL. A subsequent
study using acid neutralization however resulted in no detectable infectious virus.
Results showed that acid decreased IFN activity 2 fold. A combination of heat and acid
treatment neutralized all virus however IFN activity was decreased 4 fold relative to the
IFN standard in one sample and was undetectable following heat and acid treatment in
another sample. A titer of 1.6x102 pfu/mL was detected following centrifugation through
a 20% sucrose cushion and IFN activity was shown to be 2 fold lower relative to
untreated rIFN. A combination of acid with 20% sucrose cushion was able to remove
and inactivate all virus from one sample with 40 pfu/mL virus remaining in another.
However IFN activity was decreased 4 fold. Lastly, following one spin using the
ultracentrifugal filters, supernatants were found to have 26 pfu/mL of virus remaining
however a second spin resulted in no residual virus. IFN activity was found to be
unaffected by this technique after one or two cycles of filtration.
Discussion
Because the IFN bioassay requires that L929 cells be treated for 24 hours in
neutralized supernatant followed by another 24 hours to score inhibition of viral induced
CPE, the likelihood that results would be contaminated by non- neutralized virus in
samples treated with neutralizing antibody would be high. Therefore, this strategy would
not be appropriate for our purposes. Heat, acid, and sucrose treatments all diminished
IFN activity between two and four-fold with one sample having undetectable IFN
activity. In addition, inactivation of infectious virus was inconsistent as some samples
had no detectable virus while others demonstrated infectious viral particles as seen by
plaque assay following treatments. Therefore, these treatments would not be appropriate
as well for our studies. Ultra-centrifugal filtration was found to be the most appropriate,
effective, and reliable method. Though one spin allowed some virus to filter likely
through defects in the membrane, a second spin was able to separate all viral particles
without any reduction in IFN activity. Therefore, we concluded that two spins using the
Amicon Millipore filters at 5000rpm for 10 minutes each would be used for subsequent
studies.
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